Type 2 Diabetes\nHypertension\nEstimated glomerular filtration rate (eGFR) > 30 ml/min\nUse of Ace Inh and ARB for control of blood pressure who are willing to be placed on alternate drug(s) in the washout period for blood pressure controlClinical and radiologic diagnosis of primary knee osteoarthritis (Kellgren & Lawrence I, II or III); \nCapability to understand the Informed Consent Form; \nChronic pain for at least 3 months prior to inclusion, measured by VAS.(VAS 4 or above); \nAbsence of skin injures, infections or tumor in the target knee; \nAvailability to comply with the visits.All patients presenting for elective shoulder arthroscopic procedures will be eligible for enrollment.Age: 18 to75 years old;\nPathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring = 10mm on spiral CT scan, satisfying the criteria in RECIST 1.1);\nFailure of prior therapy (during or after treatment) in patients who have received at least two prior chemotherapy regimens;\nECOG PS of 0-2;\nHB = 90g / L\nANC = 1.5 \xc3\x97 109 / L\nPLT = 80 \xc3\x97 109 / L\nBilirubin <1.25 times the upper limit of normal (ULN)\nALT and AST <2.5 \xc3\x97 ULN; liver metastases, if any, the ALT and AST<5 \xc3\x97 ULN\nSerum Cr = 1 \xc3\x97 ULN endogenous creatinine clearance>50ml/min (Cockcroft-Gault formula)\nAn expected survival of = 3 months;\nPatient received apatinib treatment regimen at investigators' discretion;\nPatient has to voluntarily join the study and sign the Informed Consent Form for the study;\nPregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative.They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug.For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.Acutely ill hospitalised children\nNeed for intravenous fluid therapyProvision of informed consent prior to any study specific procedures;\nMen and women 18 years and older;\nGroup I PAH, defined as a mPAP=25mmHg, PCWP<15mmHg and PVR[The PVR =(mPAP-PCWP)/CO]>3.0 Woods unit.Diagnosis of schizophrenia or schizoaffective disorder \nIf entering the study as an inpatient, hospitalization was recent \nCurrently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended \nAssumes primary responsibility for taking medication \nCurrently living in a stable environmentAble to give informed consent\nRight-handed\nAge between 18-50 years old,\nPhysically and neurologically healthy [confirmed by a comprehensive medical history]\nCurrent PTSD diagnosisFemale at birth and identifies as female gender\nAge 18 years or older\nAble to understand and provide consent in English or Spanish\nHIV negative by 4th generation test (Ag/Ab test) or combination of enzymeimmunoassay (EIA) and HIV RNA\nCreatinine clearance = 60 ml/min (via Cockcroft-Gault formula)\nCondomless sex in the last 3 months with one or more male partners of unknown HIV status known to be at substantial risk of HIV infection (IDU, bisexual, sex for goods, recently incarcerated, from a country with HIV prevalence >1%, interpersonal Partner Violence);\nSTI (rectal or vaginal gonorrhea or syphilis) diagnosis during the last 6 months.Previous post-exposure prophylaxis (PEP) use during the last 12 months.Has at least one HIV-infected sexual partner for =4 weeks.Sex for exchange of money, goods or servicesMale or female term baby with gestational >37 weeks and postnatal age < or= 28 days\nBirthweight >2500g\nWritten informed consent of parent or guardianASA physical status 1 or 2\nWritten informed consent\nCardiovascular disease\nPulmonary disease\nLiver disease\nCNS disease\nAlcohol or drug abuse\nChronic intake of CNS active drugs\nBody mass index > 35\nDiabetes mellitus\nHypersensitivity or allergy to one of the study drugsPatient diagnosed by HRCT Core Lab with eligible heterogeneous disease distribution and at least one complete oblique fissure.Age from 40 to 75 years \nBMI < 32 kg/m2 \nFEV1 < 40% of predicted value, FEV1/FVC < 70% \nTLC > 120% predicted, RV > 150% predicted.Stable with < 20 mg prednisone (or equivalent) qd \nPaCO2 < 50mm Hg \nPaO2 > 45 mm Hg on room air \n6-min walk of > 50m (without rehabilitation) or > 100m (with rehabilitation) \nNonsmoking for 4 months prior to initial interview and throughout screening \nThe patient agrees to all protocol required follow-up intervals.The patient has no child bearing potential \nThe patient is willing and able to complete protocol required baseline assessments and proceduresInfants in the newborn intensive care unit\nTPN cholestasis of at least 2.5 mg/dl\nAnticipated TPN treatment for at least one month\nsigned informed consentPhase I: Patients must have histologically confirmed R/R NHL or HL (defined by WHO criteria).Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are eligible.In addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.Patients with DLBCL and HL will be eligible if there is no available standard therapy.Phase II: Patients must have histologically confirmed R/R NHL (as defined by WHO criteria).Patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.Patients with DLBCL will be eligible if there is no available standard therapy.Must have received front line chemotherapy.No upper limit for the number of prior therapies \nEvaluable Disease in the Phase I, and measurable disease in the Phase II \nAge > 18 years \nECOG performance status < 2 \nPatients must have adequate organ and marrow function \nAdequate Contraception \nAbility to understand and the willingness to sign a written informed consent documentModerate to severe rheumatoid arthritis\nTaking methotrexate without adequate control of symptoms\nHave at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease)Premenopausal women\n18-35 years old\nFSH levels < 10 mIU/ml\nAFC> 10\nRegular cycles\nBMI < 28\nSigned informed consentvalid driver's license\nenglish-speaking and literate- Patient with IVF cycle and therefore having frozen-thawed embryos\nRegular menstruation cycle\nPatient's willingness to participate in the studyThe subject must be willingly and able to provide written informed consent\nAge 19 years of age or older (The age of consent in Nebraska)\nHCV treatment-na\xc3\xafve, as defined as no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent\nHCV RNA level at most 6 months prior to the Baseline/Day 1 visit.HCV genotyping 1a, 1b, or mixed 1a/ab.Any non-definitive results will exclude the subject from study participation.Alcohol misuse as defined by the Alcohol Use Disorders Identification Test (AUDIT) score subjects must score > 8 (associated with harmful or hazardous drinking)\nHistory of a liver biopsy showing cirrhosis (e.g.Metavir score = 4 or Ishak score > 5)\nFibroscan showing cirrhosis or results > 12.5 kPa\nFIBRO Spect II index consistent with F3 or F4 AND an AST : platelet ration index (APRI) of > 2 during Screening\nLiver biopsy within 2 years of Screening showing absence of cirrhosis\nFibroscan within 6 months of Baseline/Day1 with a result of = 12.5 kPa\nFIBRO Spect II Index consistent with F0- F2 AND APRI of = 1 during Screening\nLiver imaging within 6 months of Baseline/Day 1 to exclude hepatocellular carcinoma HCC) is required\nALT < 10 x the upper limit of normal (ULN)\nAST < 10 x ULN\nDirect bilirubin < 2.0 x ULN\nPlatelets > 50,000\nHbA1c < 8.5%\nCreatinine clearance (CLcr) = 60 mL /min, as calculated by the Cockcroft-Gault equation\nHemoglobin = 11 g/dL for female subjects; = 12 g/dL for male subjects.Albumin = 2.5 g/dL\nINR = 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.Subject has not been treated with any investigational drug or device within 30 days of the screening visit.ADHDPatients undergoing surgeries in the upper limb (arm, forearm or hand)Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives\nPatient is currently benefiting from the treatment with pasireotide, as determined by the investigator\nPatient has demonstrated compliance, as assessed by the investigator, with the parent study requirements\nWillingness and ability to comply with scheduled visits, treatment plans and any other study procedures\nWritten informed consent obtained prior to enrolling in roll-over study and receiving study medication \xe2\x80\xa2 If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witnessSigned informed consent form\nMacula edema secondary to BRVO\nBCVA of 77 to 20 letters assessed with the use of ETDRS charts\nCRT <U+2267>250\xc2\xb5mGood general health\nOlder than the age of legal consent (i.e.18 years old)\nSonographic diagnosis of ovarian endometrioma with diameter at least 4cm on 2 separate scans at least 6 weeks apart\nNo contraindication to use of progesterone or combined oral contraceptive pills\nNot attempting to conceive either at the time of study entry or for at least 2 years after surgery\nWilling and able to participate after the study has been explainedPatients on chronic statin treatment (>30 days) scheduled for isolated CABG, including on- or off-pump or repeat (redo's) revascularisation procedures\nStable or unstable angina, including non ST-segment-elevation acute coronary syndrome (NSTE-ACS)\nAge = 18 years\nWritten informed consentPatients underwent percutaneous coronary intervention with drug-eluting stent;Ulcerative colitis patients with moderate to severe activity who achieved a clinical remission by the first course of corticosteroids\nNewly diagnosed or without steroid use during last 1 year\nEndoscopic Mayo subscore >0Newly diagnosed glioblastoma (GBM), WHO grade IV.Diagnosis of diabetes mellitus\nBest corrected visual acuity 20/32 - 20/320\nDiabetic macular edema involving the center of the macula\nOptical coherence tomography central subfield thickness of at least 250 micronspatients with renal cancer coming to the laparoscopic radical nephrectomy37 weeks gestation or greater\nLiving, singleton fetus\nNo major fetal malformations\nCephalic presentation\nNo prior uterine scar\nIntact fetal membranes\nQualifies for prostaglandin administration according to current Parkland protocol\nHave a cervical dilation of 2 centimeters or less, measured at the level of the internal os\nHave an indication for induction or attempted induction of labor according to Parkland protocolHIV-1 infected males or females \nover 18 years of age \nsigned informed consent \ncurrently receiving a stable antiretroviral regimen comprising of: \ntwo or more licensed NRTIs \none licensed NNRTI or boosted protease inhibitor \nno previous protease inhibitor resistance documented on HIV-1 genotypic resistance testing \nfailure of current antiretroviral regimen due to: \ntoxicity, intolerance or virological failure if receiving an NNRTI containing regimen at screening \ntoxicity or intolerance if receiving a boosted-protease inhibitor regimen at screening (with plasma HIV RNA < 400 copies/mL at screening) \nwilling to modify antiretroviral therapy, in accordance with the randomisation assignment \nno previous exposure to etravirine \nsubjects in good health upon medical history, physical exam, and laboratory testing in the opinion of the investigator \nhave no serologic evidence of active HBV infection evidenced by negative hepatitis B surface antigen \nfemale subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study: \nbarrier contraceptives (condom, diaphragm with spermicide) \nIUD or Depo PLUS a barrier contraceptive \nfemale subjects of childbearing potential must have a negative pregnancy test.Age 19 years of older\nModerate or severe claudication (Rutherford category 2 or 3)\nCritical limb ischemia (Rutherford category 4 or 5)\nPatients with signed informed consent\nTarget lesion length =150 mm by angiographic estimation\nStenosis of more than 50% in femoropopliteal artery\nAt least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel.Patients scheduled for supine-positioned elective craniotomy for supratentorial malignant and non-malignant brain tumors 3 cm or larger (measured as the largest diameter in any plane on MR images)\nASA (American Society of Anesthesiologist) status 1-3 (27)\nWritten informed consent from participating patientssymptomatic Dupuytrens contracture with palpable cord, involving MCP, total contracture size over 30 degreesSubjects admitted to the hospital with acute or chronic medical illnesses or for elective and emergency surgical illness or trauma\nKnown history of Type 2 diabetes mellitus for >3 months\nTreated with either diet alone, any combination of oral antidiabetic agents, non-insulin injectables or insulin therapy\nBlood glucose levels between >140 mg and <400 mg/dL without laboratory evidence of diabetic ketoacidosisMust have pathologically confirmed invasive adenocarcinoma or ductal carcinoma in situ of the breast.Patients must have undergone segmental mastectomy (i.e., lumpectomy).Patients must not have received prior radiation therapy to the breast.Patients must not have active local-regional disease prior to registration.Patients must not be pregnant because of the potential for fetal harm as a result of radiation treatment.Women of child-bearing age will be given a serum pregnancy test prior to study entry to ensure they are not pregnant.They will also be counseled on the importance of avoiding pregnancy and hormonal contraception while undergoing radiation therapy.Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment.All patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines.1.Male and female recipients of all races, \xe2\x89\xa518 years of age.2.Patients undergoing primary or subsequent deceased-donor or living donor kidney transplantation.3.Subject and/or guardian must be able to provide informed consent.4.Subject and/or guardian must be able to comply with the study protocol.Any patients that will be submitted to phacoemulsification surgery in the Hospital de Clinicas of State University of Campinas (BRAZIL)\nPatients over 18 years old\nPatients who are able to perform SD-OCT\nPatients who sign the consent form=18-40 year old women\nBV+ by Amsel criteria and Nugent score OR history of BV in the prior 6 months\nWilling to use the NuvaRing as directed\nNot intending or wishing to become pregnant over the course of the study\nCapable of providing written informed consent>/= 18 years old\nAtrial fibrillation or flutter on electrocardiogram\nHeart rate >110 beats/min\nSystolic blood pressure >/= 90 mmHgPatients presenting with ST-elevation acute myocardial infarction (STEMI) within 12 hours of their symptom onset in whom TIMI-3 flow was established in infarct related artery (IRA) after balloon angioplasty or thrombectomy.18 years old or older.ADHD is diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5 criteria).Substance Use Disorder is diagnosed according to DSM-5 criteria.Qb-score 1.3 or higher on at least one of the weighted summary parameters QbActivity, QbInattention or QbImpulsivity on the QbTest.Participants are given their written informed consent to participate in the study.Age = 18 years\nLaparoscopic cholecystectomy\nEmergent/elective\n=2 risk factors: diabetes mellitus, age =70 years, BMI =30, fascial enlargementNewborns weighing 1.5kg or more at birth18 years of age or older\ncapable of providing informed consentInclusion criteria includes all U.S. HCA hospitals with an adult ICU;\nNote: Unit of randomization is the hospital, but the participants are hospital adult ICUs\nAll patients within adult ICUs are included, including rare patients <18 years and >=12 years.women\nproven pelvic floor dysfunction\ninformed consentProvide written, signed and dated informed consent prior to initiating any study-related activities.Male or female >18 years of age at the time of screening\nFitzpatrick Skin phototype IV-VI, non-white race/ethnicity, including but not limited to - --African Americans, Asians, Pacific Islanders and Hispanics.Clinical diagnosis of chronic plaque-type psoriasis of the body\nPlaque psoriasis with =2% Body Surface Area (BSA) involvement (may include scalp involvement), PASI Score = 2, IGA mod 2011 score of 2 or greater (based on scale of 0-4)\nFemales of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline.While using investigational product and for at least 28 days after last application of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options d\nMust be in general good health as judged by the Investigator, based on medical history and physical examination.1. age 18-65 years, inclusive \n2. diagnosis of moderate to severe AT, confirmed by Dr. Wilson using clinical symptoms and exam findings consistent with chronic AT (>6 month duration) - which includes pain while palpating the intratendinous swelling part of the Achilles tendon and relief of pain when tendon placed under tension - and pre-procedure US \n3. self-reported AT-related pain for at least 6 months and VAS (Visual Analog Scale) pain >5 (0-10 scale) \n4. self-reported failure of eccentric exercise protocol (at least 75% completion) \n5. self-reported failure of at least 2 of the 3 most common treatments for AT (NSAIDS, rest/ice or taping) \n6. patient considered surgery but decided to wait and/or refused surgery -1.Fasting glucose > 7.0 or have diabetes medication; \n2.Male, 35-80 years; female, postmenopausal to 80 years; \n3.Agree to participant in the trial.Mexican-american\nFemale\nBMI 30-42\nwillingness to complete protocol\npre-diabetic\nEnglish or Spanish literatePatients undergoing ambulatory hand surgery for carpal tunnel and trigger finger, under local anesthesia with or without sedation.Cervical spine injury with functional loss in the upper extremity\nGreater than 4 months out from C-spine injury\nStable motor recovery\nMedically stable\nInternational Classification for Surgery of the Hand in Tetraplegia of 0-5 at 6 months\nGrade 0 finger/thumb extension at 6 months\nSubjects fluent in English or when not fluent, an appropriate translator is presentPatients undergoing surgery on shoulder, humerus, or clavicleasthma or COPDHorner's Syndrome\nHistory of taking an alpha blocker (tamsulosin/ terazosin/doxazosin/alfuzosin/silodosin) medicationParticipant aged 19 or over\nAvailable for the entire duration of the study and willing to participate on the basis of the information provided in the FIU duly read and signed.Adult patients\nKidney transplant recipients\nPatients treated by a calcineurin inhibitor and mycophenolic acid\nViremia >= 3 log UI/ml\nPatients who have given written informed consent\nNegative pregnancy test (blood \xc3\x9f-HCG dosage)Primary total hip arthroplasty (THA)Habitual dietary sodium intake > 3400mg per dayType 2 diabetes\nAge 18 - 75 years\nAnti-GAD antibodies negative (Glutamic Acid Decarboxylase)\nC-peptide levels = 1.5 ng/mL\nFasting blood glucose > 126 mg/dl\nHbA1c 8.0 - 10.5 %\nBMI 25.0 - 45.0 kg/m2\nPrevious therapy with BBIT (basal insulin and at least once daily bolus insulin)Presents to the Emergency Department (ED) and meets the clinical definition for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)\nKnown or suspected gram-positive infection.primigravida, singleton pregnancy, maternal age 18-35 years, and pregnancy duration 16-20 weeks at the time of study inclusion.patients were 18 years old or more,\nnaive to HCV treatment,\nHCV genotype 4,\ncompensated liver disease.heart failure NYHA II-IV\nprevious treatment with diuretics\nage>18 yearsPatients in the cardiothoracic intensive care after cardiac surgery with cardiopulmonary bypass\nAcute kidney injury, defined as increase in S-creatinine 50% or 27 mol/L\nNormal S-creatinine before surgerySubjects who the investigator believes can and will comply with the requirements of the protocol (i.e.return for follow-up visits, and able to converse with study personnel)\nAge 18 years or older\nUndergoing major cardiac surgery using cardiopulmonary bypasspatients = 70 years of age, undergoing a noncardiac surgical procedure under general anesthesia, with an anticipated duration of postoperative admission of at least 2 days.Adult (>18 years of age and older) patients who have or will have undergone surgical resection or biopsy of a supratentorial brain tumor and are able to consent for themselves.Able to be randomized prior to or up to 48 hours after surgery.Bloodstream infection with Enterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii (i.e.likely AmpC-producer), and susceptibility to 3rd generation cephalosporins (i.e.ceftriaxone, cefotaxime or ceftazidime), meropenem and piperacillin-tazobactam from at least one blood culture draw.This will be determined in accordance with laboratory methods and susceptibility breakpoints defined by protocols used in the recruiting site laboratories..\nNo more than 72 hours has elapsed since the first positive blood culture collection.Patient is aged 18 years and over (>=21y in Singapore).(1)= 45 years old;\n(2)A diagnosis or previous diagnosis of essential hypertension, including anyone currently taking antihypertensive drugs; or for those who have not taken antihypertensive drugs within the last 2 weeks, two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP) =90 mmHg or systolic blood pressure (SBP) =140 mmHg (the second blood pressure was measured at V1);\n(3)If a study participant is a woman of childbearing age, she agrees to use a reliable contraceptive method during the trial;\n(4)Voluntarily participates and has signed an informed consent form.(1)Completed MTHFR C677T gene polymorphism detection in run-in period or MTHFR C677T genotype already known in advance;\n(2)Exhibited good tolerance to enalapril and good overall medication compliance (>80%) in run-in period or previously exhibited good tolerance and adherence to ACEI drugs in previous medication history.(3)Voluntarily continues to participate in this study.After the investigator has taken the decision to use human insulin or insulin analogues to treat the subject, any type 2 diabetic previously inadequately controlled with two or more OADs is eligible for the study \nThe selection of the subjects will be at the discretion of the individual investigatorAge \xe2\x89\xa5 18 years (Age \xe2\x89\xa5 12 years for patients with bone sarcomas).Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]).ECOG Performance Status of 0 or 1.At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1.Baseline imaging must be performed within 30 days of dosing.At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts.Patients may have received 1-3 prior systemic therapies in the metastatic setting.Adequate organ function within 14 days of dosing \nMust be willing to provide and have available archival tissue for PD-L1 testing.Written, voluntary informed consent.Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration.Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause.Women of childbearing potential must have a negative pregnancy test \xe2\x89\xa4 72 hours prior to Day 1 of study.Effective methods of birth control include: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence.Life expectancy of >12 weeks.Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab.Above 18 years of age\nSymptomatic, permanent AF of at least three months duration\nResting heart rate =80 bpm\nSigned informed consentBMI = 35\ntype 2 diabetes\nHbA1c = 6,5 % or fasting glycemia =7mmol/l or non-fasting glycemia =11mmol/l\nable to consentMale or female, 18 years of age or older.Study eye with clinically significant diabetic macular edema (DME) with central subfield thickness \xe2\x89\xa5 350\xc2\xb5m on spectral domain OCT\nBest corrected visual acuity (BCVA) of 20/50 to 20/320 ETDRS equivalent (65 letters to 23 letters) in the study eye, with BCVA decrement primarily attributable to DME.Treatment na\xc3\xafve, i.e., no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment.In the investigator's opinion, the subject still has significant intraretinal fluid with room for improvement in both macular edema and BCVA.Intra-Ocular Pressure (IOP) is under control (i.e., IOP \xe2\x89\xa4 25 mm in the study eye) and study eye is not receiving any IOP lowering drops.Willing and able to return for all study visits.Able to meet the extensive post-op evaluation regimen.Understands and signs the informed consent form.Need for long-term oral anticoagulation;\nPatient has provided written informed consent.Males and females of 18 years of age or older at the time of the vaccination\nSevere chronic kidney disease (Stage 4 and 5)Age 18-65\nscheduled to receive ISB and general anesthesia as a day surgery patient for rotator cuff repair and acromioplasty, as a part of planned routine careWomen above 18 years of age with biopsy proven, clinically stage 1 or 2 breast cancer who will be undergoing partial mastectomy with SLNBx at Memorial HealthAll adult patients with chronic myeloid leukaemia in any phase (chronic, accelerated or blastic) who undergo allogeneic stem cell transplantation between 01/01/2010 and 30/09/2013 and have been previously treated with Nilotinib or Dasatinib, regardless of their response to these drugs.Liver cirrhosis\nAge between 18 and 70 years\nEsophageal varices with high bleeding risk: more than F2 and red color sign\nNo previous history of upper gastrointestinal bleeding\nNo previous history of endoscopic, radiologic, or surgical therapy for varices or ascites\nDo not take beta-blocker, ACE inhibitor, or nitrate\nChild-Pugh score <12Age 1-59 months,\nPlan to remain in study area greater than 6 months\nDischarged from hospital following non-trauma related admissionAcute Myocardial Infarction Undergoing Primary percutaneous coronary intervention.Women who are in their first 5 years of menopause \nHave a T score between -1 and -2.49 at the femoral neck, total hip, or L1-L4 spine \nBe 19 years of age or older \nHave their health care provider's permission to enroll in the study.Eligible patients must meet the following criteria to be enrolled in the study: \n1.Newly diagnosed, stage IV squamous cell lung cancer.This includes patients who present with disseminated metastases, and those with a malignant pleural or pericardial effusion (i.e., formerly stage IIIB in the 6th TNM staging system).2.Patients who have received prior adjuvant therapy for early-stage lung cancer are eligible if at least 12 months have elapsed from that treatment.3.Histologically confirmed squamous cell bronchogenic carcinoma.Patients whose tumors contain mixed non-small cell histologies are eligible, as long as squamous carcinoma is the predominant histology.Mixed tumors with small cell anaplastic elements are not eligible.Cytologic specimens obtained by brushings, washings, or needle aspiration of the defined lesion are acceptable.4.Patients with previous radiotherapy as definitive therapy for locally advanced non-small cell lung cancer are eligible, as long as the recurrence is outside the original radiation therapy port.Radiation therapy must have been completed >4 weeks prior to the initiation of study treatment.Patients who have received chemo/radiation for locally advanced NSCLC are not eligible.Patients who have received palliative radiation therapy for symptomatic metastases must have completed treatment >14 days prior the initiation of the study treatment.5.Presence of evaluable (measureable or non-measurable) disease.6.ECOG Performance Status of 0 or 1.7.Laboratory values as follows: \nAbsolute neutrophil count (ANC) >1,500/microL and platelets >100,000/microL (\xe2\x89\xa472 hours prior to initial treatment).Hemoglobin >9 g/dL (Note: Patients may be transfused or receive erythropoietin to maintain or exceed this level).Bilirubin < ULN.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \xe2\x89\xa42.5 times the upper limit of normal if no liver involvement or \xe2\x89\xa45 times the upper limit of normal with liver involvement.Creatinine <2.0 mg/dL, or creatinine clearance >40 mL/min (as calculated by the Cockcroft-Gault method.8.Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of treatment.Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and at least 6 months after the last dose of the study treatment.If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately.Sexually active men must agree to use a medically acceptable form of birth control during treatment and at least 6 months after the last dose.If a female partner becomes pregnant during the course of the study the treating physician should be informed immediately.9.>18 years of age.10.Ability to understand the nature of this study, give written informed consent, and comply with study requirements.11.Patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing.An exception to this is when the national/local regulations prohibits some of the key activities of this research like the export of samples to third countries, storage of coded samples or global gene expression profiling without a pre-specified list of target genes.If tissue is not available, a patient will still be eligible for enrollment into the study.Patients undergoing total knee arthroplasty under spinal anaesthesia\n45y or older\nASA 1-3\nBMI 18-35Persistent primary or recurrent trans-sphincteric anal fistulaAge 60 years or older.Current diagnosis of major depressive disorder (DSM-IV-TR), single episode, recurrent or chronic, without psychotic features, as detected by MINI and clinical exam.Minimum MADRS score = 15.Mini-Mental State Exam = 24.Fluent in English.generally healthy grade 1-2 school children\nwith written parental consent\nwith at least 1 sound and fully erupted permanent first molarAmerican Society of Anesthesiologist (ASA) status I-II adult patients undergoing elective laparoscopic cholecystectomy.Elective surgery for thoracic aneurysmDSM-IV or DSM-5 diagnosis of schizophrenia or schizoaffective disorder\nMale or Female\nAge: 18 to 65 years\nCaucasian or Non-Caucasian\nSmoke at least 10 cigarettes daily\nUrine cotinine level ?100 ng/ml (NicAlert(r) reading ?3)\nAgrees to wear a head mounted display (HMD) for up to 45 minutes\nAble to complete the Evaluation to Sign Consent (ESC) with minimum score of 80%planned sequential both-sided lower third molar extraction (split-mouth) with osteotomy (with or without upper molar extraction in local anesthesia)\nable to understand the study and the NRS scaleMale participants between 18 and 40 years-old\nWritten informed consent signed by the participantVestibular schwannoma advised to surgical treatment\nNo measurable remaining vestibular functionMale\n18 years of age\nPresenting with hernia requiring surgical interventionChildren aging between 3 and 6 years\npresenting good health conditions\nwhose parents or legal guardians accept and sign the consent form\nwith at least one occlusal or occlusal proximal caries lesion in primary molars\nonly occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvementPatients both sexes\nAge between 31 and 60 years\nDiagnosis of diabetes according ADA criteria:Clinical diagnosis of calculous cholecystitis.1.Males and females age \xe2\x89\xa518 years in second relapse or refractory.2.Males and females age \xe2\x89\xa560 years in first relapse or refractory.3.Must have baseline bone marrow sample taken.4.Morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS with \xe2\x89\xa520% bone marrow or peripheral blasts), as defined by the World Health Organization (WHO) criteria, confirmed by pathology review at treating institution.5.Able to swallow the liquid study drug.6.ECOG performance status of 0 to 2 \n7.In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents.The use of chemotherapeutic or antileukemic agents other than hydroxyurea is not permitted during the study with the possible exception of intrathecal (IT) therapy at the discretion of the Investigator and with the agreement of the Sponsor.8.Persistent chronic clinically significant non-hematological toxicities from prior treatment must be \xe2\x89\xa4Grade 1.9.Prior therapy with FLT3 inhibitors is permitted, except previous treatment with AC220.10.Serum creatinine \xe2\x89\xa41.5 \xc3\x97 ULN and glomerular filtration rate (GFR) > 30 mL/min \n11.Serum potassium, magnesium, and calcium levels should be at least within institutional normal limits.12.Total serum bilirubin \xe2\x89\xa41.5 \xc3\x97 ULN \n13.Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) \xe2\x89\xa42.5 \xc3\x97 ULN \n14.Females of childbearing potential must have a negative pregnancy test (urine \xce\xb2-hCG).15.Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.16.Written informed consent must be provided.1.Male and female subjects must be 18 years of age or older and ambulatory.2.Females of child-bearing potential (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test.3.A documented history of severe Symptomatic Orthostatic Hypotension (SOH) that, in the judgment of the treating physician, has required treatment with midodrine HCl , and has been at a stable dose for at least 3 months.4.The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out.American Society of Anesthesiologists Classification I-III\nNormal cognitive function in order to sign written, informed consent and to understand trial protocol\nAgreement to the trial protocol, including the randomized mannerAge = 18 years of either gender\nWritten informed consent must be obtained before any intravitreal injection of bevacizumab is performed\nVisual impairment predominantly due to abnormal new vessel ingrowth and/or macular edema.The presence of fluid (intraretinal, subretinal or sub-RPE) detected clinically or on the ocular coherence tomography.Post menopausal women with a history of estrogen positive breast cancer who are receiving aromatase inhibitors for at least one month.Patients must complain of mild to moderate arthralgia.Ability to understand and sign informed consent.Patients meet criteria for low to moderate risk for moderate exercise based oon the ACSM guidelines.patient 18 years old and more\nwith multiple sclerosis according to the criteria of Mac Donald 2010 : relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP)\nfor which treatment with dimethyl-fumarate has been prescribed\nfollowed at the Rothschild Foundation in the Neurology Department\nhaving given written consent to participation in the studyAbility to understand and the willingness to sign a written informed consent document\nAge= 18 and= 75 years\nClinical/ Histological/ cytological/ Imaging examination proven Oral/Oropharynx Squamous-cell carcinoma (Tongue, buccal mucosa, mouth floor, hard palate, Molar area), the depth of invasion > 4mm in preoperative assessment\nIn line with clinical stage I / II stage (T1-2 N0 M0; AJCC 2010) and receiving surgical resection\nKPS= 70\nNormal bone marrow reserve function and normal liver, kidney function\nExpected survival period= 6 monthsPatients older than 18 years\nClassification of the American Society of Anesthesiologists (ASA I-III)\nNo cognitive deficits\nSigned informed consent prior to surgeryBody mass index (BMI): 18 \xe2\x89\xa4 BMI \xe2\x89\xa4 32 kg/m\xc2\xb2 \nPostmenopausal state revealed by: \nMedical history, if applicable (natural menopause at least 12 months prior to first study drug administration; or surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administration), in addition: in women < 65 years old, follicle stimulating hormone (FSH) > 40 IU/Lwomen and men between 18 - 80 years of age\ntype 2 diabetes mellitus\nearly to moderate stage diabetic retinopathy (ETDRS: 20 (microaneurysms only) to 35 (microaneurysms/ hemorrhages and/or hard exsudates)) in one or both eyes\nstable HbA1c (\xc2\xb1 0.5%) for at least 12 weeks\nantidiabetic treatment with either diet, metformin, DPP4, GLP1, pioglitazone, acarbose, or respective combinations\nHbA1c = 6.5 and = 10.0 %\nbody mass index < 46 kg/m2\noffice blood pressure = 150/95 mmHg (confirmed on a second day; 24h ambulatory blood pressure measurement (ABPM) is allowed to check accuracy of office values; inclusion with 24h mean blood pressure = 145/90 mm Hg is possible); patients with hypertension should be treated according to current treatment guidelines\nat least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy\nhysterectomy\n= 50 years and in postmenopausal state > 1 year\n< 50 years and in postmenopausal state > 1 year with serum follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or women of childbearing potential with a negative serum beta human chorionic gonadotropin (\xc3\x9f-hCG) pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 4 days following the last administration of study medication:\ncorrect use of one of the following accepted contraception methods: hormonal contraceptives (combined oral contraceptives, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUD/IUS) or a double barrier method, e.g.condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository)\ntrue abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)\nsexual relationship only with female partners\nsterile male partners\nsigned written informed consent and willingness to comply with treatment and follow-up procedures\ncapability of understanding the investigational nature, potential risks and benefits of the clinical trialcurrent diagnosis of narcolepsy with cataplexy OR healthy controlChildren receiving amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) due to acute otitis media or acute sinusitispatients who underwent successful TAVI\nwith any approved TAVI device\nvia transfemoral access\nwith use of any of the approved vascular closure devices\nprovided written informed consentPatients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy \nThe patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present) \nPatients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry \nMust have a life expectancy of greater than three (3) months \nKarnofsky Performance Status > 60 \nFemale patients must have a negative serum pregnancy test at screening.(Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.)age=65 years\ndiagnosis with mantle cell lymphoma\nAnn Arbor stage II,III or IV\nECOG=1 or if ECOG=2 but recover after pretreatment.full term singleton pregnant women\nScheduled for elective Cesarean Delivery\nAged between 18 and 40 yearshistory of significant bleeding (i.e.bleeding which required intervention or hospitalization), even in the absence of anticoagulation treatment at the time of the bleeding event, or\na cardioembolic event, which occurred on anticoagulation, or\na high risk profile of the patient, defined as a CHA2DS2-VASc score = 3 and a HAS-BLED score = 2Current DSM-IV diagnosis of cannabis dependence, >1 week detoxified and abstinent;\nAble to provide written informed consent and to comply with study procedures.Dutch speaking (Dutch as primary language).Be scheduled for trans-jugular liver biopsy the day of the ultrasound procedure.Be at least 21 years of age.Be medically stable.If a female of child-bearing potential, must have a negative pregnancy test.Be conscious and able to comply with study procedures.Have read and signed the IRB-approved Informed Consent form for participating in the study.Symptomatic patients with heart failure (men and women) aged >18 years,\nFunctional class II, III or IV by the New York Heart Association (NYHA)\nLeft ventricular ejection fraction <35%\nIschemic and nonischemic etiology\nType B natriuretic peptide (BNP) >150 pg/ml (or pro-BNP [N-terminal-proBNP] = 600 pg / ml) or if the patient was hospitalized for cardiac decompensation within the preceding 12 months, BNP >100 pg/ml (or N-terminal-proBNP = 400 pg / ml)moderate to severe Crohn's Disease (basic HBI = 7) with stenosisMale or female subjects aged =18 to =65 years\nGeneral good health as established by medical history and physical examination\nWritten informed consent\nFemales of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study.Abstinence is acceptable.Available for all visits scheduled in this study.full term\nsingleton pregnant women\nscheduled for elective cesarean deliverySingle unit implant rehabilitation\nMaxilla and mandible\nMust accept treatment plan\nMust sign informed consent\ndental extraction performed at least 3 month prior\nMust have at least 6 mm of residual bone\nAbsence of oral lesions\nkeratinized tissue must be presentPatients with a confirmed diagnosis of: \n1.Stage 4 colon cancer either s/p metastasectomy or post-initial chemotherapy or maintenance "standard of care", either involving 5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab alone.Patients in maintenance cohort must have had 2 consecutive CT scans showing stable disease and not be experiencing significant prior treatment-related toxicity above Grade 1.2.Pancreas cancer, either s/p resection and adjuvant chemotherapy or locally advanced pancreas cancer s/p chemotherapy and radiation.Initial chemotherapy or radiation therapy may have been stopped between 2 weeks and 2 months prior to study start, and patients must have recovered from prior treatment related toxicity to grade 1 or less.Prior surgery, including tumor resection or metastasectomy must have been performed at least 4 weeks prior to study enrollment.No concomitant anti-cancer treatment is allowed \nAge >/= 18 years \nPerformance status of 0-1 \nAdequate hepatic, bone marrow, and renal function \nPartial thromboplastin time (PTT) must be </= 1.5 x upper normal limit of institution's normal range and INR (International Normalized Ratio) < 1.5.Life expectancy >/= 4 months for maintenance cohorts and >/= 6 months for adjuvant cohorts \nWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and must not be lactating.Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consenttreatment-naive patients with B-cell lymphoma\nHBsAg positive at baseline\ntreated with rituximab-based immunochemotherapy\nlife expectancy of more than 3 monthsProvision of fully informed consent prior to study specific procedures.Patients must be >= 19 years of age\nRET fusion positive or FGFR2 fusion/other FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy.ECOG Performance status0-2\nHave measurable or evaluated disease based on RECIST 1.1 as determined by investigator.Absolute neutrophil count >= 1.5 x 109/L, Hemoglobin >= 9g/dL, Platelets>=100 x 109/L Bilirubin <= 1.5 x upper limit of normal AST/ALT <= 2.5 X upper limit of normal(5.0 x upper limit of normal, for subject with liver metastases) Creatinine<= 1.5 X UNL\nPatients of child-bearing potential should be using adequate contraceptive measures should not be breast feeding and must have a negative pregnancy test prior to start of dosing\nAdequate heart functionsatisfying DSM-V criteria for ED and for half of the patients in addition \nhave a history of childhood trauma.3-17 years\nweight </= 100kg\nscheduled for urologic or orthopedic procedure necessitating intrathecal morphine\nability to use verbal or pictorial pain assessment tools and techniques\ninformed consent and (if applicable) assentAdult outpatients (18 years or older)\nroutinely referred for small bowel video capsule endoscopy (CE)Before participate in the study, patients must understand the treatment plan and willing to participate in the study.Patients must have signed an approved informed consent.Histopathologic confirmed squamous cell carcinoma of head and neck ,including oral cavity, oropharynx, larynx, or hypopharynx.Ages=65 years,Not limited to gender.ECOG performance status =2.Patients with surgical contraindication or reject to surgery.Postoperative TNM(primary tumor,regional nodes,metastasis) staging III~IV, positive surgical margin.without evidence of distant metastases.No contraindication to chemoradiotherapy.Life expectancy > 3 months.Available Organ function: white blood cell=3.5\xc3\x97109/L, Neutrophils =1.5\xc3\x97109/L, Hemoglobin =80g/L, Blood platelet>100\xc3\x97109/L; Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)= 2.5 upper limit of normal(ULN); Total bilirubin (TBIL) <1.5 ULN;serum creatinine=1.5 ULN; creatinine clearance of = 50ml/minSouth Australian secondary school students in years 10, 11, and 12 in 2017\nWritten parental consent for those under the age of 18\nWritten student consent assent for those under the age of 18 (or if 18 years old and older consent for themselves)\nAvailable at school for at least the first pharyngeal swab and willing to comply with study proceduresHealthy patients age 18 and older\nBreech presentation\nSingleton gestation .scheduled for ECV desiring CSE.Probable or definite diagnosis of autoimmune hepatitis according to the International Autoimmune Hepatitis Study Group criteria\nFirst presentation of AIH requiring treatment according to the current EASL guidelines\nAge = 18 years\nMust provide informed consent and agree to comply with the trial protocolAll patients admitted to the ICU in septic shock\nAll patients that develop septic shock while in the ICUAged over 18\nPrimary symptom of chest pain\nNo contraindication to CTA\nWilling and able to provide written informed consentASA I and II women\n18-45 yrs old\nSingleton pregnancy\nCervical cerclage 1st or 2nd trimester of pregnancy undergoing with spinal anesthesia\nHeight 150 - 180 cm\nBMI = 40 kg/m2.males and females greater than or equal to 18 years of age\ncurrent regular user of e-cigarettes (use at least once daily for the past 30 days) with nicotine strength > 6mg/ml\nhealth medical history\nabstinent from any tobacco/nicotine use for 4 hours prior to imagingAge between one year and 18 years\nSepsis due to MDR or minimally susceptible gram-negative bacteria\nHistory of MDR gram-negative infection or sepsis due to organisms sensitive to colistin.Culture result consistent with MDR gram negative for this febrile neutropenic episode.Patient in sepsis and colistin was administered empirically to increase antibiotic coverage.1.Women 18 to 40 years of age inclusive who can give written informed consent \n2.Available for all visits and consent to follow all procedures scheduled for the study \n3.Agree to daily application of gel and monitoring as per Daily Monitored Adherence (DMA) method \n4.Healthy and self-reported sexually active \n5.HIV-negative as determined by a HIV rapid test at time of enrollment \n6.On a stable form of contraception and willing to continue on this stable method of contraception, OR, Have undergone surgical sterilisation at least 3 months prior to enrollment \n7.In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses \n8.Upon pelvic/speculum examination and colposcopy at the time of enrollment, the cervix and vagina appear normal as determined by the investigator \n9.Asymptomatic for genital infections at the time of enrollment \n10.Willing to refrain from use of vaginal products or objects within 14 days prior to enrollment and for the duration of the study \n11.Willing to answer acceptability and adherence questionnaires throughout the study \n12.Willing to refrain from participation in any other research study for the duration of this study \n13.Willing to provide adequate locator information for study retention purposes and be reachable per local standard proceduresIntrauterine fetal death as confirmed by absence of cardiac motion on ultrasound by Attending physician at the time of admission to the hospital.Estimated gestational age greater than 20 weeks\nHemodynamically stable and appropriate for induction of labor as per primary clinical health team in house\nWomen with one prior low transverse cesarean deliveryMen or women, 18 to 65 years old with a BMI of 35 kg/m2 or greater who will be undergoing bariatric surgery (VSG and RYGB)\nSigned written informed consent\nWomen of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug\nWomen must not be breastfeedingpatients with FEV1 / FVC <70%patients undergoing venous malformation embolization operation through general anesthesia.aged 18-65 years old.operating time varies 1-4h,and extubation after the operation.Age greater than or equal to 18 years\nHave RA, as defined by the 1987 revised American College of Rheumatology criteria\nIn sustained clinical remission for the last 6 months while receiving treatment with either etanercept, infliximab, or adalimumab, and greater than or equal to 1 DMARD (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine).DAS28 should be less than 2.6 on each visit over the preceding 6 months, with at least one visit 2-4 months before enrollment.If there is no visit 6 months before enrollment, the nearest visit in the 6-12 month period before enrollment should be considered and have a DAS28 less than 2.6.Subjects chronically infected with HCV Genotype 1 \nHCV RNA viral load of \xe2\x89\xa5 10*5* IU/mL (100,000 IU/mL) at screeningAdult kidney transplant recipients > 18 y.o.Kidney Transplant recipients, after the first episode of cytomegalovirus infection, using the current immunosuppressive regimen: azathioprine or mycophenolate, tacrolimus and prednisone.Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II.Informed consent of parent(s) or legal guardian; informed consent or assent of subject as applicable.Male or female children between the ages of 10 and 35 years with congenital heart disease that has been palliated with a Fontan circulation.Ability of perform a maximal exercise test as defined by a respiratory exchange ratio (RER) greater than 1.0 at the time of maximal exerciseAge over 18 years\nPatients with rectal cancer stage: cT1-2-3, cN0-1, cM0.Tumor equal or below 10 cm from the anal verge, candidates to (ETM) low anterior resection and anastomosis, with or without preoperative chemo-radiotherapy.Adenocarcinoma of low or moderate differentiation\nASA I, II, III.Scheduled to undergo revision total knee arthroplasty> 18 years old\nAcute symptomatic BV\nSigned informed consent\nInsufficient knowledge of German\nIlliteracy\nPregnancy\nAcute illness\nKnown allergies against ingredients of the investigational productsInformed consent\nDiagnosis of type 2 diabetes (HbA1c > 48 mmol/mol)\nAge older than 30 yearsCurrent diagnosis of otolaryngeal cancer and undergoing surgery with general anesthesia\nCompetent to provide informed consentScheduled for bilateral varus rotational osteotomy (VRO) with or without associated soft tissue and osseous proceduresSymptomatic primary knee osteoarthritis with failed conservative treatment at least 3 months\nKellgren-Lawrence grade I-III\nGave informed consent\nCan do questionnairesMale \nAge between 18 and 49 years old; \nWilling to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications); \nWilling to strictly follow the study protocol; \nCapacity for understanding and signing in the Informed Consent Form; \nTo understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion; \nIntellectual level which allows to filling in the diaries for registering of symptoms at home; \nWilling to undergo to serological testing to HIV, HBV and HCV; \nBeing in good health, with no significant medical history; \nPhysical examination at screening period without clinically significant changes; \nLab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision.1.Patient is over 18 years old.2.Patient is scheduled for a non-emergency procedure.3.Subject signs and dates a written informed consent form (ICF) and indicates an understanding of the study procedures.Age = 15 years old\nHospitalization with acute undifferentiated fever (temperature > 37.5 C, tympanic) =14 days or patients admitted to hospital with a history of fever = 14 days who subsequently develop fever within 24 hours of admission\nClinically suspected scrub typhus: defined as acute undifferentiated fever with no clear focus of infection and negative malaria blood smear and/or negative malaria RDT.Patients may have one, none, or a combination of other clinical findings such as eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal discomfort.A positive scrub typhus RDT (Scrub Typhus IgM RDT, InBios International, Seattle, WA, USA) and/or positive PCR-based detection of O. tsutsugamushi DNA from the admission blood sample\nWritten informed consent and/or, written informed assent as required\nAble to take oral medicationCorneal ulcer that is smear positive for either bacteria or filamentous fungus\nPinhole visual acuity worse than 20/70 in the affected eye\nNot treated already with antimicrobial medications at presentation\nAge over 18 years\nBasic understanding of the study as determined by the physician\nCommitment to return for follow up visitsPatients are of American Society of Anesthesiologists (ASA) physical status I and II, aged 8-14 years old, of both gender, with suspected acute appendicitis scheduled for laparoscopic appendicectomy.Undergoing mid-urethral sling surgery\nHave symptoms of both stress and urgency urinary incontinence\nAble to consent, fill out study documents, and complete all study procedures and follow-up visits\nAt least 18 years of age\nEnglish speaking\nBe able and willing to learn clean intermittent self catheterization technique18 years or older patients who are proven to be infected by Helicobacter pylori based on positive in Urea Breath Test or positive in histopathologic examination of biopsy in antrum and corpus of gaster through esophagoduodenoscopy.Aged 18 years or older\nPreviously taken one or more statins\nWithdrawn from statins because of perceived side effects\nDeveloped side effects within 2 weeks of initiation\nClinical indication for statins for primary or secondary prevention of cardiovascular disease or dyslipidaemia, on either no medication or non-statin lipid lowering therapy (e.g, ezetimibe)The patients signed the written informed consent\nThe patients present with operable unilateral invasive breast cancers without distant metastasis(stage I, II, and III)\nThe breast tumor's positive ER/PR rate is <1%, and positive ER-beta1 rate is =10% by IHC.The patients have no history of neoadjuvant hormone therapy.The patients have normal cardiac functions by echocardiography.The patients' ECOG scores are =0-2.Female patient who is = 18yrs, and = 65yrs.The patients are non-pregnant, and disposed to practice contraception during the whole trial.The patients underwent neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection) after diagnosis of breast cancer.The patients underwent chemotherapy, radiation therapy or targeted therapy(herceptin) after surgery according to the 2013 NCCN guideline.The results of patients' blood tests are as follows:Healthy\nMale\n>7 Metabolic Equivalents\nWritten informed consent\nChronic pain syndrome\nDrug abuse\nAlcohol abuse\nSuspicion of neurologic dysfunction at tested sites\nOngoing treatment with antidepressants\nOngoing treatment with analgesics\nPretreatment with any CYP3A inducers or inhibitors\nKnown allergy to tested drugs\nElevated eye pressure\nObstructive uropathy\nHeart disease\nPulmonary disease\nNeurological disease\nPsychiatric illnessDiagnosis of emphysema confirmed by CT scan.If a report of past CT scan is not available at site documenting then a CT scan is to be performed at screening \nMale or female patients at least 18 years of age.Able and willing to sign an informed consent.Patient with record of congenital AAT deficiency of phenotype PiZZ (homozygote) or other rare phenotypes related to AAT deficiency and with AAT serum level \xe2\x89\xa4 11 micromole.For patients receiving IV AAT augmentation therapy the serum AAT level threshold does not apply.FEV1/SVC <70% of predicted value post bronchodilator (SVC is slow VC) and FEV1 < 80% of predicted value post-bronchodilator \nHistory of at least two moderate or severe exacerbations that required change in treatment (antibiotics, systemic steroids, hospitalization) in the last 18 months prior to date of screening , with at least one of these occurring within the last 12 months prior to screening.Ability to comply with completion of electronic diary.Ability to self-administer inhaled AAT.No significant abnormalities in serum hematology, serum chemistry and serum inflammatory / immunogenic markers according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.No significant abnormalities in ECG per investigator judgment.Negative for HBsAg and for antibodies to HCV, HIV-1.AAT deficient patients who are either na\xc3\xafve (not receiving IV augmentation therapy) or AAT deficient patients (receiving IV augmentation therapy), if they have been stable on regular therapy for at least 3 months prior to the screening visit and are willing to continue the same regime throughout this trial.Note that only sites in Germany can recruit patients who are currently being treated with IV AAT.Patients who stopped IV augmentation treatment 6 months prior to screening date and will not re-start this treatment for the course of the study will be considered Na\xc3\xafve.Non-pregnant, non-lactating female patients, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator, or who are at least 2 years post-menopausal or surgically sterilized.Diagnosis of sacroiliitis\nAge 18 to 80 years old\nChronic low back pain\nSI joint pathology is the predominant source of pain\nPositive Fortin Finger Test (PMT)\nJoint anatomy is identifiable using ultrasonography\nPatient has no other comorbidities that contraindicate the procedure\nPatient has attempted physical therapy and corticosteroid injections with local anesthetic -Previous injections of lidocaine and corticosteroid provided at least minor immediate relief\nPatient must not have had a corticosteroid injection in the SI joint within the last three months\nPatient must consent to the procedureAll children scheduled for outpatient MRI scans with expected duration of scan between 30 minutes and 75 minutes.Aged 5 years to less than 12 years at Visit 1.At least 15 (25%) children of the total study population must be aged 5 to less than 8 years.Male or pre-menarchial female subjects.Subjects must be pre-adolescent without any signs of puberty (Tanner Stage 1).Normal range for their height and weight.Weight and height measurements should fall within the percentile range 3-97% of normal values for age according to Danish growth charts.Have a documented diagnosis of persistent asthma, as defined by the National Institutes of Health for at least 3 months prior to the Screening Visit.A pre-bronchodilatory forced expiratory flow in 1 second (FEV1) at Visit 1 (Screening) >=80% predicted.There should be no Short acting beta-agonist (SABA) use within 4 hours of this measurement.Using one of the following asthma therapies prior to entry into the study: SABA inhaler alone (e.g.salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g.cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <=400 micrograms (mcg) total daily dose).There must be no ICS use within 2 weeks of Visit 1 (Screening).Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study.Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement.The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC).(2) Subject and their legal guardian(s) understand that the study requires them to be treated on an outpatient basis.(3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call.Male or Female.No age restriction.Diagnosed with an infection related stone.Medically fit for definitive surgical management of stone.Life expectancy greater than one year.Stone free after definitive surgical therapy defined as fragments less than 3mm.Signed written informed consent.Age 18 to 65.Normal and healthy (immune competent) as determined by medical history, physical exam, vital signs and clinical laboratory tests during the screening period.If all lab results for quantitative IgA immunoglobulin level are lower than 15% below normal range, the subject may not proceed further in the screening process.Subject must meet all required subject suitability criteria that pertain to normal source plasma donors.Negative HIV serology during screening period.Subject must have been previously immunized for smallpox, at =3 years prior to commencement of screening assessments, and vaccination history must be confirmed by oral or written history and the presence of a visible pathognomonic smallpox vaccination scar.Female subjects of childbearing potential must agree to use highly effective birth control methods.Ultrasound confirmed complete moleprimary total knee replacement surgery\nASA (american society of anesthesiologists) class 1-3Primary B-NHL, PTCL (ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma were excluded) or HL patients confirmed by histopathology;\nAges =18 years old, < 80 years old;\nECOG (Eastern Cooperative Oncology Group)score: 0-2\nAt least one measurable lesion;\nExpected survival time=3 months;\nLiver function: transaminase=2.5\xc3\x97 upper limit of normal value,bilirubin=1.5\xc3\x97upper limit of normal value;\nRenal function: serum creatinine is 44-133 mmol/L;\nRoutine blood test:WBC=3.0\xc3\x97109/L,Neutrophils=1.5\xc3\x97109/L,Hb=100g/L,Platelet=80\xc3\x97109/L; LVEF=50%;\nNew York Heart Association (NYHA) heart function classification is I-II grade\nsigned informed consent.Age = 18 years\nAmerican Society of Anesthesiologists Classification I-III\nNormal cognitive function in order to sign written, informed consent and to understand trial protocol\nAgreement to the trial protocol, including the randomized mannermajor depressive episode in type2 bipolar disorder or bipolar disorder NOS.(MADRS more than 20 point)\n18years to 65years\nsubjects who sign the informed consent documentAge 18 or older.Patients diagnosed with acromegaly with GH-secreting pituitary adenoma on sellar MRI, meeting the biochemical criteria outlined above (refer to 1.Diagnosis of acromegaly) and with typical acromegalic features.No prior use of somatostatin analogues.Adequate hepatic and renal function\nProvision of a signed written informed consentWomen be at least 18 years of age\nHave symptoms of vaginal odor and or/discharge\nMeet the clinical (Amsel) criteria for BV\nWilling to participate in researchASA (American Society of Anesthesiologists) class 1 & 2,\nundergoing day-case knee arthroscopy1.Males and females \xe2\x89\xa5 18 years old.2.Clinical diagnosis of type 1 diabetes for at least one year.3.The subject will have been on insulin pump therapy for at least 3 months and currently using a fast actin insulin analog (Lispro, Aspart or Guilisine).4.Last (less than 3 months) HbA1c \xe2\x89\xa4 10%.5.Currently using carbohydrate counting as the meal insulin dose strategy.adult female partner\naged 18 to 40 years.scheduled for elective cesarean section.Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trialDiagnosis of DSM 5 Anxiety Disorder\nStable medical history and general health\nOn stable anti-parkinsonian therapy for 2 weeks before enrollmentPregnant women admitted to Women health hospital with a diagnosis of severe pre-eclampsiaMetabolic Syndrome (ATP III)\nModerate to severe OSAAll infertile women treated with intracytoplasmic sperm injection (ICSI)/Fertilization in Vitro and Embryo Transfer (FIVET)\nLess than or equal to (<=) 1 previous failed embryo transfer\nEumenorrheic normo-gonadotropic women\nBasal follicle-stimulating hormone (FSH) <=12 International unit per liter (IU/L)\nAnti-mullerian hormone (AMH) greater than (>) 1.1 nanogram per milliliter (ng/mL)\nOvarian Reserve: number of antral follicles 2 millimeter (mm) between 6 <= antral follicle count (AFC) <= 16\nFollicles > 16 mm at the triggering day between 5-14\nBody Mass Index (BMI) between 18 <= BMI <= 27 kilogram per meter square (kg/m^2)\nIndication for Fresh Embryo transfer\nNormal uterine cavity on ultrasound exam (e.g., no presence of hydrosalpinx)\nUndergoing Assisted Reproductive Technique (ART) and oocyte maturation by human chorionic gonadotropin (HCG) triggering\nProgesterone (P4) serum level at the HCG triggering day <= 1.5 ng/mL (Day O/Randomization)\nEstradiol (E2) <= 3000 picogram/milliliter (pg/mL) at the human chorionic gonadotropin (HCG) triggering day (Day 0/Randomization)\nSubjects must have read and signed the Informed Consent Form prior to study-specific-procedures not part of standard of care\nOther protocol defined inclusion criteria could applyAge = 65 years with one additional stroke risk factor (hypertension, diabetes, heart failure history of or left ventricular ejection fraction <0.40), previous stroke or transient ischemic attack).Atrial fibrillation and not on oral anticoagulation (OAC) therapy but eligible\nAtrial fibrillation on sub-optimal OACHealthy adults 30- 65 years old,\nBMI 25-35 kg/m2,\nnondiabetic as defined by fasting plasma glucose <126 mg/dL\nLipids: one group with an LDL =/>130 and Triglycerides < 150 mg/dL The 2nd group will have and LDL=/>130 mg/dL and Triglycerides =/>150 mg/dL but less than 400 mg/dL.Meibomian Gland Dysfunction\nEligible for heat treatment\nOcular Surface Disease Index (OSDI) >12\nQuality or expressibility score =20 years old: >1 or >20 years old: =1\nNon-invasive tear film break-up time (NITBUT) <10 s in at least one eye\nSchirmer-1 test >5 mm after 5 minInformed consent as documented by signature (see informed consent form)\nPrimary ITP according to the definition of Rodeghiero et al.(52) and a platelet count of <30x109/l\nAge range: 18-45 years\nPreviously treated patients, with failure or intolerance to first-line therapy, or relapse after first-line therapy, i.e.corticosteroids, intravenous immunoglobulin (IVIG), or anti-D immunoglobulinsChronic hepatitis B,\nAntiviral experienced,\nCurrently on long term TDF anti-HBV treatment,\nHBV DNA < 6 log IU/ml (LLOD)\nAble to sign the consent form of anticipating in the studyPrimary periampullary tumor\nR0, R1 resection\nChronic pancreatitis requiring pancreatoduodenectomyPatients aged of 18 and over,\nSatisfying the 1987 American College of Rheumatology (ACR) criteria for RA\nReceiving a prescription of Adalimumab 40 mg subcutaneous every two weeks.Motor complete tetraplegia for at least 3 months\nAge from 18 to 74 years\nBody mass index (BMI) from 18 to 35kg/m2\nInformed consent as documented by signatureWomen with expected difficult IUD insertion like nulliparous women and women with previous cesarean section.age <2 years\nindication of general anesthesia with tracheal intubation\ninhalational induction scheduled\nwritten informed consent of both parentsSubjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.A male or female aged 61 years or above at the time of the first vaccination.Written informed consent obtained from the subject.Healthy subjects or subjects with well controlled underlying disease.HbA1c > 13.0 %\nNo treatment with insulin or oral agents for 6 months\n20 = Age < 80 yearsNo response to more than one antiarrhythmic drug, or unwilling to receive long-term drug treatment.Can provide informed consent form expressing willingness to participate in the study and comply with follow-up tests and evaluation procedures.Aged 18-80 years.Aged 18 years or older\nScheduled for invasive coronary angiography1.Patients \xe2\x89\xa5 18 years-old from "Instituto Telet\xc3\xb3n Santiago" and "Hospital Cl\xc3\xadnico Mutual de seguridad".2.C5 to T12 spinal cord injury, classified as ISNCSCI grades C and D \n3.Traumatic and non-traumatic, non-progressive lesions \n4.Onset > 6 months \n5.Ability to ambulate with or without assistive devices \n6.Ability to follow verbal or visual commands \n7.Signed informed consentnon-valvular atrial fibrillation\nnondiabetic patients\ntype 1 and 2 diabetic patientsAll patients admitted to the Duke CICU, who require intubation and sedation for mechanical ventilation that is expected to be >24 hours in duration will be included, unless they meet the specified exclusion criteria.Patients intubated within one hour prior to care transition to the CICU will also be screened for inclusion.Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e.women of child bearing potential are not allowed to be included into the study.In cases of doubt a pregnancy test should be performed.(NB -post menopausal women currently receiving hormone replacement are permissible) \nAcute myocardial infarction < 12 h defined as: \n1.Angina or equivalent symptoms > 20 min and \n2.ST elevation in 2 contiguous ECG leads (= 2 mm precordial lead, = 1 mm limb lead).This ECG recording serves as baseline ECG, i.e.ECG I.Planned primary percutaneous coronary intervention \nThe subject has given written informed, dated consent to participate in the studyPregnant patients who require a scheduled or non-urgent cesarean birth\nPatient able to receive neuraxial analgesia\nPatient able to give verbal and written consent for both cesarean birth and studyNonsurgical neonates and babies up to age 6 months with INR 1.5 or more who are deemed clinically to need plasma infusion.Patients undergoing laparoscopic assisted donor nephrectomy\nPatients that have elected to have a nerve block\n18 years of age or older\nPatients of ASA status I - IIIAge 3 to 18 years on day of surgery\ndiagnosis of spinal deformity\nundergoing elective posterior spine multi-level instrumentation surgeryType 1 diabetes according to ADA criterias <5 years.Age= 18 years and less than 70 years.Non-obese: defined as BMI less than 28 kg/m2\nPositive for at least one of the anti-islet autoantibodies: GADA, IA2A, ZnT8A\nFasting or postprandial plasma C-peptide more than 100 pmol/L\nWritten informed consent from the patient or family representative.Planned non-cardiac surgery at least after 12 months of implantation of drug eluting stent\nLow or intermediate risk level surgery\nWritten informed consentDiagnosis of sickle cell disease \nClinically significant disease defined as at least 1 painful episode per year averaged over the previous 3 years or a history of priapism, stroke, acute chest syndrome, avascular necrosis, multi-organ failure or the need for chronic narcotic medications for pain from sickle cell disease \nMust have failed a previous attempt at treatment with hydroxyurea defined as the inability to achieve a significant absolute increase in % fetal hemoglobin or the inability to tolerate hydroxyurea treatment due to severe side effects such as but not limited to myelosuppression, gastrointestinal symptoms, edema or hepatic enzyme elevations or have contraindications to hydroxyurea \n18 years of age or older \nHematologic laboratory values as outlined in the protocol \nNon-hematologic laboratory values as outlined in the protocol \nMust agree not to donate blood or other bodily fluid while taking the study drug and for 28 days thereafter \nWomen of child-bearing potential (WCBP) must have a negative serum pregnancy test 72 hours or less prior to starting treatment \nWomen of child-bearing potential and men must agree to use 2 forms of adequate contraception prior to study entry and for the duration of study participation1.Age: 18 years and older.2.Sex: Male and non-pregnant, non-lactating female \n1.Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration.If dosing is scheduled on Sunday or Monday, the HCG pregnancy test should be given within 48 hours prior to dosing of each study period.An additional serum (Beta HCG) pregnancy test will be performed upon completion of the study.2.Women of childbearing potential must practice abstinence or be using an acceptable form of contraception throughout the duration of the study.Acceptable forms of contraception include the following: \n(1) intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or (2) barrier methods containing or used in conjunction with a spermicidal agent, or (3) postmenopausal accompanied with a documented postmenopausal course of at least one year or surgical sterility (tubal ligation, oophorectomy or hysterectomy).3.During the course of the study, from study screen until study exit - including the washout period, women of childbearing potential must use a spermicide containing barrier method of contraception in addition to their current contraceptive device.This advice should be documented in the informed consent form.3.Weight: At least 60 kg (132 lbs) for man and 48 kg (106 lbs) for women and within 15% of Ideal Body Weight (IBW), as referenced by the Table of ""Desirable Weights of Adults"" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).4.All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, 12-lead ECG, hepatitis B and hepatitis C tests, HIV test, and urine drug screen including amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication.Females 18-65 years old who undergoing colposcopic directed biopsyParticipants having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy.Confirmed diagnosis (clinical and histological features) of Hailey Hailey or Darier diseases.Moderate to very severe lesions located in large folds \nPatient aged 18 ans or more \nPatient with health coverage \nPatient who have signed the consent form \nPatient proficient into filling out the questionnaires.all adult patients with a nasal or facial skin/soft tissue defect requiring reconstruction limited to or including a full-thickness skin graftSubject or legal representative has voluntarily signed the informed consent approved by the Institutional Review Board,\nHip fracture surgery scheduled under general anesthesia\nSubject is 65 years or older on the day of surgeryacute myocardial infarction or \nischemic cardiomyopathy with or without previous myocardial infarction or \ndilated cardiomyopathy due to valvular heart disease, hypertensive heart disease, history of myocarditis (no active myocardial infection present)Patients diagnosed with primary biliary cholangitis\nTreated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and suboptimal response to Ursodeoxycholic Acidselective operation of inguinal hernia repair<U+3001>orthopedics operation or general surgery operation in children\naged 3-9 years\nASA I - II\nenter the operating room by himself without parents\nnormal liver and kidney function\nno history of anesthesia medication allergy.=18 years old, men or post-menopausal women (women with no periods for 12 months or more, or those who have had a surgical menopause)\nTreated hypertensive patients with an average daytime ambulatory blood pressure measurement (ABPM) <150/95mmHg on stable doses of one or more antihypertensive medication (at least one of which should be; an ACE inhibitor, angiotensin receptor blocker or diuretic) for 3 months, or untreated hypertensive patients with an average daytime ABPM =135/85 but <150/95.Adult subjects aged 18 years or older\nScheduled for elective posterior lumbar spinal fusion surgery between 1 and 3 levels18-50 ages\nSingleton pregnancy\nCervical length <=25mm between 18(0) and 23(6) weeksAcute Coronary Syndrome group: 40 patients with type 1 myocardial infarction within 21 days prior to the imaging visit and invasive coronary angiography with angiographic evidence of at least a 50% stenosis in one or more coronary arteries.Only patients undergoing PCI will be included in the study.Stable Ischemic Heart Disease group: 40 patients who have undergone invasive coronary angiography within 21 days prior to the imaging visit, with history of typical angina prior to the angiogram, but no prior myocardial infarction or coronary revascularization.have no prior CAD associated event (no prior myocardial infarction, acute coronary syndrome, coronary angiogram, or PCI),\nhave CAC between 10 to <1000, and\nmatch to patients in the ACS group by gender, age by decile, and CAC category (using CAC categories of 10 to <100, 100 to <400, 400 to <1000).Controlled hypertension: systolic BP < 150 and diastolic BP < 90 mmHg in persons aged 60 years or older, systolic BP < 140 and diastolic BP < 90 mmHg in persons 40 through 59 years according to the JNC 8th guideline\nEvidence of diastolic dysfunction showing E/E' > 10\nThe patient agrees to the study protocol and the schedule of clinical and echocardiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical sitePatients needed to pericardiocentesis during RFCA for paroxysmal or persistent atrial fibrillation.Patients = 18 years of age\nSubjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol\nEstablished diagnosis of UC and moderate-to-severe disease activity, defined as a Mayo score of 6-12, with an endoscopic subscore =2.Patients had an inadequate response to, or had failed to tolerate, 1 or more of the following conventional therapies: oral 5-aminosalicylates, oral corticosteroids, azathioprine (AZA), and/or 6-mercaptopurine (6MP); or corticosteroid dependent (ie, an inability to taper corticosteroids without recurrence of UC symptoms).Patients concurrently treated with oral 5-aminosalicylates or corticosteroids were to receive a stable dose for at least 2 weeks before baseline, and patients receiving AZA and/or 6MP were to receive a stable dose for at least 4 weeks before baseline.Patients were required to maintain stable doses of their concomitant UC medications during the study.Female subjects of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 6 months thereafter OR\nSurgical sterilized female patients with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy OR\nPostmenopausal women with postmenopausal defined as permanent cessation >1 year of previously occurring menses.Female subjects' serum pregnancy test performed at the screening visit and urine pregnancy test performed at the baseline visit must be negative.Subjects have following investigations within 1 month prior to enrolment.Routine bloods including U&E, FBC, LFTs, inflammatory markers (CRP) and albumin will be measured.Medical history, concomitant medications\nIntradermal reaction to Tuberculin (PPD skin test) or Mycobacterium tuberculosis antigenspecific interferon-gamma release assay (IGRA)\nTB screening: chest X-Ray unless performed in the last 6 months\nStool examination for enteric pathogens including Clostridium difficile\nInclusion/exclusion criteria\nInformed consent\nMayo score (including sigmoidoscopy unless performed in previous 3 months)\nPatient's weight and height and abdominal circumferenceSevere or uncontrolled infection.Sensitive to the product or other genetically engineered biological products from Escherichia coli strains.Mental or nervous system disorders.Severe heart, lung and central nervous system disorders.Pregnant or lactating women.TBIL(total bilirubin ), ALT(alanine aminotransferase),AST(glutamic-oxalacetic transaminase) > 2.5\xc3\x97ULN(upper limit of normal); if it were caused by liver metastases, TBIL, ALT,AST >5\xc3\x97ULN.Cr(creatinine) >1.5\xc3\x97ULN.35-75 years old;\ndiagnosed as type 2 diabetes according to the criteria of the World Health Organization in 1999.Major spine surgery scheduled as part of clinical care\n18-80 yearsBiopsy-proven LN Class III/IV\xc2\xb1V (ISN/RPS 2003), with biopsy performed within 12 weeks of randomization.Positive anti-dsDNA.Active LN with proteinuria (urine protein/creatinine ratio >1.0 or 24-hr urine protein >1.0 g at baseline), with or without hematuria.Both 'incident' (i.e.new) patients and 'flare' patients can be included.a very high cardiovascular risk and LDL-cholesterol> 1.8 mmol / l\na high cardiovascular risk and LDL-cholesterol> 2.5 mmol / l\nPatient with a high or very high cardiovascular risk treated by lipidlowering therapy with statinDiagnosed Iron deficiency anemia.H-pylori positive cases.Second trimester pregnancy.Previous diagnoses of COPD and HF under optimized clinical treatment as judged by the accompanying physician\nReduced left ventricular ejection fraction (<50%)\nNon-reversible airway obstruction (post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80 %)\nRespiratory muscle weakness (Pi,max < 70cmH2O)\nPersistent dyspnea on daily life (Baseline Dyspnea Index focal score <or= 8).Written informed consent\nAge =18 years\nHas undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgeryMen and women aged 18-45 years.Diagnosis of functional dyspepsia, based on the Rome IV criteria (2016).GIS score of at least 6.Negative H. pylori test .Availability of a signed patient information sheet (Informed Consent form) for participation in the clinical trial.Patients who agree to use an effective method of contraception throughout the clinical trial.self-reported healthy adults between the ages of 18-60 who are fluent in English.Diagnosis of uncomplicated gastroschisis\nGestational age >33 weeks at time of delivery\nWeight >1900g at time of delivery\nTransfer of patient to Riley Hospital for Children prior to any abdominal surgeryOver 18 years of age; Systemically healthy; Non-smoking;\nWith good oral hygiene;\nAbsent irreversible pulpal alteration;\nWith the presence of a non-carious cervical lesion (LCNCs) that needs to be restored.This lesion should be non-carious, non-retentive, with at least 1 mm and up to 3 mm depth, should involve both enamel and dentin of vital teeth without mobility, and present hypersensitivity;\nPresence a natural tooth of the same position of the restored tooth, but in the opposite arch of the same jaw to be considered for the positive control;\nPeriodontal parameters : Depth Probing (PS), Visible Plaque Index (IPV), Gingival Index (GI) and Probing Bleed Index (SS).The normal included were: PS = 1 to 3 mm, GI = 0, IPV = score 0 e SS = score 0.First or second single kidney (cadaveric or living donors) transplant recipients.Considered for a standard immunosuppressive protocol.Must be capable of giving written informed connect for participation in the study for 24 months.Women with a singleton pregnancy undergoing cesarean section after 37 weeks of gestation.Unilateral leg pain secondary to lateral stenosis, disc protrusion or herniated disc.Age between 18 and 80 years.Moderate to severe pain (NVS>4).Right proficient oral and written language.healthy\nno allergy known to these drugs\nsecond trimester abortionAdult patients (18years old or older) undergoing living-donor or deceased-donor liver transplantationHBsAg and HBeAg positive for more than 6 months, HBV DNA detectable with ALT level abnormal lasted for three months and at least time190 IU/L or liver puncture biopsy demonstrated apparent inflammation, never treated before enrolled.age =18 at screening\nnot intending to move away from the clinic's catchment area for the next 2 years\nHIV-1 antibody negative\nreports commercial sex work\ncontact information is provided\nwritten informed consentMale and female patients, age 18-75 yrs.COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 =92% at 750 m.\nBorn, raised and currently living at low altitude (<800m).Written informed consent.Subject is 65 years old who is able and willing to give an informed consent.Patients undergoing planned trans-femoral TAVI.Calculated eGFR below 60ml/min/1.73m2 (MDRD)patients with a diagnosis of either cervical, thoracic, or lumbar facet or sacroiliac joint pain who have responded to medial branch blocks and are already scheduled for bilateral radiofrequency ablations\nage greater than 18 years old\nEnglish speakingWomen with POI: For the purpose of the research women is considered to have POI if she is aged less than 40 years and has amenorrhea of at least 4 month with FSH level above 25 IU/L (repeated twice >4 weeks apart).Male and female subjects between 40-85 years old will be enrolled.Younger subjects are not included as the risk for brain amyloid lesions is too low\nAll subjects will speak English as their first language or demonstrate proficiency in English (defined as reaching a scaled score of > 11 on the WAIS vocabulary test).All subjects will have normal cognition at baseline: a Clinical Dementia Rating CDR=0, Global Deterioration Scale GDS<2.All subjects will be in good general health and able to participate in the LP and imaging exams.This determination is made by the study neurologist and reviewed at a consensus meeting for each subject.Female with a persisting pregnancy of unknown location: \nA pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging.A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa.Ultrasound must be performed within 7 days prior to randomization.Persistence of hCG is defined as at least 2 serial hCG values (over 2-14 days), showing < 15% rise per day, or < 50% fall between the first and last value.Patient is hemodynamically stable, hemoglobin >10 mg/dL \nGreater than or 18 years of ageLocalized intermediate-risk or high-risk prostate cancer cT3\nGleason score = 7 (3+4 and/or 4+3) and/or\nPSA = 20 ng/ml\nintact preoperative erectile function with an IIEF = 21 (IIEF-6).Patients with diagnosis of cerebral palsy.Patients' curator must be able to give voluntary consent.Methadone-maintained cocaine-dependent patients use between 1g to 2g a day; 1 to 3 times a weekA formal diagnosis of Autism or Pervasive Developmental Disorder not otherwise specified (PDD-NOS), given by a child neurologist.Age: 10-18 years.A signed parental consent form.Body Mass Index (BMI) = 35 kg/m2\nHbA1c = 5.7%\nAbility to speak and understand EnglishA diagnosis of VTE in outpatient clinic or as discharge diagnosis after hospitalization.A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit.Adults (18 and older) with physiologically confirmed SA or mild-moderate asthma and followed by an asthma specialist for at least 6 months.Must agree to have regular clinic visits (minimum 3-4 per year for SA, 1-2 for mild-moderate asthma).Must have good compliance with medications Patients with asthma and COPD.diabetes mellitus type 1Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years)\nInformed consent signed\nMedical examination performed prior to participation in research\nPatients without history of inner ear disease\nRecipient of a French social security schemesuspicion of nonfunctional P-NET on primary CT (i.e hypervascularity) or MRI\nsigned informed consentDiagnosed with Beta-Thalassemia Major and receiving regular blood transfusion and on iron chelating therapy.Weight: equal to or over 35 kg.Normal renal function.F; age 18 to 70\nAmerican Society of Anesthesiologists (ASA) I e II;\nbreast cancer ( DIN 2 e 3, o LIN 2 e 3 sec.Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection;\nimmediate sub-pectoral prosthetic reconstruction;\nsigned informed consent.Participants having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy.Healthy children aged 6 months to 72 monthssuccessful left atrial appendage occlusion with Amulet device within 37 days prior to randomization.treatment with dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) between left atrial appendage closure and randomization\nparticipant's age 18 years or older at the time of signing the informed consent form\nparticipant is willing to follow all study procedures; especially randomized antiplatelet treatment regimen and follow-up visits with transesophageal echocardiography when applicable\nparticipant is willing to sign the study informed consent formAge greater than 18 \nPlanned thoracoscopy with low probability(by surgeon estimate) of conversion to open procedureAged =18 years\nClinical diagnosis of acute coronary syndrome\nIn the opinion of the attending clinician requires dual anti-platelet therapy with aspirin and a P2Y12 receptor antagonist\nResident in Scotland with a Community Health Index (CHI) number\nThe attending clinician has equipoise regarding the duration of therapy\nProvision of informed consentOf either gender, aged \xe2\x89\xa519 and \xe2\x89\xa470 years \nAtopic dermatitis subjects who are coincident with Hanifin and Rajka diagnosis criteria \nSubacute and chronic atopic subjects who have atopic dermatitis symptoms continually at least 6 months \nSubjects with over moderate atopic dermatitis (SCORAD score > 20) \nSubjects who understand and voluntarily sign an informed consent formNeed of lower third molar surgeriesNAChildren with clinical diagnosis of PWS;\nAge range: 7 to 14 years-old;\nVoluntarily participated and Written informed consent signedAge range: 14 to 65 years-old;\nClinically diagnosed of Port-wine Stain;\nPatients receiving hemoporfin based upon the clinical judgment of the investigator;\nWritten informed consent signed and agreed to receive periodic follow-up18 years of age or older;\nSuffer from schizophrenia/schizoaffective disorder meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria;\nHave a total baseline score on the Brief Psychiatric Rating Scale (BPRS) = 45;\nBe capable and willing to provide written informed consent to participate in this study;\nAgree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and testsHIV controlled on therapy for at least 12 weeks\nViral load < 200 copies\nBMI >27 to 45\nDiagnosis of DM type 2 with A1-C >7 to 15\nParticipants must be willing to comply with all study related procedures18 years of age or older \nHistologically confirmed diagnosis of melanoma, breast cancer or gynecologic cancer at MSKCC \nHave one of the following disease histories: \nNewly-diagnosed or recurrent (local, regional, metastatic) malignant melanoma or breast cancer patients in whom SLN mapping is indicated \nResidual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas \nPrior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region.Newly diagnosed patients with previous excisional biopsy.OR \nNewly-diagnosed gynecologic cancer patients in whom SLN mapping and surgical excision is indicated OR \nNormal baseline cardiac function based upon pre-operative evaluation \nAt the discretion of the operating surgeon, ANC>1000/mcl and platelets>100,000/mcl.At the discretion of the operating surgeon, Bilirubin level of < 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert's).For melanoma patients, If patients have a history of malignancy other than melanoma, and other skin cancers in the past five years, their inclusion is up to the discretion of the physician.All patients of childbearing and child-creating age must be using an acceptable form of birth control \nWomen who are pre-menopausal must have a negative serum pregnancy testAt least 18 years of age \nNo more than 20 wk of gestation \nGiven Ante-natal Cards of the Ghana Health Service \nCompleted the initial routine ante-natal examination at the clinics \nHIV negative or status unknown (as from the Ante-natal card) \nFree from chronic disease e.g.malignancy requiring frequent medical attention (as from the Ante-natal card) \nResiding in the Manya Krobo or Yilo Krobo district \nPrepared to sign an informed consent \nLiving in the area throughout the duration of the study \nAcceptance of home visitorsPatient >18 years of age\nPatient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD)\nPatient is eligible for PCI\nPatient is willing and able to provide informed written consent\nPatient not able to receive 12 months of dual anti-platelet therapy\nFailure of index PCI\nPatient or physician refusal to enroll in the study\nPatient with known CYP2C19 genotype prior to randomization\nPlanned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure\nAnticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery\nSerum creatinine >2.5 mg/dL within 7 days of index procedure\nPlatelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure.History of intracranial hemorrhage\nKnown hypersensitivity to clopidogrel or ticagrelor or any of its components\nPatient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint\nPatient previously enrolled in this study\nPatient is pregnant, lactating, or planning to become pregnant within 12 months\nPatient has received an organ transplant or is on a waiting list for an organ transplant\nPatient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure\nPatient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.)Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)\nConcomitant use of simvastatin/lovastatin > 40 mg qd\nConcomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine)\nNon-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g.cancer)\nKnown history of severe hepatic impairment\nPatient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions\nPatient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding\nInability to take aspirin at a dosage of 100 mg or less\nCurrent substance abuse (e.g., alcohol, cocaine, heroin, etc.)Current height less than 5th percentile AND/OR\nPredicted adult height (based on bone age) more than 10 cm below target height (mid parental height)\nEvidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl18 - 64 years old\nAble to give consent\nunprotected sex (in past 6 months) with 1 or more men of unknown HIV status\nevaluated for an STI within 6 months prior to screening\nsex in last 6 months with an HIV-infected partner\nIDU with report of using previously used or shared needles in past 6 months or has been in a methadone, buprenorphine, or suboxone treatment program in past 6 months or engaging in high-risk sexual behaviors\nindividuals engaging in transactional sex (i.e sex for money, drugs, or housing)\nInfrequently uses condoms during sex with 1 or more partners of unknown HIV status who are known to be at substantial risk of HIV infection (IDU or bisexual male partner)\nCrCl = 60 ml/min\nHIV- uninfected women desiring PrEPAt least 18 years of age\nSigned informed consent\nAfrican American race\nHistory of a solitary renal transplant\nStable tacrolimus dose for at least 2 weeks prior to randomizationThe treating physician has chosen Ventavis as a suitable long-term treatment for the patient \nPatient with primary pulmonary hypertension (i.e.Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension) and classified as NYHA functional class III (NYHA = New York Heart Association) \nNo prior treatment with Ventavis or other active treatments for primary pulmonary hypertension within 6 weeks of date of study inclusion (unless otherwise advised by Bayer Schering Pharma)Diagnosis of idiopathic Parkinson's disease that is optimally treated (motor fluctuations <20% of subject's awake time).Subjects may be on levodopa therapy but must be stable at the time of entry into the study\nSexually active (i.e.=1 attempt/week) males, 40 - 64 years of age (inclusive) at time of screening\nDiagnosis of moderate erectile dysfunction (defined according to the NIH Consensus Development Panel on Impotence) for more than 6 months and demonstrating and incomplete response to tadalafil alone\nSubject demonstrating an IIEF-5 drug-free baseline score that is = 10 but = 16, and an IIEF-5 tadalafil-alone baseline score that is = 18\nSubject in a stable heterosexual relationship for at least 6 months.(2)\nSubject motivated to seek treatment for erectile dysfunction.Subject with a total serum testosterone level = 300 ng/dL, with or without supplementation\nHoehn and Yahr Scale score of 1 - 3\nPatient able to consent and comply with protocol requirementsAxial spondyloarthritis (ASAS criteria) and radiologic sacroiliitis as detected either by MRI or X-ray.All subjects underwent a detailed history and systemic physical examination including neurologic and musculoskeletal evaluations.To rule out any confounding etiologies, basic diagnostic laboratory tests including complete blood count and acute phase reactants (erythrocyte sedimentation rate and C-reactive protein) were performed.The patients diagnosed as having acute non-specific low back pain according to history and physical examinations were invited to participate and will be informed about the purpose and course of the study.A primary complaint of pain in the area between the 12th rib and buttock crease without leg pain\nFemale or male, 20 - 80 years of age\nLow back pain of less than six weeks' duration; and at least moderate pain intensity (NRS<U+2267>4)Postmenopausal women\nAge 60-80 years\nT-score according to DXA: <-2.5\nindication for osteoporosis therapy according to international guidelinesWomen aged 20-49; \nHaving a regular menstrual cycle of which the menstrual period is between day 3-7, and the period between day 25-35; \nExcluding internal and surgical disease (after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine).Age 18 years or older\nSymptomatic or asymptomatic coronary artery disease patients\nMLA(minimal luminal area)<4mm2\nplaque burden>70%\nLipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy) (defined as maxLCBI4mm>315)\n2 target vulnerable lesions\nEligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular Scaffold or Everolimus Eluting Stent\nWilling and able to provide informed written consent\nReference vessel diameter 2.75-4.0\nLesion length = 40Referred for surgery for open reduction and internal fixation for ankle fracturesubjects older than 35 years\ndiagnosis of moderate to very severe COPD (FEV1 <80% predicted), according to the GesEPOC criteria, established at least 3 months\ncurrent or former smoker with an accumulated consumption >10 packs x year\nhospital admission for COPD exacerbationParkinson disease diagnosed by United Kingdom Parkinson's disease Society Brain Bank Criteria\nPostural instability and gait disturbance phenotype\nHoehn and Yahr stage = 3\nMini-Mental status examination = 24Diagnosis of sleep disordered breathing or obstructive sleep apnea\nChildren undergoing elective tonsillectomy or adenotonsillectomy at Children's Healthcare of Atlanta Egleston location\nParent or legal guardian willing to participate, and able to understand and sign the provided informed consentLVAD on warfarin requiring temporary interruption of anticoagulation for proceduresPatients older than 18 years\nIschemic symptoms or evidence of myocardial ischemia (inducible or spontaneous) in the presence of >50% de novo stenosis located in native coronary vesselsPerimenopausal women complaining of abnormal uterine bleeding (menorrhagia, metrorrhagia, polymenorrhoea or polymenorrhagia) without local gynecological cause.Failure of medical treatment for at least 3 months.Clinical Administered PTSD Scale 5 Monthly version Criteria A and >30 pointsNACHB patients who had received single NAs for more than 12 months.Hepatitis B e antigen (HBeAg)-negative.Hepatitis B surface antigen (HBsAg) positive and <1000 IU/mL.Hepatitis B virus DNA <100 IU/mL.CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.Men and women 35 to 70 years of agePatients undergoing SSRF at Denver Health Medical CenterPatients aged at least 18 years\nPatients with chronic heart failure present for at least 12 months\nConfirmed presence of iron deficiency\nSerum haemoglobin of 9.5 to 14.0 g/dL1.Subjects must have recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with measureable disease (as defined by RECIST 1.1.)after first or second line platinum-based chemotherapy, for which treatment with PLD is indicated.Platinum-based therapy is defined as treatment with carboplatin, cisplatin or another organoplatinum compound.Platinum-resistant is defined as having a platinum-free interval (PFI) of < 12 months after first- or second-line platinum-based chemotherapy, or having disease progression while receiving second-line platinum-based chemotherapy.Subjects are allowed to have received, but are not required to have received: \none additional cytotoxic regimen and/or PARP inhibitor for management of recurrent or persistent disease.biologic therapy (e.g., bevacizumab) as part of their primary treatment regimen or part of their treatment for management of recurrent or persistent disease.2.Histologic documentation of the original primary tumor.3.Documented radiographic disease progression < 12 months after the last dose of first- or second-line platinum-based chemotherapy.4.Subjects in Phase 2 must have disease amenable to biopsy and must be willing to undergo pre- and post-treatment tumor biopsies.Optional for Phase 1.Note: archival tissue will be requested for all subjects preferably from primary tumor site prior to cancer treatment; however, archival tissue is not a requirement for study entry.5.ECOG performance status of 0 or 1.6.Laboratory parameters for vital functions should be in the normal range.Laboratory abnormalities that are not clinically significant are generally permitted, except for the following laboratory parameters, which must be within the ranges specified, regardless of clinical significance: \nHemoglobin: \xe2\x89\xa5 9 g/dL \nNeutrophil count: \xe2\x89\xa5 1.5 x 109/L \nPlatelet count: \xe2\x89\xa5 100,000/mm3 \nSerum creatinine, \xe2\x89\xa4 1.5x Institutional Upper Limit of Normal (ULN), or Creatinine Clearance \xe2\x89\xa5 50 mL/min (by Cockcroft-Gault formula) \nSerum bilirubin: \xe2\x89\xa4 1.2 mg/dL \nAST/ALT: \xe2\x89\xa4 2.5 x ULN \nAlkaline phosphatase: \xe2\x89\xa4 2.5 x ULN \n7.Age \xe2\x89\xa518 years.8.Able and willing to give valid written informed consent.9.Body weight > 30 kgdiagnosis of ADHD\nparental permission and/or teen consent/assent as appropriate\nbetween 16-25 years of age\nIQ greater than or equal to 70\npermit or license to drive\nability to read and understand EnglishSubjects aged 18 years or older, at the time of signing the informed consent.Subjects with documented physician diagnosis of asthma as their primary respiratory disease.ACT score <20 at screening visit.Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = [cigarettes per day smoked/20] multiplied by number of years smoked).Male or female subjects will be included.A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: (i) Not a woman of childbearing potential (WOCBP).(ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 5 days] after the last dose of study treatment.Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and protocol.Subject understands and is willing, able, and likely to comply with study procedures and restrictions.Subject must be able to read in a language supported by the smart phone app in their region.Subject must have been on maintenance therapy (Fixed dose combination ICS/LABA) for 3 months, cannot have changed dose in the month prior to screening and be able to change to an equivalent dose of RELVAR/BREO for the duration of the study.Other background asthma medication such as anti-leukotrienes and oral corticosteroids are permitted provided the dose has been stable for 1 month prior to screening.Subject must be able to change to Salbutamol/Albuterol MDI rescue for the duration of the study and judged capable of withholding albuterol/salbutamol for at least 6 hours prior to study visits.Subject must have their own Android or iPhone operating system (IOS) smart phone and a data package suitable for the installation and running of the app and sending and receiving data.Data used by the CIS is approximately 1 megabyte (MB) per month as a maximum; this is less data than a 1 minute video streamed from YouTube (2MB).Subjects must be willing and able to download the app on their personal smart phone and keep it turned on for the duration of the study.This will also require Bluetooth to be turned on for duration of the study.Subjects will also have to turn on mobile data for the app for the duration of study; unless travelling and when extra data roaming costs could be incurred.ACT score <20 at randomization visit (visit 2).presence of typical HF symptoms and signs\nLV ejection fraction = 50\nelevated levels of NT-proBNP (at least >125 pg/ml)\nechocardiographic structural (a left atrial volume index > 34 mL/m2 or a left ventricular mass index =115 g/m2 for males and =95 g/m2 for females) or functional alterations (E/e'=13 and a mean e' septal and lateral wall < 9 cm/s).All patients admitted at the Gynecological emergency Unit at Hospital de Cl\xc3\xadnicas de Porto Alegre scheduled for uterine evacuation with <12 weeks of gestation.Age greater than 18\nNOSE score greater than 55\nNasal septal deviation on examAdult men and women> 18 years old\nPresence of sustained ventricular tachycardia with HR> 120 bpm\nSystolic blood pressure> 90 mmHg\nNo signs of poor peripheral perfusion\nAbsence of dyspnea\nAbsence of severe angina\nSigned consent formPatients scheduled for thyroidectomy with general anesthesia in the University of Chile Clinical HospitalA positive history of chronic claudication,\nExercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon,\nArterial occlusive disease per ankle Brachial index measurements and/or other imaging modalities,\nStable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control for 6 weeks.Male or female = 18 years of age at Visit 1.Sweat chloride equal or greater than 60 mEq/L by quantitative pilocarpine iontophoresis test.Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene\nAbnormal nasal potential difference (NPD) as measured by a change in NPD in response to a low chloride solution and isoproterenol of less than -5 mV.Documentation of the presence of an acute pulmonary exacerbation, based on CF Foundation guidelines, as diagnosed by a faculty member of the Denver Adult CF Program.Respiratory culture(s) demonstrating evidence of Pseudomonas aeruginosa or Achromobacter species airway infection.Subject is able to produce sputum, undergo phlebotomy, and provide written consent.The subject's treating physician has determined that they should receive either tobramycin or colistin intravenously as one of the designated agents for their APE treatment.Subjects who are able to receive either tobramycin or colistin as part of their antibiotic regimen will be randomized into one of three arms.If a treating physician deems that a subject cannot receive tobramycin due to vestibular toxicity, ototoxicity or bacterial resistance, the subject will be randomized to either standard or PK-adjusted colistin.Menopausal women with breast cancer treated and using tamoxifen or aromatase inhibitor.With hot flashes and with or without active sexual life.Male or female between, and including, 6-12 weeks (42 to 90 days) of age at the time of the first vaccination.Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol \nWritten informed consent obtained from the parent or guardian of the subject.Free of obvious health problems as established by medical history and clinical examination before entering into the study.Born after a gestation period between 36 and 42 weeks.Completed "ALO-IIT-012(PEAK study)", without major protocol deviations.Male, or female, 19 years to 75 years.Female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study\nSubjects completed PEAK can be included within 30 days after End Of the Study\nSubjects completed PEAK can be included if their treatment is the same as randomized even after 30 days of End Of the Study.Epilepsy partial seizure subjects.Currently taking 1 to 3 antiepileptic drugs.Patients on regular hemodialysis 3sessions/wk.Recent catheter insertion at beginning of the study.Both males and females.Age group = 18 ys.1.Age 18 years or older \n2.Diagnosis of venous leg ulcer(s), as clinically determined by the investigator by a positive venous reflux test (venous refilling <20 seconds) using Doppler ultrasound for at least 4 weeks prior to screening day, which have not adequately responded to conventional ulcer therapy.3.Designated venous leg ulcer meets the following criteria at both the screening and baseline visits.If the patient has multiple ulcers, at least one ulcer must meet the following criteria at both the screening and baseline visits: \n1.Present for at least 4 weeks \n2.CEAP Classification Stage 6 \n3.Surface ulcer with an area > 15cm2 post debridement \n4.Viable, granulating wound (investigator discretion) \n4.Ulcers that extend through the epidermis but not through the muscle, tendon, or bone (Stage II or III ulcers as defined by the IAET).5.Female patients of childbearing potential must have a negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence throughout until 2 weeks after the last administration of study drug \n6.Signed informed consenttype 2 diabetic, age 18 and over, informed consent,Provision of written informed consent (by patient or appropriate designee according to local regulations) prior to any study specific procedures.Aged 18 years or older, male or female.History of stable angina pectoris with angiographic evidence of CAD (diameter stenosis = 50%) in major, i.e., left main, left anterior descending, left circumflex, and right coronary arteries.History of previous myocardial infarction (MI)\nHistory of coronary revascularization, i.e., percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG), not including the elective PCI during the index hospitalization\nDocumented history of type 2 diabetes mellitus.Post-procedural residual diameter stenosis of the treated lesions < 20% in patients with stent implantation or < 50% in those with balloon angioplasty\nPost-procedural thrombolysis in myocardial infarction (TIMI) grade 3 flow in treated vessels\nNegative cardiac troponin test before the index elective PCI.Taking Clopidogrel 75 mg daily dose for at least 7 days or taking Clopidogrel 75 mg daily dose for less than 7 days but with 300 to 600 mg Clopidogrel loading dose before PCI.Taking acetylsalicylic acid (ASA) 100 mg daily treatment for at least 7 days or taking ASA 100 mg daily dose for less than 7 days but with 300 mg ASA loading dose before PCI.have a negative urine or blood pregnancy test at enrolment and prior to randomization;\ncurrently be using a hormonal contraceptive and agree to continue its use in addition to using double-barrier local contraception (i.e., intra-uterine device plus spermicidal and condom for male partner) from screening through study completion.scheduled for Nuss procedure for pectus excavatum correction\nat least 13 years old at the time of the procedureHistologically confirmed primary breast cancer\nPlanned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy\n=19 years of age\nAble to provide verbal consentaged = 6 months\nsign the informed consent form\nthe legal guardians participate in all the planned follow-up and be able to comply with all research procedures\nthe subjects have completed the basic immunization of 2 needle recombinant hepatitis B vaccine, there is no inoculation history of EV71 vaccine, and no history of EV71 infection\nthe last vaccination intervals = 14 days\ntemperature = 37<U+2103>\naged = 6 months\nsign the informed consent form\nthe legal guardians participate in all the planned follow-up and be able to comply with all research procedures\nthere is no inoculation history of EV71 vaccine, and there is no history of EV71 infection\nthe last vaccination intervals = 14 days\ntemperature = 37<U+2103>\naged = 8 months\nsign the informed consent form\nthe legal guardians participate in all the planned follow-up and be able to comply with all research procedures\nthere is no inoculation history of EV71 vaccine, and there is no history of EV71 infection\nthe last vaccination intervals = 14 days and the last attenuated live vaccine intervals=28days\ntemperature = 37<U+2103>\naged = 8 months\nsign the informed consent form\nthe legal guardians participate in all the planned follow-up and be able to comply with all research procedures\nthere is no inoculation history of EV71 vaccine, and there is no history of EV71 infection\nthe last vaccination intervals = 14 days and the last attenuated live vaccine intervals = 28 days\ntemperature = 37<U+2103>Scheduled to undergo bilateral palatine tonsillectomy as the only procedureBetween the age of 25 to 65 at baseline\nBe willing to participate in a smoking cessation program\nBe willing to attend all clinic visits\nMust be currently smoking at least \xc2\xbd pack/day at baseline (confirmed with cotinine level and CO Smokerlyzer\n>5 pack-year history of smoking\nGlobal Initiative for Chronic Obstructive Lung Disease (GOLD) 0: FEV1=0.80 and FEV1/FVC>0.70 Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC)\nGOLD 1: FEV1=0.80 and FEV1/FVC < 0.70\nGOLD 2: 0.50=FEV1<0.80 and FEV1/FVC < 0.70\nBe willing to abstain from using any nicotine patches, e-cigarettes, or marijuana for the duration of the study.Male or female patients = 18 and = 85 years of age\nWomen of child bearing potential must test negative on standard pregnancy test (urine or serum)\nPatients with body weight = 55 kg and = 140 kg and body mass index (BMI) = 18 kg/m2\nPatients diagnosed severe sepsis / septic shock at admission on Intensive Care Unit who can be enrolled within 90 min after admission OR patients diagnosed severe sepsis / septic shock during Intensive Care Unit stay who can be enrolled within 90 min after diagnosis\nPatients where antibiotic therapy has already been started (prior to randomization)\nPatient who are fluid responsive.Fluid responsiveness is defined as increase of > 10% in mean arterial pressure (MAP) after passive leg raising (PLR)\nSigned informed consent by patient, legal representative or authorized person or deferred consentAdult males and females who are 18 years of age or older.Evidence or suspicion of upper gastrointestinal bleed (GIB)\nPatient with known or suspected cirrhosis\nUpper GIB secondary to bleeding esophageal varices as show by esophageal endoscopy, requiring endoscopic band ligation (EBL) at presentation\nWilling and able to provide informed consent for study, or have a Legally authorized representative (LAR) provide consent if the patient is unable to do sowomen previously diagnosed with generalized vulvodynia \nwomen previously diagnosed with localized vestibulodynia,18 years or older\nChest radiograph showing new opacities.Cough\nProduction of sputum\nTemp >38,0 \xc2\xb0C or <36,0 \xc2\xb0C\nAudible abnormalities by chest examination compatible with pneumonia\nLeukocytosis (>10.000 cells/mm3), leftward shift (>10%) or leucopenia (<4000 cells/mm3)\nC-reactive protein > 15 mg/l (three fold higher than the upper limit of normal)Children aged 3-16 with a parent/guardian (hereafter termed parent) reported history of allergy to a penicillin antibiotic in which the reported allergic reaction occurred at least six months prior to the current PED visit.Only children well enough to be discharged to home at the conclusion of the PED visit are eligible.Scheduled back surgeryNon-affective psychosis \nPremorbid IQ of over 70 \nA service user of the early intervention service \nAged 18 or over (up to the age of 35 which is the limit for the early intervention service) \nPsychiatrically stable enough to attend to completion (no hospitalisations or medication changes in last 4 weeks)Patients undergoing surgery with general anesthesia,\nPatients weighing = 80 pounds who are not -intubated prior to surgery,\nPatients who are able to give informed consent.Subject are at least 18 years of age \nSubject has confirmed Pulmonary Hypertension and Interstitial Lung Disease \nSubject are able to complete study procedures, such as spirometry, and Pulmonary Exercise test.Possible or probable Alzheimer's disease (National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria), with Mini-Mental State Exam (MMSE) score of 10-26 inclusive; MMSE scores above 26 in those who nevertheless meet criteria for AD may be allowed with Steering Committee approval on a case by case basis \nClinically significant apathy for at least four weeks for which either 1) the frequency of apathy as assessed by the Neuropsychiatric Inventory (NPI) is 'Very frequently', or 2) the frequency of apathy as assessed by the NPI is 'Frequently' or 'Often' AND the severity of apathy as assessed by the NPI is 'Moderate' or 'Marked' \nA medication for apathy is appropriate, in the opinion of the study physician \nProvision of informed consent for participation in the study by patient or surrogate (if the patient is unable to provide informed consent) and caregiver \nAvailability of primary caregiver, who spends greater than ten hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study \nSufficient fluency, of both the patient and caregiver, in written and spoken English to participate in study visits, physical exams, and outcome assessments \nNo change to AD medications within the month preceding randomization, including starting, stopping, or dosage modifications \nTreatment with stable doses of selective serotonin reuptake inhibitor antidepressants(SSRIs) is appropriate if stable for 3 months prior to randomization.Other psychotropics(with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis.Age between 20 and 80 years\nPatients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks\nModified Lanza Score grade 0-1 measured by upper gastrointestinal endoscopy\nmild gastrointestinal symptom\nCreatinen in blood = 3mg/dl\nBUN = 50mg/dl\nBirilubin = 3mg/dl\nAST and ALT = 80U/LPatients aged =50 years with DM2 and symptomatic PAD diagnosed clinically (according to Fontaine criteria, stage IIa or IIb and III) and by measuring the <U+0391><U+0392><U+0399>.Subjects = 19 or = 75 years of age\nSubjects undergoing treatment for type 2 diabetes\nSubjects undergoing treatment of statin for hypercholesterolemia\nFasting LDL-C = 250mg/dL at the screening visit\nFasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit\nFasting TG<500mg/dLDiagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl)\nUlcer located on the legs or feet, stage III or IV (Wagner Classification System)\nThe subject agrees to comply with study protocol requirements and all follow up visit requirements.1.Signed informed consent \n2.Healthy subjects aged between 18 years and 45 years inclusive \n3.Weighing at least 50 kg \n4.Volunteers must be hospitalized on Days 1-4, 7-9, and 17-20 for pharmacokinetic assessments for each biomarker and TPV/r (Days 7-9 and 17-20) \n5.Volunteers must be willing to complete all study-related activities \n6.Each volunteer must have a valid social security number \n7.Each volunteer must have acceptable medical history, physical examination and laboratory testMales and females 21 years of age or older;\nUndergoing elective primary, resurfacing arthroplasty, revision, or second stage re-implantation total hip replacement;\nUndergoing elective primary, revision, or second stage re-implantation total or uni compartmental knee replacement;\nPatient has necessary mental capacity to participate and is able to comply with study protocol requirements;\nPatient is willing and able to give informed consent; and\nPatient is willing to be randomized and participate.Males and females aged between 18 to 75 years.Adult patient under guardianship with consent obtained and the legal guardian's authorisation obtained.Single stroke having occurred more than 6 months before (previous TIA is accepted).Capable of understanding instructions and participating in the definition of a therapeutic goal (Boston Diagnostic Aphasia Examination (BDAE) < 3).Having previously undergone BTI.The last injection must have been performed at least 4 months prior to inclusion.Affiliation to the French social security regime or a similar regime.Patient (or the legal guardian if under guardian adult patient) has signed the informed consent form.patients aged >18, <75, left ventricle ejection fraction (LVEF) >50%, multivessel coronary disease detected by coronarography, indication to receive a CABG, stable CAD.All diabetics and non diabetics..Inclusion criteria are American Society of Anesthesiologists (ASA) physical status I-III, age between 18 and 70 years and body mass index (BMI) between 20 and 35 kg/m2.Male and female adolescent patients, aged 13 to 17 years, diagnosed with RLS based on the IRLSSG consensus criteria (Allen RP 2014) (Appendix 2).Total RLS severity score of 15 or greater on the IRLS rating scale at Visit 1 (screening) and at Visit 2 (baseline) (Appendix 8).RLS symptoms for at least 4 of 7 consecutive evenings/nights during the screening period.Body weight greater than 33.4 kg and a healthy weight using age-based body mass index (BMI) range 5th-85th percentile at screening and baseline.Appendix 3 contains BMI-for-age charts that can be consulted.Estimated creatinine clearance of at least 60 mL/min (using the Cockcroft-Gault equation) at screening only.Signed patient and parent Institutional Review Board (IRB)-approved informed consent/assent form (as applicable) before any study-related procedures are performed.Phase 1 Specific Patient at least 18yrs of age with histologically confirmed CLL/SLL or B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma).Phase 2a Inclusion \nHistological evidence: FL Grade 1-3A/iNHL, with relapsed or refractory disease (iNHL includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or refractory.Received BCR and/or BCL2 inhibitors were intolerant or had relapsed/refractory disease afterwards.Prior treatment for lymphoid malignancy for progressive /refractory disease \n\xe2\x89\xa5 1 prior regimen (min 2 cycles) with antibody conjugate, cytotoxic chemotherapy, or TKI alone or in combination.Measureable disease defined as: \xe2\x89\xa5 1 lesion \xe2\x89\xa5 1.5 cm single dimension via CT, CT/PET with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenstr\xc3\xb6m's macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0 \nAbility to provide diagnostic reports \nGeneral Inclusion \nECOG Score of 0 or 1.Hematologic ANC > 1000/uL and platelet > 75,000/uL, \nSerum creatinine of < 1.5 ULN or calculated CrCl of > 50 mL/min \nBilirubin < 20.0mg/dL (if Gilberts then < 2.5 mg/dL) and AST/AST < 2.5 ULN1.Subject has a history of GTC seizures, either primary GTC or partial onset seizures with secondary generalization.2.Is being admitted to a hospital for routine vEEG monitoring related to seizures.3.Male or female between the ages of 2-99.4.Has an upper arm circumference which is adequate for proper fit of the EMG monitor (at least 14cm).5.If female and of childbearing potential, has a negative pregnancy test.6.Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.7.Subject and/or Primary Caregiver must be competent to follow all study procedures.8.Is able to read, speak, and understand English.Elective Cardiac surgery\nAmerican Society of Anesthesiologists physical status class I-IIIChronic hepatitis B (HBsAg positive > 6 months)\nHBeAg negative within six months prior to initiation of peginterferon alfa-2a\nHBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a\nCompensated liver disease\nAge > 18 years\nWritten informed consentHistologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease, and a candidate for chemotherapy.Human epidermal growth factor receptor 2 (HER2)-positive.No prior chemotherapy for their metastatic breast cancer (MBC).Measurable disease.Age \xe2\x89\xa5 18 years.For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception or 2 effective forms of non-hormonal contraception by the patient and/or partner.Contraception use must continue for the duration of study treatment and for at least 6 months after the last dose of study treatment.Male patients whose partners are pregnant should use condoms for the duration of the study.CHB patients who had received NAs for more than 12 months.Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive.Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL.Hepatitis B virus DNA not detectable(Roche Cobas).Healthy Volunteers: \nAge of at least 18 years \nExistence of a contraceptive method for women of child-bearing age \nPerson affiliated to social security or beneficiary of such a scheme \nSigned consent form \nSystemic sclerosis patients: \nSystemic sclerosis meeting the EULAR criteria.Presence of at least 2 ischemic digital cutaneous ulcerations on two different fingers, with digital ulcers classified as "active ulcers" according to the North American working group definition: epithelial denudation is clearly Visible at one place and the bed of de-epithelialized ulcer can be seen; Ulcerations distal to the proximal interphalangeal joint, not associated with calcinosis or bony relief.Ulcers whose major axis measured with the electronic caliper is \xe2\x89\xa5 2 mm \nAge greater than or equal to 18 years \nExistence of a contraceptive method for women of reproductive age \nA person who is or is a beneficiary of social security \nInformed and signed consent signed by the patient or his / her legal representative.Age greater than or equal to 18 years old\nRequirement for vasoactive drugs via a central venous catheter for the treatment of shock.Shock will be defined as mean arterial pressure less than 70 mmHg or systolic blood pressure less than 100 mmHg despite administration of at least 1000 mL of crystalloid or 500 mL of colloid, unless there is an elevation in the central venous pressure to > 12 mmHg or in the pulmonary artery occlusion pressure to > 14 mmHg coupled with signs of tissue hypoperfusion (e.g.altered mental state, mottled skin, urine output < 0.5 mL/kg body weight for one hour, or a serum lactate level of > 2 mmol per liter).Currently smoke at least ten cigarettes a day\nHave been smoking for at least one year\nMeet criteria for schizophrenia, schizoaffective disorder, or another psychotic disorder based on structured clinical interview\nCan speak and write fluent conversational English\nAre between 18 and 70 years of age\nAre willing to make a smoking cessation attempt\nScore 26 or higher on the Montreal Cognitive AssessmentPediatric patients with deep dental decay in primary molars\nTeeth with signs and symptoms of reversible pulpitisbreast cancer\nundergoing unilateral mastectomy with or without axillary node dissection\nreceived adequate oral and written information about the study and signed an informed-consent formPresent to ED primary for management of LBP, defined as pain originating between the lower border of the scapulae and the upper gluteal folds.Flank pain, that is pain originating from tissues lateral to the paraspinal muscles, will not be included.Musculoskeletal etiology of low back.Patients with non-musculoskeletal etiologies such as urinary tract infection, ovarian cysts, or influenza like illness will be excluded.The primary clinical diagnosis, at the conclusion of the ED visit, must be a diagnosis consistent with non-traumatic, non-radicular, musculoskeletal LBP.Patient is to be discharged home.Patients admitted to the hospital are more likely to be treated with parenteral medication and therefore are not appropriate for this study.Age 18-64 Enrollment will be limited to adults younger than 65 years because of the increased risk of adverse medication effects in the elderly.Non-radicular pain.Patients will be excluded if the pain radiates below the gluteal folds in a radicular pattern.Pain duration <2 weeks (336 hours).Patients with more than two weeks of pain are at increased risk of poor pain and functional outcomes.(9)\nPrior to the acute attack of LBP, back pain cannot occur more frequently than once per month.Patients with more frequent back pain are at increased risk of poor pain and functional outcomes.(9)\nNon-traumatic LBP: no substantial and direct trauma to the back within the previous month\nFunctionally impairing back pain: A baseline score of > 5 on the Roland-Morris Disability QuestionnaireMale or female =18 years of age at Visit 1\nDocumentation of a CF diagnosis\nEnrolled in the Cystic Fibrosis Foundation National Patient Registry (CFFNPR) prior to Visit 1 (US sites only)\nAt the time of Visit 1, there is a plan to initiate IV antibiotics for a pulmonary exacerbation\nPerformed spirometry at Visit 1 and Visit 2 and willing to perform spirometry at Visit 3\nCompleted the CRISS questionnaire at Visit 1 and Visit 2 and willing to complete the Cystic Fibrosis Respiratory Symptoms Diary (CFRSD) questionnaire at Visit 3\nWilling to adhere to a specific treatment duration determined by initial response to treatment and subsequent randomization\nWilling to return for follow up Visit 3\nWritten informed consent obtained from the subject or subject's legal representativeWomen with singleton pregnancy.History of preterm labor and/or midtrimester miscarriage in a previous pregnancy.Cervical length of 15-25 mm by transvaginal sonography (TVS) at 16-24 weeks of gestation.Mild-to-moderate RDS;\nPostnatal age 2 to 48 hours;\nGestational age 27 0/7 to 36 6/7 weeks;\nTreated with nasal CPAP modalities = 5 cm H2O and FiO2 between 0.30 and 0.60 for at least 2 hours to maintain SpO2 90-95%;\nInformed consenthistologically confirmed metastatic cancer that is not amenable to surgery or radiation therapy with curative intent \nmeasurable lesion by CT or other techniques according to RECISTPatients with a histologically or cytologically proven diagnosis of NSCLC \nUnresectable (locally advanced) stage IIIa or IIIb disease \nInitial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus \nLife expectancy greater than or equal to 6 months \nEstimated weight loss less than or equal to 10% in the 3 months before study randomization \nMeasurable disease \n18 years of age or older \nEastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 \nHemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization \nAbsolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization \nPlatelet count greater than or equal to 100 x 10^9/L \nSerum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) \nSerum creatinine less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min) \nFemales of childbearing potential: negative serum or urine pregnancy test \nPatient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product.Patients with reproductive capability must agree to practice adequate contraception methods.Recipient is Age = 18 years\nSerum ALT within normal limits with no history of liver disease\nLack of sensitization (i.e.PRA < 20%) that would be expected to result in a high likelihood of needing aggressive immunosuppression to treat rejectionBorn at University of New Mexico Hospital\nGreater than 34 weeks gestation\nPrimary in-utero drug exposure was opioids other than buprenorphine\nMaternal or infant urine drug screen positive for methadone and/or opioids on admissionDiagnosis of Type 1 diabetes (for at least a year)\nOn multiple daily insulin injections, including basal long-acting insulin and rapid-acting insulin before each meal.HbA1c < 75 mmol/mol (9.0%)\nParticipant and/or parent/legal guardian willing and able to give informed consent for participation in the study.Family have a freezer in which to safely store the test meals.In the Investigator's opinion, is able and willing to comply with all trial requirements.Patient age >= 18 years\nZubrod performance status of 0-3\nT1-3 N0 M0 adenocarcinoma of the prostate\nProstate volume = 100 cc\nSigned study-specific consent form\nExtension of local tumor to involve adjacent organs other than seminal vesicles (T4)\nProstate volume > 100 cc\nNodal involvement\nMetastatic disease\nPrior pelvic radiotherapy except as part of combination therapy for prostate cancer\nHistory of scleroderma\nPatients with psychiatric or addictive disorder that would preclude obtaining informed consentNon-ventilated Patients over the age of 65Men or women aged 18 years or older\nPatients presenting for CMR with the clinical diagnosis of hypertrophic cardiomyopathy based on left ventricular wall thickness of at least =15 mm in the absence of any other cardiac or systemic cause of hypertrophy\nPatients presenting for CMR with the clinical diagnosis of idiopathic dilated cardiomyopathy based upon left ventricular ejection fraction =40%, LV end-diastolic diameter =55 mm or left ventricular end-systolic diameter =45 mm, and the absence of coronary stenoses on angiography.Patients presenting for CMR evaluation of chest pain but without evidence of obstructive coronary artery disease either by coronary angiography or stress testing.Patient must meet 1987 ACR criteria\nAge > 18 years of age\nBaseline DAS28/Erythrocyte Sedimentation Rate (ESR) >=3.2\nStable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs)\nStable prednisone <10mg or equivalent\nPower Doppler score of >=10Having been diagnosed with primary OCD as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-) criteria;Cleaning or checking as primary OCD symptoms\nYale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of = 16\nNever receiving adequate treatment or stop receiving treatment for at least 8 weeks\nHaving an education degree of high school or above\nAccepting to participate in the studySubjects scheduled for laparoscopic unilateral inguinal hernia repair\nASA 1 or2.Age >18 years.Men and women aged > 18 years\nAngiographically confirmed acute massive pulmonary embolism with involvement of Central pulmonary arteries.endovascular mechanical thrombus fragmentation + thrombolytic therapy (using recombinant tissue activator of plasminogen), performed for treatment of the above-mentioned pulmonary embolism in less than 48 hours before randomization.The patient should be randomized no earlier than 24 hours after procedures endovascular mechanical thrombus fragmentation + thrombolytic therapy\nWritten informed consent signed by patient.Age 65 - 79\nHistory of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease)\nCancer, with no active treatment in the last year\nMCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2\nDecline physical function (walking speed < 1 m/s) Group 3 (Either or both)\nAbdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90\nAbdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consentMale and female individuals between ages of 18 to 70 years old \nMultiple contiguous gingival recession defects on a minimum of two adjacent teeth, exhibiting 3mm or more recession on at least one of those teeth \nNo prior surgical treatment in the sites planned for therapy \nMinimum of 2 mm of keratinized gingiva \nAbsence of cervical restorations extending to the CEJ \nMiller class 1, 2 and 3 recession defects will be included \nAvailability to undergo treatment and return for follow up visits at specified post-operative intervalsPatient with spontaneous intracranial hemorrhage or traumatic intracranial hemorrhage or patient requiring neurological surgery\nCoagulation disorder defined by PT less than 60%Aged between 18-70 years\nMeets the Diagnostic and Statistical Manual (DSM) IV and DSM-V diagnostic criteria for generalised anxiety disorder (GAD) based on structured interview (Mini International Neuropsychiatric Interview-Plus 6 [MINI-Plus 6].Note that while the MINI-Plus 6 uses the DSM-IV criteria, the same criteria are used in the DSM-V).Presents with anxiety (Hamilton Anxiety Rating Scale = 18) at the time of study entry\nFluent in written and spoken English\nProvides a signed copy of the consent form\nPrimary diagnosis other than GAD\nPresentation of moderate to severe depressive symptoms (Montgomery-Asberg Rating Scale: MADRS = 18 at time of study entry or = 24 at any time during study)\nPresentation of suicidal ideation (= 3 on MADRS suicidal thoughts domain at time of study entry or at any time during study)\nCurrent diagnosis of bipolar disorder or schizophrenia on structured interview (MINI Plus)\nCurrent substance/alcohol use disorder on structured interview (MINI Plus) Page 21 of 39 Commercial-in-Confidence\nCurrently taking an antidepressant, mood stabiliser, antipsychotic, anticonvulsant, warfarin or thyroxin, or current regular use (more than 2 days per week) of a benzodiazepine or opioid-based analgesic\nCurrent use of a psychotropic nutraceutical (e.g.St John's wort)\nPrevious intolerance to kava\nThree or more failed trials of pharmacotherapy for the current GAD episode\nRecently commenced psychotherapy (within four weeks of study entry)\nKnown or suspected clinically unstable systemic medical disorder\nDiagnosed hepato-biliary disease/inflammation\nElevated liver enzymes at baseline blood test\nPregnancy or breastfeeding, or trying to conceive\nNot using medically approved contraception (including abstinence) if female and of childbearing age\nUnable to participate in all scheduled visits, treatment plan, or other trial procedures according to the protocol (except for the optional genetic component)a crown-rump length = 6mm and no cardiac activity OR\na crown-rump length <6mm and no fetal growth at least one week later OR\nAt least one week after diagnosis OR a discrepancy of at least one week between crown-rump length and calendar gestational age\nIntra-uterine pregnancy\nWomen aged above 16 years\nHemodynamic stable patient\nNo signs of infection\nNo signs of incomplete abortion\nNo contraindications for mifepristone or misoprostolSingleton pregnancy;\n8-22 weeks gestation\nPrevious pregnancy complicated by gestational diabetes=32 weeks gestational age at birth\n=6 weeks postnatal age at randomization\nRemains hospitalized after birth (has never been discharged home)\nTreating clinician deems infant eligible to receive 2-month vaccines\nEnglish- or Spanish-speaking parent(s)/legally authorized representative(s) (LAR(s))\nNot planned for discharge within 60 hours of study entry\nThe parent/guardian must be willing and capable of providing permission for their child to participate through the written informed consent processChildren aged 0-59 months living with families registered in the rural Bandim Health Project Health and Demographic Surveillance Site are included, provided a parent/guardian consent.Has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber intraocular lens \nHas a potential post-operative pinhole corrected Snellen VA of at least 20/200 or better in both eyesAge = 18 years and NYHA (New York Heart Association) functional class II, III and IVbetween 7 to 70 years of age\nfluent in English or Spanish\nplans to receive care in the Community Health Center during the next year\npresents with signs and symptoms of a SSTI\nwilling/able to provide informed consent1.Presence of bacteremia due solely to: \nS. aureus on at least 1 blood culture within 72 hours of beginning study drug (Cohort A) OR \nMRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment (Cohort B).2.Male or female \xe2\x89\xa5 18 years of age.3.If female of childbearing potential must be willing to practice sexual abstinence or dual methods of contraception during treatment and for at least 30 days after the last dose of study drug.4.Expectation of survival for at least 2 months.Inpatient or outpatient age 8-19 years inclusive; participants must live with a parent, guardian, or caregiver;\nFluent in English;\nDiagnosed or told by a clinician that they have any of the following bipolar spectrum disorders (BSD): bipolar I, bipolar II, unspecified bipolar and related disorders, Disruptive Mood Dysregulation Disorder (DMDD), cyclothymic disorder, other specified bipolar and related disorders, as well as mood disorder not otherwise specified (if diagnosed in the past as per DSM-IV);\nBody mass index >85%ile for age and sex by standard growth charts;\nReceived a new or ongoing prescription for at least one SGA (i.e., olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone, iloperidone, lurasidone, paliperidone, brexpiprazole or cariprazine) that is not prescribed as a PRN medication;age 18 years or older\npatients undergoing invasive procedures via the radial or femoral arteriesIrritable Bowel Syndrome (IBS) (ROME III criteria): subtype with diarrhea or mixed form\nage 18-65 yearsChildren 7-17 with moderate to severe pain requiring around the clock treatment with an opioid analgesic.Be an experienced opioid user, defined as any subject treated with opioid therapy, equivalent or equal to >20 mg per day of morphine, for a period of 3 consecutive days immediately prior to first day of dosing.Age over 18 years,\nGeneral Condition WHO 0, 1 or 2,\nASA Class I and II, eligible for endoscopic or surgical treatment with curative intent,\nHistological diagnosis of high grade glandular epithelial neoplasia (Vienna 4-1 to 4-46), possibly multifocal or stage 0 (Tis, N0, M0),\nEndoscopic and histological confirmed diagnosis of intestinal metaplasia,\nHistological diagnosis confirmed by two endoscopies with biopsies and two pathological readings; biopsies should be carried out according to the protocol of the SFED (four-quadrant biopsies every cm) with at least once acetic acid for staining.Operators describe Barrett's esophagus using he SFED planimetric model.The final exam will be no more than two months before the date of treatment and should have been achieved in investigator establishment,\nMinimum 1 cm,\nMaximum 12 cm.the resected lesion must have been well differentiated and confined to the mucosa (m2 maximum) on histological analysis,\nresection should be more than two months,\nresection must have been macroscopically complete laterally,\nresection must have been histologically complete in depth,\nresection must have been histologically complete laterally with regard to the microinvasive cancer, that is to say with a clear margin of safety (margin may be high-grade dysplasia provided that the latter has not macroscopic translation),\nAt least one endoscopic and histologic follow-up should be conducted with dye in a period of less than two months before the date of treatment, and at the investigator establishment.Patient may take an inhibitor of proton pump equivalent to 2 times 40 mg of esomeprazole,\nNo mediastinal or celiac, or suspected metastatic lymph nodes by EUS,\nAffiliation to a social security system or similar,\nLack of participation in another clinical study,\nInformed consent signed.NAAccepted for CABG surgery\nTreatment with Ticagrelor within 48 hoursPatients with T2DM and CAS as defined below: \nClinical definitions \nT2DM: Diagnosed according to the WHO criteria [53].CAD:Presence of any one of the following: Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( >50% stenosis of one vessel), percutaneous or surgical coronary revascularisation.Aged between 18 and 75 \nProvided written consent for participation in the trial prior to any study-specific procedures or requirements.Male and females between ages 18-85 years of age\nSCI ( =1 month of injury)\nASIA A, B,C and D\nSCI above L5\nAble to perform a visible contraction with dorsiflexor and hip flexor muscles (allowing testing of largely impaired patients)\nAble to ambulate a few steps with or without an assistive device\nMale and females between ages 18-85 years of age\nAble to walk and complete lower-limb tests with both legspatients with severe left ventricle dysfunction with an ejection fraction (EF)=40%, being scheduled for revascularization.Female \nAge \xe2\x89\xa518 years \nPatients with a lesion > 0.5 cm in largest diameter size, initially scored BI-RADS\xc2\xae 3, 4a, 4b or 4c in B-mode ultrasound \nInformed consent about histological examination (core cut biopsy (CCB), vacuum-assisted biopsy (VAB), fine needle aspiration (FNA) or surgery) has already been given in the course of clinical routine \nSigned informed consent of study participationCases (with a history of TBI): \n1.Ages 50-95 years \n2.History of traumatic brain injury of sufficient severity to have resulted in medical attention (ascertained via the Ohio State University TBI Identification Questionnaire\xe2\x80\x94OSU TBI-ID, and based on DoD/VA criteria) \n3.Residence in AFRH-Washington D.C. or the Veterans Home of California-Yountville \n4.MMSE score \xe2\x89\xa5 20 \n5.Capacity to provide consent to participate in research (assessment made by study physician) \n6.Ability to read and write English \nControls (without a history of TBI): \n1.Ages 50-95 years \n2.No history of traumatic brain injury of sufficient severity to have resulted in medical attention (ascertained via the Ohio State University TBI Identification Questionnaire\xe2\x80\x94OSU TBI-ID) \n3.Residence in AFRH-Washington or the Veterans Home of California-Yountville \n4.MMSE score \xe2\x89\xa5 20 \n5.Capacity to provide consent or assent to participate in research \n6.Ability to read and write English -T2DM as defined by American Diabetes Association (ADA) criteria\nAdult patients with T2DM who are indicated to receive liraglutide, not as first-line therapy, in addition to diet and exercise to improve glycemic control\nHemoglobin A1c (HbA1c) = 9%\nAge = 18 years old\nBody mass index (BMI) = 27 Kg/m2 and/or waist circumference = 102 cm (40 inches) in men and 88 cm (35 inches) in women, respectively.Clinically and angiographically stable CAD who requires CABG as part of the standard medical care, as CAD does not represent a contraindication for using liraglutide.The stability of the CAD further warranties that study patients will not be exposed to higher risk by using liraglutideproven acute deep venous thrombosis, less than 21 days and who were referred to the interventional radiology department.Age >/=18 years at screening\nPatients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features: (i) at least one clinical relapse over a 6-month period prior to screening; (ii) AND/OR at least one T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI) performed over a 3 months period prior to screening with no change of Disease-Modifying Treatment(s) (DMT) compared to a previous MRI performed within 24 months before screening\nFor women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 12 months after the last dose of ocrelizumab\nParticipants should be beneficiary of healthcare coverage under the social security system20-40 years old women\nSpontaneously ovulating women\nTreated in our IVF unit for frozen-thawed embryo transfer\nAt least one top quality embryoVeteran receiving care within the Veterans Health Administration healthcare system\nAge 18 years\nPhysician diagnosis of chronic heart failure, American Heart Association Stage C-D\nLVEF <45%\nNo change in active cardiac medications for 4 weeks prior to randomization\nAbility to provide informed consent\nModerate to severe central or mixed central and obstructive sleep apnea, defined as an apnea-hypopnea index (AHI) 15 events per hour, with a central AHI >5 events/hourAge > 40 years (45)\nPrimary knee osteoarthritis diagnosed using the American College of Rheumatology criteria (46)\nUndergoing elective, primary and unilateral total knee arthroplasty\nAmerican Society of Anesthesiology (ASA) physical status class 1-3\nBMI < 40 kg/m2-Patients residing in the following clinical states wit!be considered: A.Rising PSA: Patients with a history of localized disease who have undergone definitive radiation or surgery.These patients must demonstrate progression of disease biochemically as outlined below.Patients in this group may not have radiographically evident disease.B. Non-castrate metastatic: Patients must present with radiographic evidence of metastatic disease at the time of diagnosis or after treatment for localized disease.These patients must show newly detected disease or progressing disease in bone or in soft tissue.Biochemical progression is defined as: minimum no.of determinations: 3 Interval: >2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50% \nDiagnosis of prostate adenocarcinoma histologically confirmed at MSKCC.Patient must have level of serum testosterone above the lower limit of normal.Karnofskcy performance status (KPS) >_70%.Patients must have adequate organ function as defined by the following laboratory criteria: \nWBC >_3500/mm3, platelet count >_100,000/mm3.Bilirubin <2.0 mg/dl or SGOT <3.0 X the upper limit of normal.Creatinine <_1.6 mg/dl or creatinine clearance >_60 cc/min.Prior hormonal therapy is allowed as: \n1.Neoadjuvant treatment prior to radiation therapy or radical prostatectomy, provided that the total duration of exposure does not exceed 10 months.2.One cycle of intermittent therapy up to a maximum exposure of 10 months.Patients must be at least 18 years of age.Patients must have signed an informed consent document stating that they understand the investigational nature of the proposed treatmentSubjects undergoing burn excision surgery for standard of care purposes\nMale or female >= 18 years of age\nSubject or subject's medical decision maker agrees to participate in this study and provides informed consent1.Diagnosed with symptomatic sacral perineurial cysts(e.g., lumbosacral or perineal pain, fecal or urinary functions change, sexual function change, lower limb radiation pain, muscle abate, paresthesia, etc)\n2.Visual analog scale more than or equal to 4\n3.Signed the informed consent\n4.Years, range 18-60\n5.Self-rating anxiety scale (SAS) and self-rating depression scale (SDS) scores < 50\n6.No Congenital,Mental and other Nervous system diseases\n7.No Serious Cardiac,Pulmonary,Hepatic and Nephritic disease\n8.No history of drug allergy\n9.No pain(including dysmenorrhea) or drug use (e.g., antipyretics,sleeping pills) within the last month\n10.MRI finding of sacral perineurial cysts, but without any clinical symptoms, included in the negative control group\n11.MRI finding healthy volunteers don't have sacral perineurial cysts, included in the negative control groupblank control groupMale and female subjects aged 9 to 17 months on the day of inclusion \nInformed consent form has been signed and dated by the parent(s) or other legally acceptable representative(s) (if applicable) \nSubject and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and to comply with all trial procedures.Lobectomy or pneumonectomy\nEsophagectomy\nRadical (total) cystectomy\nPancreatectomy\nPartial hepatectomy\nHyperthermic intraperitoneal chemotherapy (HIPEC)\nGastrectomy (subtotal or total)\nCholecystectomy or bile duct resectionAdult patient (male or female) requiring emergency endotracheal intubation.Healthy males between 18 and 45 years of age (inclusive).Body mass index to be between 18 to 30 kg/m2 (inclusive) as calculated by weight(Kg)/height(m2).Subjects were to have no clinically significant abnormal findings on physical examination, ECG, medical history, or clinical laboratory results during screening.Subjects were to, in the opinion of the investigator, have no clinically significant abnormal findings of renal and hepatic function as determined by serum creatinine, total bilirubin, and transaminase levels.Subjects were to be non-users of tobacco products (minimum of 6 months prior to the start of the study).Subjects were to have a negative screen for HIV I and II, HBsAg, and antibody to Hepatitis C virus.Subjects were to have a negative urine screen for alcohol, drugs of abuse (screening only), and cotinine.Subjects were to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g.female condom or occlusive cap with spermicide) during the study and for 3 months following administration of the study drug.Subjects were able to comply with the protocol and the restrictions and assessments therein.Subjects were to give voluntary written informed consent to participate in the trial.1.Menstruating females 10-19 years of age \n2.Non-smoker \n3.Physician and patient have agreed to initiate Lysteda \n4.Diagnosis of HMB based on the medical judgment of the principal or site investigator \n5.Subjects must report menstrual periods occurring within 21-60 days from the start of one period to the start of the next menstrual period \n6.Negative pregnancy test \n7.Informed consent obtained and signed \n8.Informed assent obtained and signed \n9.Understanding of study procedures \n10.Ability to comply with study procedures for the entire length of the study \n11.Subjects should be either sexually inactive (abstinent) or agree to use a barrier method with spermicide in the event of sexual activity throughout the study periodAge: 60-85 years, right-handed;\nDiagnosis: Major depression, unipolar (by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)IV (SCID-R) and DSM-IV criteria);\nAge of onset of first episode = 50 years with up to three depressive episodes;\nSeverity of depression: A 24-Item Hamilton Depression Rating Scale (HDRS) = 20.Patients with craniotomy for supratentorial tumors under general anesthesia\nAmerican Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients\nElective surgery\nPatients with Glasgow Coma Scale (GCS) 15/15Infection with Plasmodium falciparum or P. vivax either alone or mixed\nAge >12 months\nWeight >5kg\nLiving in the study clusters\xe2\x80\xa2 All patients attending for a routine diagnostic endoscopic procedure at St Mary's Hospital NHS Trust for dyspepsia and abdominal painAged 18 years or older, male or female.Systolic heart failure with New York Heart Association (NYHA) class II-III.Left ventricular ejection fraction (LVEF) less than 40% by echocardiography during screening and randomization.SCH (TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference range).Having received standard HF therapy for at least 2 weeks, having reached target dose or max tolerable dose.Provided informed consent.female or male of 50 to 85 years old with a care giver \nMini Mental Status (MMS) test between 16 to 26 inclusive \nClinical Dementia Rating (CDR) test inferior or equal to 1 \nNational Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for an Alzheimer's disease \nDiagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test positive for dementiaSubjects aged 18 to 80 years old\nOverweight or obesity (BMI =25 kg/m2)\nPrevious diagnosis of type 2 diabetes, fulfilling at least one of the following criteria: 1) current treatment with oral antidiabetic drugs and/or insulin; 2) a fasting glucose value above 126 mg/dl on at least 2 occasions; 3) blood glucose level at 2 hours after an oral glucose tolerance test is equal to or more than 200 mg/dl; or 4) a glycated hemoglobin (HbA1c) level > 6.5 %\nClinical diagnosis of diabetic nephropathy, with a urinary albumin/creatinine ratio >30 mg/g and an estimated glomerular filtration rate more than 20 ml/min per 1.73 m2.Treatment with stable doses of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or anti-aldosterone agents in the last four weeks.Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.Written informed consent obtained from the subject prior to performing any study specific procedure.A male or female between, and including, 18 and 50 years of age at the time of the first study visit.Healthy subjects as established by medical history and clinical examination before entering into the study.Healthy subjects with no medical conditions that, in the opinion of the investigator, prevents the subject from participating in the study.Subjects must weigh at least 110 pounds (50 kg), but not to present obesity (BMI < 32kg/m2).Female subjects of non-childbearing potential may be enrolled in the study.Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.has practiced adequate contraception for 30 days prior to vaccination, and\nhas a negative pregnancy test on the day of vaccination and\nhas agreed to continue adequate contraception during the entire treatment period and for 1 month, after completion of the vaccination series.Normotensive controls\nStage I (140-159/90-99 mmHg) untreated subjects with essential hypertension\nPatients with PA and stage I (140-159/90-99 mmHg) hypertensionRecently diagnosed type 2 diabetic patients.Fasting plasma glucose between 200-300 mg/dl (A1C level between 7% and 10%).Those who age between 30 and 80 years old and can inject insulin by themselves.Males and females aged 18-40 years of age at the time of vaccination in good health as determined by medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator \nAble to provide informed consent indicating that they understand the purpose of this study and are willing to adhere to the procedures described in this protocol \nIf the subject is a female of childbearing potential, she must use adequate contraceptive precautions (e.g., intrauterine contraceptive device, oral contraceptives or other equivalent hormonal contraception) for 2 months prior to vaccination and continue to use such precautions for a minimum of three months after vaccination.She must also have a negative urine pregnancy test within 24 hours prior to receiving study vaccine.Women at least one year post-menopausal or surgically sterile will not be considered of childbearing potential.Willing to receive the unlicensed vaccine given as an IM injection \nWilling to provide multiple blood specimens collected by venipuncture1.Male or female, 18-75 years old.2.Has a diagnosis of WHO Group 1 PAH.3.Right heart catheterization performed at Screening with results that are: \n1.Mean pulmonary arterial pressure \xe2\x89\xa525 mmHg (at rest) and \n2.Pulmonary venous hypertension (measured as pulmonary capillary wedge pressure (PCWP) \xe2\x89\xa415 mmHg.If PCWP is not available, then mean left atrial pressure or left ventricular end-diastolic pressure \xe2\x89\xa415 mmHg in the absence of left atrial obstruction.and \n3.Pulmonary vascular resistance (PVR) \xe2\x89\xa5300 dyn\xe2\x80\xa2s/cm5 (3.75 Wood units) \n4.Has WHO/NYHA-FC of II or III.5.Be on stable dose of at least one of the following PAH-specific therapies: endothelin receptor antagonist, an agent acting on the nitric oxide pathway (phosphodiesterase type 5 inhibitor or soluble guanylate cyclase stimulator), and/or a prostacyclin or prostacyclin analog.6.Has a 6-minute walk distance that is \xe2\x89\xa5150 and \xe2\x89\xa4500 meters.7.Have a ventilation-perfusion scan that rules out thromboembolic disease.Adult Patients with Overt Hepatic Encephalopathy.Patients scheduled for dental extraction and treated with edoxaban, apixaban, rivaroxaban or dabigatran\nNot having taken the direct oral anticoagulant on the day of the extraction\nProvision of signed and dated informed consent form\nStated willingness to comply with all study procedures and availability for the duration of the studyTerm singleton infants (>37 weeks gestational age)\nBirth weight > 2500g\nHealthy at inclusion\nBreastfed exclusively or predominantly (>50% meals) at inclusion\nNo previous iron supplementation\nNo previous blood transfusion\nInformed consent given\xe2\x89\xa518 years of age undergoing open-heart surgery (sternotomy, including minimally-invasive sternotomies)Patients undergoing small bowel video capsule endoscopyaged between 3 - 36 months\nhaving primary corrective heart surgeryHas a HCC diagnosis confirmed by radiology, histology, or cytology (fibrolamellar, and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) \nHas Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach \nHas a Child-Pugh A liver score within 7 days prior to first dose of study medication \nHas a life expectancy of >3 months \nHas at least one measurable lesion based on RECIST version 1.1 as determined by investigator \nHas Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 7 days prior to receiving the first dose of study medication \nHas documented objective radiographic progression during or after treatment with sorafenib or oxaliplatin-based chemotherapy, or else intolerance to sorafenib or oxaliplatin-based chemotherapy \nFemale participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy \nFemale and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medicationASA 1 \nASA 2 \nPts have current treatment plan at OHSU for extraction of some or all of remaining teeth and scheduled for delivery of a removable appliance post extraction \nTeeth used are able to be isolated with rubber dam \nUnderstand and sign consent formPatients aged 7 years and older must have provided written assent accompanied by written informed consent from patient's representative\nClinical diagnosis of stable plaque psoriasis with involvement of = 10% body surface area (excluding face and scalp)\nPhysicians Global Assessment score of 3 or 4 at baselinepatients affected by mono-lateral symptomatic knee articular degenerative pathology with history of chronic (for at least 4 months) pain or swelling;\nimaging findings of degenerative changes of the joint (osteoarthritis or chondropathy with Kellgren Lawrence Score from 0 to 3 at X-ray evaluation).choroidal neovascularization caused by age-related macula degeneration \nno previous treatment \na follow-up at least 12 months \na baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chartPatients with diagnosis of multiple myeloma according to criteria of the International Myeloma Working Group \nPatients in whom a LEN-DEX-based treatment regimen is indicated \nAdult patients \xe2\x89\xa5 19 years of age who are able to freely provide informed consentASA physical status I-III;\n18-85 years of age, inclusive;\nsurgery less than 3 hours.Type I diabetic patients\nParturients presented for Cesarean sectionType 2 diabetic patients\nAge = 50\nGlycemic control: HbA1c = 10.0%\n10 = Beck Depression Inventory (BDI) <30 points\nParticipants who can undergo contraception in case of being in childbearing period\nUnderstands the study procedure, alternatives, and risks and voluntarily agrees to participate by giving written informed concentSubject must have a diagnosis of COPD based on the American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria.Male or female subjects, aged >=40 years.Females must be of Non Child Bearing Potential.The definition of Non Child Bearing Potential is as following: Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy, or females who are post-menopausal.Have diagnosed COPD stage III or IV according to GOLD criteria: a baseline post-bronchodilator Forced Expiratory Volume, measured at 1 second (FEV1) <50% of predicted normal and a baseline post- bronchodilator FEV1/Inspiratory Vital Capacity (IVC) ratio <70%.Have experienced at least 2 moderate or severe COPD exacerbations leading to medical consultation (requiring oral corticosteroids or increasing dosage of oral corticosteroids and/or antibiotics or hospitalization) within the 12 months preceding Visit 1.Have stable COPD medication within 4 weeks prior to Visit 1 (no new medication added and no dosage changes in medication).Current or ex-smokers with a smoking history of at least 10 pack years (number of pack years = [number of cigarettes per day / 20] x number of years smoked, e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years).Are currently managed at home (outpatients), are ambulatory and able to travel to the clinic.Subjects can be treated with all relevant COPD medication.This includes vaccines, inhaled short-acting beta-2-agonists as needed, short-acting or long-acting anticholinergics (tiotropium), systemic beta-2-agonists, theophylline, mucolytics, antioxidants, beta-1-agonists (for cardiovascular indication), non-invasive ventilation, long term oxygen therapy and can have Cor Pulmonale.A signed and dated written informed consent is obtained prior to participation.Able to comply with the requirements of the protocol and be available for study visits over 52 weeks.White Brazilian of European descent\nFulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD\nEligibility to immediate-release MPH (IR-MPH) treatmentModerate to advanced generalized chronic periodontitis\nBody mass index: > 18.5 kg/m2\nMinimum of 12 natural teeth\nSmokers, non-smokers or former-smokersSubjects who voluntarily consented, after listening enough explanation for this study and investigational product.Adult over 50 years of age.At least one of the knee pain VAS score is 40mm or more.Patients who require medication for more than 12 weeks due to osteoarthritis symptoms.Those who are able to follow the requirements of this clinical trial, such as being able to trace during the clinical trial period and to read and write the VAS questionnaire.Those who weigh more than 40kgNon-ST segement elevation acute coronary syndromePatients with heart transplantation\nPatient with coronary artery disease\nAge between 18 and 80 yearsAdequate performance status: \nBreast - Karnofsky score > 50; \nOvarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score \xe2\x89\xa42 \nIf female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation.Normal organ function within 14 days of study entry \nDiagnosis of one of the following malignancies: \nMetastatic breast cancer (BR) \nMetastatic ovarian cancer (OV) \nMetastatic endometrial cancer (EM) \nMetastatic cervical cancer (CX) \nMeasurable metastatic disease (>1cm) in at least one site other than bone-only \nProgression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease \nProgression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive.If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen.Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) \nPrimary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma).Subjects must have failed at least two previous chemotherapy regimens.Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens.Measurable metastatic disease \nHistologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens \nMeasurable metastatic disease \nHistologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens.normal full term single pregnancy\nage 18 years or more\nBMI 20 - 35 kg/m2\nwritten informed consent obtainedMen or women at least 19 years of age\nType 2 diabetes mellitus\nStable coronary artery disease\nGlobal myocardial perfusion reserve (MPR) index < 2.5\nThe patient or guardian agrees to the study protocol and the schedule of clinical and dynamic SPECT follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.Healthy adults 18-45 years of age \nNon-smoking \nNon-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures) \nBody mass index (BMI) less than or equal to 32 \nMedically healthy on the basis of medical history and physical examination \nHemoglobin > or = to 11.5g/dL \nCompletion of the screening process within 28 days prior to dosing \nProvision of voluntary written informed consentHistory of allergic rhinitis\nWheezingASA I-III\nColonoscopy\nWritten informed consent from participating subjectOsteonecrosis\nplanned decompression surgery with autologous stem cell transplantHas given written informed consent.Male or female outpatients aged at least 18 years and not more than 45 years.Has a diagnosis of major depressive disorder by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.Current HAMD-17 score = 20 and the duration of the index episode is greater than or equal to four weeks.Diagnosis of heart failure according to Framingham criteria\nInformed consent\nAge 18 years or aboveMen and women patients, with age ranging 40-80.Suspected coronary artery disease who are supposed to undergo invasive coronary angiography with appropriate clinical indications\nPatients who are willing to sign the informed consent formWomen (18-75 years) with suspected UTI\nat least two symptoms of UTI (dysuria, urgency of micturition, frequency, lower abdominal pain)\nWritten informed consentH pylori infection failed after at least two eradication therapies\naged 20 years or greater\nwillingness to receive rescue therapyChildren born outside the cluster, and returning more than 72 hours after the delivery\nChildren that the nurse evaluates to die within the next 24 hours.the patients undergoing ascending, arch and/or proximal descending aorta surgery with cardiopulmonary bypass\n20 - 100 yrs oldmajor elective gastrointestinal, gynecological, prostate or bladder surgery patients who are = 60 years old.the surgery is laparoscopic surgery and is expected to last for = 2 hours under general anesthesia and the patient will stay in hospital for at least 7 days after surgery.lack of serious hearing and vision impairment and be able to read so that neurobehavioral tests can be performed.Healthy male or female adolescents, age 12 to 17 years (inclusive) at Screening, with a body mass index (BMI) that is greater than or equal to the United States-weighted mean of the 95th percentile based on age and sex with a body weight greater than 60 kilograms (kg).Participants with Type 2 diabetes mellitus (T2DM) may have a pre-existing or new diagnosis of T2DM.HbA1c =6.5%\nfasting plasma glucose (FPG) =126 mg/dL (7.0 mmol/L)\nParticipants and their families not planning to move away from the area for the duration of the study\nParticipants able and willing to comply with all aspects of the study, including a standardized, reduced calorie diet and an age appropriate, increased physical activity program\nParticipants considered in stable health in the opinion of the investigator\nAble and willing to support and supervise study participation in the opinion of the investigator, including consideration of any existing physical, medical, or mental condition that prevents compliance with the protocol\nAble and willing to personally comply with and execute all aspects of the study requirements for the caregivers or guardiansPatients with de novo stenotic lesions who are suitable for coronary stenting with drug-eluting stentBlood culture-proven typhoid fever (S. typhi or S. paratyphi) \nSigned informed consent to participate in the study.Subjects undergoing a single level lumbar decompression and fusion\n> 18 years of age and < 70 years of age\nThe subject is willing and able to understand, sign and date the study specific patient informed consent and HIPAA authorization to volunteer participation in the studyAge between 18 and 78 year-old.Previous liver transplantation(more than 6 month).Genotype 1 and 4 infection.Hepatitis C recurrence defined by the presence of abnormal liver function test, positive HCV-RNA, histological signs of hepatitis C recurrence.Viral load \xe2\x89\xa510000UI/mL.Immunosuppression with tacrolimus and/or mycophenolate (Prednisone use is allowed at low dose, \xe2\x89\xa410 mg/d).Treatment na\xc3\xafve or treatment experienced (Peg-RBV or triple therapy).Written maternal informed consent\nSingleton pregnancy\nGestational age = 37 weeks,\nASA I\nBMI < 30\nfetus in cephalic presentationMale or female patients age 18 years or older, with relapsed or refractory sALCL who have previously received at least 1 multiagent chemotherapy\nBidimensional measurable disease\nAn Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nFemale patients who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to practice true abstinence\nMale patients who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence\nClinical laboratory values as specified in the study protocolASA I & II, Nulliparous and Multiparous, Spontaneous/Induced/Augmented Labor, Early active labor (cervix <5 cm (if known)), Pain (VPS) > 3, 18-45 years of agehealthy parturients with uncomplicated, single gestation pregnancies, full term (38-42 weeks of gestation) pregnancy, agreed to participateFemale patients older than 18 years.Patients who agree to participate in the study.Those that meet the ACR 1990 and 2010 criteria for Fibromyalgia.No previous use of vitamin D.\nPatients diagnosed with primary or secondary fibromyalgia.Male and female patients, age 18-75 yrs.COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 =92% at 750 m.\nBorn, raised and currently living at low altitude (<800m).Written informed consent.Adult patients up to age 75 years, undergoing elective, ambulatory, arthroscopic rotator cuff repair.De novo kidney transplants\n20 - 65 years old\naspartate aminotransferase/alanine aminotransferase within 2 times the upper limit of normal rangeAge from birth to 21 years \nAll solid organ transplant recipients receiving their care at Seattle Children's Hospital \nSigned consent, and when age appropriate, signed assentPaediatric subjects aged =28 days (= 1 month) to <18 years, requiring non-emergent open hepatic, abdominal, retroperitoneal, pelvic or thoracic (non-cardiac) surgical procedures.i) The first 36 subjects to be enrolled will be subjects aged =1 years to <18 years.ii) The next 4 subjects to be enrolled will be subjects aged =28 days to <1 year.The subject's parent/legal guardian must be willing to give permission for the subject to participate in the trial, and provide written informed consent for the subject.In addition, assent must be obtained from paediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the trial.If the paediatric subject is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the trial), the parent/legal guardian's written Informed Consent for the subject will be acceptable for the subject to be included in the study.Presence of an appropriate mild or moderate bleeding soft tissue or hepatic parenchyma Target Bleeding Site (TBS) identified intra-operatively by the surgeon;\nAbility to firmly press trial treatment at TBS until 4 minutes after randomisationSubjects aged 12-65.Confirmed idiopathic pulmonary hypertension, connective tissue disease associated pulmonary hypertension, congenital heart disease(with Eisenmenger syndrome) associated pulmonary hypertension.Baseline 6-minutes walking distance 150m-550m.WHO pulmonary hypertension function II-III with non-responder to calcium channel blockers.Documented written informed consent.Adult men who have sex with men, and transgender women\nUnaware of HIV status at enrollment in follow-up cohort\nHigh risk for HIV infection\nWilling to test for HIV\nNo prior ART, including prior administration of pre- and post-exposure prophylaxis in the last 30 days\nWilling to provide informed consentHistologic or cytologic diagnosis of stage IIIB/IV NSCLC \nECOG PS: 0,1 \nUnidimensional or bi-dimensional measurable disease \nReceive prior treatment including first-line platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor \nEvidence of disease progression \nLife expectancy >12 weeks \nNeutrophils > 1.5 109/l, Platelets > 100 109/l, Hemoglobin > 9g/dl, Total bilirubin < 1.5 UNL, AST (SGOT) and ALT (SGPT) < 2.5 UNL, Alkaline phosphatases < 5 UNL, Creatinine < 1 UNLHealthy male and/or female subjects between the ages of 18 and 55 years, and a body mass index (BMI) of \xe2\x89\xa5 18 and \xe2\x89\xa4 33 kg/m2 with body weight \xe2\x89\xa5 50 and \xe2\x89\xa4 90 kg at screening.Females must have been surgically sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingo-oophorectomy; proper documentation required) at least 6 months before screening, or be postmenopausal (defined as 24 consecutive months without menses before screening, with a follicle-stimulating hormone [FSH] level of > 40 IU/L at screening).Community in a school district that is within the study area\nArea within each school district that is in need of a wellAge : 18-65\nPatients with major depressive disorder according to DSM-IV criteria that have lasted >8 weeks\nMADRS total score of 18 or higher\nPatients who responded inadequately (a score of >18 on the MADRS) to first-line antidepressant treatment of 4 week duration\nCurrent use of standard antidepressant treatment in monotherapy or combination of 2 antidepressants : escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine ER(150-225mg/d)The study will include 40 post-deep peel women (exoderm), older than 18 years old, treated by the same dermatologist (dr. Landau).The treatment group will receive 5 consecutive daily hyperbaric treatments, 1 hours long each, at 2 ATF, starting from day 7 to peel.Prior to treatment, each patient will be signed on informed consent and will have complete physical examination.The control group will be matched by the following parameters: age, skin color and type, and indication for peeling, and will be picked up by the dermatologist.Subject's ability to lay in a supine position with their hands at their sides during CVP measurements \nA consent form signed by the patient or patient's representative \nSubjects that are age 18-90 \nSubjects that have an indwelling CICC and are transitioning to a PICC for long-term IV access \nCICC placed in the internal jugular vein or subclavian vein positionHistory of falls or dizziness at exit from bed in the morning (at least two incidents in the past year)\nAt least 20/200 corrected visual acuity\nStable health\nNormal hearingBV positive by Nugent score\nHIV negative\nCapable of providing written informed consentMen and women 18-89 years old\nwith the diagnosis of sepsis (as specified below) within the previous 24 hours\nwho require mechanical ventilation, and\nprovide informed consent either personally or by an authorized representative.Males and females who are at least 18 years of age at time of enrollment.Subject understands the investigational nature of the study and provides written, informed consent.traumatic spinal cord injury at least one year ago\nregular bowel care routine (at least four weeks)Adult patient being referred for clinically indicated positron emission tomography myocardial perfusion imaging at the Centre hospitalier de l'Universit\xc3\xa9 de Montr\xc3\xa9alPatients undergoing a high tibial osteotomy (HTO)\nPatients undergoing tibial tubercle osteotomy (TTO) with or without medial patello-femoral ligament (MPFL) reconstructionStage IA or IIA disease\nNot specified\nNo prior therapydiagnosed with PD by a neurologist (Fahn and Elton, 1987); \naged 30 to 85 years; \nat modified Hoehn and Yahr (H&Y) stage 1.5 to 3 (Hoehn and Yahr ,1967; Goetz et al., 2004); \nable and willing to give written consent for participation in the study; \nliving at home in the community; \nable to walk independently for 30 metres with or without an assistive device.Age 18 years or older\nBlunt or penetrating trauma\nRequires VTE thromboprophylaxis\nHigh-risk for VTEAge = 19 and = 70 years;\nPresence of liver cirrhosis\nSerum albumin level = 3.5g/dl, ultrasound or CT scan confirmed ascites (=Grade 1)\nNo administration of diuretics and BCAA within the past 1 week\nVoluntary consent to take part in this trialControl: devoid of any systemic or neurological diseases\nChronic migraine: by ICHD-III (International Classification of Headache Disorder) criteria\nFibromyalgia: by ACR (American College of Rheumatology) 2010 criteriaSingleton pregnancy = 37 weeks gestation\nPatient presented for induction of labor who is determined to be a candidate for oxytocin\nCephalic presentation\nReassuring fetal health assessment (no abnormal findings in fetal assessment, see below)\nMeeting one of the following BMI category:Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.Diagnosed epileptic patients of either sex with age between 10-19 yrs (<19yrs), coming to the medicine Out Patient /In Patient Departments and undergoing AED therapy for more than 6 months.Epileptics with high homocysteine levels i.e.> 10.9 \xc2\xb5mol/L (Normal homocysteine levels are 4.3-9.9 \xc2\xb5mol/L for male and 3.3-7.2 \xc2\xb5mol/L for female adolescent and a high homocysteine concentration is deaned as at least 11.4 \xc2\xb5mol/L for male and at least 10.4 \xc2\xb5mol/L for female.Gender mean of high homocysteine concentration is 10.9 \xc2\xb5mol/L) [5]1.Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures; \n2.Healthy, premenopausal female age 18-47; \n3.History of menstrual events that occur in regular cycles \n4.Agreement not to attempt to become pregnant \n5.Agrees to use double-barrier contraception during the study and for 30 days after discontinuation of study medication.Acceptable double-barrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intra-vaginal spermicide; \n6.Has a negative pregnancy test at the Screening visit.An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history \n7.Normal laboratory values or clinically insignificant findings at screening as determined by the Investigator; \n8.Subject is willing to remain in the clinic overnight for PK assessment on Days 0 and 8 \n9.Ability to complete the study procedures in compliance with the protocol.Patients must be at least 21 years old.The patient must have severe, symptomatic (ACC/AHA Stage D symptoms) tricuspid regurgitation (TR) as assessed by 2D echocardiogram with evidence of peripheral and central venous congestion (specifically lower extremity edema and abdominal ascites requiring diuretics.)The patient must be evaluated by a "heart team" of physicians including an interventional cardiologist, cardiothoracic surgeon, heart failure specialist, and imaging specialist, and presented for review at a local multi-disciplinary conference.By consensus, the heart team must agree (and verify in the case review process) that valve implantation will likely benefit the patient.The heart team must agree that medical factors preclude operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement.Also, other factors which may increase the patients perceived surgical risk for inclusion in the trial will be clearly delineated if they are present.These include, but are not limited to the following as defined by VARC 2: Frailty, Hostile chest, porcelain aorta, IMA or other critical conduit crossing the midline or adherent to the posterior table of sternum, severe right ventricular (RV) dysfunction.The surgeons' consultation notes shall specify the medical or anatomic factors leading to that conclusion.At least one of the cardiac surgeon assessors must have interviewed and examined the patient.The study patient provides informed consent and agrees to comply with all required post-procedure follow-up visits, including annual visits up to 5 years.outpatients aged 18-70 years\nconfirmed diagnosis of H. pylori infection by at least one of the following methods: 13C-urea breath test, histology, rapid urease test or bacterial culture\nan intention of H. pylori eradication treatment and have written inform consent\nability to read short messages on the mobile phoneEarly Syphilis Cases Determined to Be Serofast at 6 Months after Initial TreatmentMale or non-pregnant female between the ages of 18-65\nPatients willing and able to sign the informed consent\nPatients able to comply with follow-up requirements including self-evaluations\nPatients requiring a primary total knee replacement\nPatients with a diagnosis of osteoarthritis, traumatic arthritis, or avascular necrosisMale or female patients 2 to 16 years of age\nPatients who require at least 80% of their caloric intake as PN at study start, and in whom an indication for PN is expected for at least 5 days\nPatients who require a central venous line to receive PN or already have a central venous line in place for other reasons\nWritten informed consent from legal representative(s)HBsAg and HBeAg positive for more than 6 months, HBV DNA detectable with ALT level abnormal lasted for three months and at least time190 IU/L or liver puncture biopsy demonstrated apparent inflammation, never treated before enrolled.18-65 years old\nMale or female\nDiagnosed with GAD according to DSM-IV\nHAMA score=17\nProvide with written informed consent\nAgree to be washed-out for two weeks if receiving SSRI, SNRI or NASA.Must be an outpatient with a primary DSM-IV Obsessive-Compulsive Disorder.Patients must have a score of greater than 20 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS; Goodman et al., 1989b).Diagnosis of comorbid DSM-IV major depressive episode will be allowed in the study provided that the diagnosis is secondary to OCD, they have a baseline Montgomery Depression Rating Scale (MADRS) score of less than or equal to 19, and the onset of OCD predates the onset of the current episode of depression by five or more years.The ability to comprehend and comply with protocol requirements.Written consent must be provided prior to study entry.All women of childbearing potential (WOCBP) must be practicing a medically acceptable method of birth control\nAll female subjects of childbearing potential (WOCBP), including those who are practicing a medically acceptable method of birth control, must have a negative serum pregnancy test within 72 hours prior to the start of study medication.Adult men and women (=18 years).Receptors of a first kidney transplant from an incompatible HLA living donor (at least 1 mismatch HLA at any antigenic level).AB0 compatible transplant.Patients with a calculated PRA of 0% by solid phase technique and absence of anti-HLA class I and class II antibodies by single antigen test (Luminex\xc2\xae).Patients who agree to participate in the Trial by signing the Specific Informed Consent of this study.Potentially fertile women should use high reliability contraceptive methods (Pearl-Index <1) in order to avoid pregnancy during the entire duration of the study and up to 6 weeks after the end of their treatment with Mycophenolate Mofetil (MMF).Potentially Fertile Women include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or who is not post-menopausal (defined as amenorrhea = 12 consecutive months, or women who are receiving hormone replacement therapy with a documented level of follicle stimulating hormone (FSH)> 35 mlU / ml).Potentially fertile women must have a pregnancy test with a negative result in the 72 hours prior to the start of the trial.Sexually active males (including vasectomized males) who are being treated with MMF must accept the use of barrier contraceptive methods during MMF treatment and for 90 days thereafter.Potentially fertile partners of these patients should use a reliable contraceptive method during the same period, in order to minimize the risk of pregnancy.Patients must agree not to donate blood during treatment with MMF and during the 6 subsequent weeks.Males should not make a sperm donation during MMF treatment and up to 90 days after completion.Patient with "de novo" heart Failure and LVEF <= 40% admitted in hospital, without contraindications for BB prescription with cardiologist up-titration prescription and without having achieved BB target dose previous discharge and signing informed consent.Subjects must be female\nSubjects must be 18 years or older\nSubjects must be undergoing unilateral or bilateral mastectomy with tissue expander reconstructionAdult patient, age 18-80 years old, with ruptured aneurysm(s) who experience cerebral vasospasm post operatively within 3-21 days.Antiretroviral naive\nTaking Kaletra containing regimen with suppressed viral load.Taking an NNRTI or integrase containing regimen without prior history of use of PI for more than 2 weeks\nTaking an NNRTI or integrase containing regimen with prior exposure to PI greater than 2 weeks.It must be clearly stated in the source document that PI was switched to another agent for convenience.Taking another PI containing regimens with suppressed viral load.It must be clearly stated in source document that if another PI was used for greater than 2 weeks the regimen was switched to another agent for convenience.Subjects with prior history of PI use may be enrolled, if there is a genotype showing no resistance to Kaletra Other Inclusion criteria\nBe at least 18 years of age and able to give informed consent.Diagnosed with TB by criteria per Brazilian Ministry of Health\nHave a good clinical response to TB.Tolerating tuberculosis therapy containing rifampin for the 2 weeks prior to screening,except for persons taking protease inhibitors at time of diagnosis of TB.,.Subjects taking protease inhibitors will be screened and initiate visit 1 within 3 days of starting TB medication\nHIV positive with documentation present in source document.Have a CD4 cell count greater than 50 cells/mm3if not taking ART.Persons with cd4 < 50 may be enrolled, if it is felt that in the best interest of the patient, that enrollment in the study will allow for quicker initiation of antiretroviral therapy than referral to another treatment center.intolerance of or allergy to ticagrelor or prasugrel\nhistory of any stroke, transient ischemic attack or intracranial bleeding\nknown intracranial neoplasm, intracranial arteriovenous malformation or intracranial aneurysm\nactive bleeding, clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding\nfibrin-specific fibrinolytic therapy less than 24 h before randomization, non-fibrin-specific fibrinolytic therapy less than 48 h before randomization\nknown platelet count < 100.000/\xc2\xb5L at the time of screening\nknown anemia (hemoglobin <10 g/dL) at the time of screening\noral anticoagulation that cannot be safely discontinued for the duration of the study\nINR known to be greater than 1.5 at the time of screening\nchronic renal insufficiency requiring dialysis\nmoderate or severe hepatic dysfunction (Child Pugh B or C)\nincreased risk of bradycardia events (Sick Sinus, AV block grade II or III, bradycardia-induced syncope)\nindex event is an acute complication (< 30 days) of PCI\nconcomitant medical illness that in the opinion of the investigator is associated with a life expectancy < 1 year\nconcomitant oral or i.v.therapy with strong CYP3A Inhibitors (e.g.ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice > 1 L/d), CYP3A substrates with narrow therapeutic indices (e.g.cyclosporine, quinidine), or strong CYP3A inducers (e.g.rifampin/rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital ) that cannot be safely discontinued\n=1 doses of ticagrelor or prasugrel within 5 days before randomisation\nno written informed consent\nparticipation in another investigational drug study\nprevious enrolment in this study\nfor women of childbearing potential no negative pregnancy test and no agree to use reliable method of birth control during the study\nPregnancy, giving birth within the last 90 days, or lactation\ninability to cooperate with protocol requirementsMidsubstance pain in the achilles tendon\nSymptoms for at least 3 months\nUltrasound scanning at the first visit shows thickness of the achilles tendon above 7 mm or 20% thicker than the contralateral.Patient can read and understand danishPatients with STEMI undergoing primary PPCI\nAge > 18 years oldFor healthy individuals: Healthy, without allergies and with the age of 18 years or above.For patients: Burn injury exceeding 6-8 Total Burned Surface Area %Patients provided written informed consent;\nPatients aged between 18 and 75 years;\nKnee symptomatic OA (Kellgren-Lawrence grade 1-4)\nFailure of conservative treatment for at least 3 months;\nPatients agreed to actively participate in the rehabilitation protocol and follow-up program;\nMale or female patients;\nWomen of childbearing age had to use a proven method to prevent pregnancy, before the surgical treatment.Male sex\nASA status I or II\nBMI between 20 and 34 kg/m2\nCruciate ligament of the knee reconstructive surgery\nNo contraindications to general and regional anesthesiaelective procedure\nweight over 40 kg\nAmerican Society of Anesthesiology class I-III\nfirst upper GI endoscopy procedure\nfinnish or/and swedish speakingPathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT); Patients must have previously untreated locally advanced or metastatic NSCLC; Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R).Aged 25-80 at screening.Subjects older than 80 will be allowed at the discretion of the PI.Ambulatory (defined as able to ambulate at least 10 meters, with or without assistance).Clinical Diagnosis of PD based on the United Kingdom Brain Bank diagnostic criteria for PD.At least 8 micturitions per 24 hours and\nAt least 3 urgency episodes per 3-day diary.A MoCA score between 19 and 28 (inclusive) at screening.For those on cognitive enhancers (donepezil, rivastigmine, memantine, galantamine) a MoCA score between 19 and 29 (inclusive) at screening.Provide informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.Be cognitively capable, in the opinion of investigator, to understand and provide such informed consent.Be cognitively capable to complete the required questionnaires and assessments, OR have a care partner who is willing and capable to assist them in the completion of these tasks.Be on a stable regimen of antiparkinson's medications at least 30 days prior to screening, and be expected to remain on a stable dose for the duration of the study.If taking cognitive enhancers (donepezil, rivastigmine, memantine, galantamine), must be on stable dose at least 30 days prior to screening, and be expected to remain on a stable dose for the duration of the study.ST-segment elevation acute myocardial infarction patients during the first 12 hours of sympton onset;\nIntention to perform primary percutaneous coronary intervention;\nSigned informed consent;\nPatient eligible for transradial and transfemoral primary percutaneous coronary intervention, being pre-requisites: (a) familiarity of the operator with the radial and femoral techniques using vascular closure devices, (b) agreement of the operator to use the access route determined by the randomization process.age 35-75 years;\nDiagnosis of Type 2 Diabetes from at least 3 years;\nHbA1c < 10%;\nnormal blood pressure or controlled hypertension;\nBMI < 40;Estimated glomerular filtration rate =20 mL/min and <60 mL/min\nHgb =8.5 g/dL and =11.5 g/dL\nSerum ferritin =500 ng/mL and transferrin saturation (TSAT) =25%\nSerum intact parathyroid hormone =600 pg/mLPatients should have at least 12 teeth present \nPatients with Moderate to Advanced Chronic periodontitis \nPatients with 2 or more interproximal sites (not on same tooth) with probing pocket depths of 5mm or more and 2 or more interproximal sites (not on same tooth)of probing attachment loss of 4mm or more which bled on probing.Provide written informed consent before beginning any study related activities \nBe between age 18 and 55 years \nBe able to speak, read and write English and follow simple instructions for completing self-rated scales \nMeet DSM-IV criteria for BPD as assessed by the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II).adult patients\nASA class 1 to 3 patients\npatients scheduled for elective breast mastectomy or quadrantectomyMen or women aged 18-60 years.Primary psychiatric diagnosis of Major Depressive Disorder, without psychotic features, confirmed via SCID-IV structured diagnostic interview.Screening Hamilton Depression Rating Scale (HAMD) = 18; and Baseline HAMD = 15.If the patient is a woman of child-bearing potential, she must agree to use an acceptable form of birth control for duration of study participation.Able to understand and provide informed consent for participation.histologically diagnosed primary classical osteosarcoma in extremities\nstaging IIB\nMRI showing no skip lesion\nreceive standard neo-adjuvant chemotherapy, adjuvant chemotherapy,and standard surgical treatmentsubmucosal,\nintramural or subserosal leiomyomas,\nsymptoms of menometrorrhagia,\nmenstrual disorder,\ninfertility,\npelvic painMale and/or female healthy volunteers, age 18 to 55 years.Females must be of non-childbearing potential.Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, diet restrictions and other trial procedures.obese : weight for height > median + 3 standard deviations\nsimple obesityMen and women older than 18 years, scheduled consecutively to perform a coronary procedure in the department of hemodynamics of the National Institute of Cardiology "Ignacio Chavez".Patients may have any of the following indications for cardiac catheterization: Thoracic pain under study.Stable chronic coronary disease.Acute myocardial infarction with ST segment elevation, not perfused (without timely reperfusion therapy) with less than 4 weeks of evolution.Acute myocardial infarction with ST-segment elevation, successful thrombolytic therapy, which will undergo drug-invasive therapy.Acute myocardial infarction without ST segment elevation.Unstable angina.Any acute coronary syndrome, to intervene non-infarct-related artery.Disease of any heart valve.Myocarditis or pericarditis.Dilated cardiomyopathy.Patients in renal or cardiac transplantation protocol for any etiology.Congenital heart disease that requires knowing the coronary anatomy prior to surgical correction.The planned procedure can be any of the following: For diagnostic purposes (coronary angiography only, left catheterization, left and right catheterization).For therapeutic purposes: percutaneous coronary intervention (PCI), with or without stent placement.A priori access must be right or left radial artery.Radial arterial pulse may be present or absent by palpation.Modified Allen or Barbeau test should be positive (presence of collateral palmar flow).patients who need suturing for laceration under procedural anesthesia using ketamineAge between 0 and 18 years\nVenous pH less than 7.25\nKetonuria as confirmed on urine point-of-care testing or urinalysis\nHyperglycemia (Serum glucose > 200 mg/dl)\nSerum bicarbonate <15 mmol/L\nPICU admissionAge 35-70 years old\nFasting blood glucose 100-125 mg/dLSymptoms of ischaemia.New or presumed new significant ST-T wave changes\nDevelopment of pathological Q waves on ECG.Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.Patients with informed consents\nWithout basal disorders of neurology and psychiatricsDiagnosis of dyslipidemia: The existence of a previous clinical diagnostic of dyslipidemia associated with lipid-lowering therapy.It is also considered patients who have an altered analytical, using the following cutoffs: total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40 mg / dl or LDL-cholesterol = 150 mg / dl.Lipid-lowering treatment and diet, stable in the last month.A concentration of LDL-cholesterol above 100 mg / dl, in the month prior to inclusion.An apnea-hypopnea index between 5-30 h-1histologically proven prostate adenocarcinoma within 1 year of enrollment\nLow risk: Gleason <or=6 & PSA <or=10 & Clinical Stage T1b-T2a,Nx or N0, Mx or M0\nIntermediate risk:Gleason <or=6 & PSA<or=10 & Clinical Stage T2b OR Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b OR Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0\nECOG Performance Status 0-1\nNo prior prostate radiation or other definitive therapyMales or females above the age of 18\nPatients undergoing laparoscopic or robotic colorectal resectionschildren and teenagers aged less than 20 years,\nhistory of gastrectomy,\ngastric malignancy, including adenocarcinoma and lymphoma,\nprevious allergic reaction to antibiotics (bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline) and PPI (esomeprazole),\ncontraindication to treatment drugs,\npregnant or lactating women,\nsevere concurrent disease,\nconcomitant use of clopidogrel, or (9) Unwilling to accept random assignment of subjectsWomen subjected to ICSI through controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRH antagonist.Patients suspected to have vitamin B12 deficiency defined as a plasma vitamin B12 below the reference interval (<200 pmol/L).Currently Homeless\nSmoked at least 100 cigarettes in lifetime\nAUDIT score of > or equal to 5, < or equal to 26\nAged 18 years or older\nWilling to attend study sessions and follow other study protocol1.Male or female of any race, at least 18 years of age at Visit 1 Screening.2.Has provided verbal and written informed consent.3.Be able and willing to follow instructions, including participation in all study assessments and visits.4.Currently being treated for glaucoma using at least two medications, and be willing to continue on the same regime.5.Suffers from at least two of the symptoms in the GLIA\xe2\x84\xa2 Glaucoma Medication Ocular Side Effect Symptoms Questionnaire at a severity of 2 (moderate) or more.6.If a woman of childbearing potential, have a negative urine pregnancy test at Visit 1 and be using an adequate method of birth control throughout the study period.patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months\nstable metabolic status\nbenign diseasePatients with either Relapsing-remitting MS (RRMS), Secondary progressive MS (SPMS), or Primary progressive MS (PPMS) by McDonald 2010 criteria.Patients defined by subtype based on 2013 updated phenotypic criteria.prospectively with an EDSS change of at least 1.0 points over the last two years, or\nretrospectively, with any significant change in motor function over at least one year, unrelated to relapse.55 years of age or older at time of randomization;\nNo evidence of recent new inflammatory disease activity (inactive by the Lublin criteria16) with no new relapse for at least five years and no new MRI lesion for at least three years\ninterferon \xc3\x9f-1a,\ninterferon \xc3\x9f-1b,\nglatiramer acetate,\nnatalizumab,\nfingolimod,\ndimethyl fumarate, or\nteriflunomide; continuously for no less than 5 years.Taking most recent DMT continuously* for no less than two years.Willing to be randomized per this protocol; each patient will be questioned as to their willingness to stay in the trial regardless of the group to which group they are randomized.Willing to follow the protocol\nContinuously will be defined as no less than 75% of all prescribed doses, with no time of greater than four weeks from last intended dose to have missed a dose (8 weeks for natalizumab, i.e.one missed dose).Age >18 years old\n1cm squared surface area\nVenous incompetence confirmed by clinical assessment and duplex ultrasound scan\nNo evidence of arterial disease (Arterial Duplex or Ankle Brachial Pressure Index >0.9)\nPatients able to complete trial procedures\nPatients with a life expectancy of greater than 1 yearAdult (age 18 years and older)\nPatients with end-stage renal disease(ESRD)/chronic kidney disease(CKD)stage 51.Age \xe2\x89\xa5 18 years \n2.Patient with breast cancer, histologically proven, metastatic or locally advanced \n3.Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part).4.Patient with at least an assessment of the response to Eribulinparturient in labour without cervical dilation and regular uterine contractionsIs between 18 and 40 years of age (inclusive) \nHas had a self-reported visual exam in the last two years \nIs an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) \nHas a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) \nHas a spectacle cylinder up to 0.75D in each eye.Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye.Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses.Has clear corneas and no active ocular disease \nHas read, understood and signed the information consent letter.Patient contact lens refraction should fit within the available parameters of the study lenses.Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so).Is willing to comply with the visit scheduleCouple must have been in a new relationship that started no more than six months prior to study entry\nBoth partners plan on remaining in Montreal for at least 1 year\nPlan on having continued sexual contact with partner\nBe willing to comply with study proceduresDiagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients who need dapsone administration.Subjects are dapsone-naive.All subjects must have a clinical need for treatment with dapsone that precedes the decision to participate in the study.All subjects are willing to complete the 6-weeks period clinical trial.All subjects are written informed consent.Able to give fully informed consent in writing \nMales or females aged >/= 50 years \nNo significant disease or drug use \nAbsence of any sign of dementia/cognitive impairment in neuropsychological examinationsPatients for brain imaging: \nPatient and designee capable of giving fully informed consent in writing \nPatient fulfils DSM-IV and NINCDS-ADRA criteria for probable Alzheimers diseaseSigned informed consent form\nMale or female of aged 50 years or older\nTypical AMD and PCV patients\nBCVA of 24 letters or overSymptomatic paroxysmal AF who had at least one AF episode electrocardiographically documented within one (1) year prior to enrollment.Documentation may include electrocardiogram (ECG); Transtelephonic monitoring (TTM), Holter monitor or telemetry strip\nFailed at least one antiarrhythmic drug (AAD) (Class I or III antiarrhythmic drugs) as evidenced by recurrent symptomatic AF, or intolerable to the AAD\nAge 18 years or older\nSigned Patient Informed Consent Form (ICF)\nAble and willing to comply with all pre-, post-, and follow-up testing and requirementsMale or female on stable dose of IgPro20 (Hizentra) therapy.Women of childbearing potential must be using and agree to continue using medically approved contraception (which must be discussed with the study doctor) and must have a negative pregnancy test at screening.Subjects with PID, eg, with a diagnosis of common variable immunodeficiency or X-linked agammaglobulinemia, as defined by the Pan American Group for Immune Deficiency and the European Society of Immune Deficiencies.With infusion parameters as specified below:\nExperience with pump-assisted infusions of IgPro20 at the tolerated flow rate of 25 mL/h per injection site for at least 1 month prior to Day 1.Total weekly IgPro20 dose of = 50 mL (= 10 g).Experience with pump-assisted infusions of IgPro20 at tolerated volumes of 25 mL/injection site for at least 1 month prior to Day 1.Experience with frequent (2-7 times per week) infusions of IgPro20 at the tolerated flow rate of approximately 0.5 mL/min (equivalent of 25-30 mL/h) per injection site for at least 1 month prior to Day 1.The dose (volume) per injection site should not exceed 25 mL.Patients with histologically confirmed diagnosis of prostate cancer who have not yet developed bone metastases \nProstate cancer patients with a rise in PSA under hormone therapy.PSA criteria: \nPatients who have undergone prostatectomy: any rise in PSA or \nPatients without prostatectomy: 2 consecutive rises in PSA levels relative to a previous reference value, separated by one month.The first measurement must occur one month after the reference value and must be above the reference value.The second confirmatory measurement taken one month after the first measurement must be greater than the first measurement.Previous chemotherapy or radiotherapy must have been performed \xe2\x89\xa5 8 weeks prior to study entry.Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (patients that spend less than 50% of time in bed during the day) \nAdequate liver function - serum total bilirubin concentration less than 1.5 x upper limit of normal value \nAge: \xe2\x89\xa5 18 years \nPatient has given written informed consent prior to any study-specific procedures.Patients with psychiatric or addictive disorders which prevent them from giving their informed consent must not enter the study.Adults over 18 years of age\nSymptomatic GSV or SSV vein reflux > 0.5 seconds on colour Duplex\nVaricose vein tributary requiring treatmentRecipient is Age = 18 years\nMet MGH transplant center criteria, listed for liver transplant\nHCV naive\nAble to sign informed consentThe group of patients who participated in the study included adults aged at least 19 years among the atraumatic CA outpatients who came to the ER and received CPR.planned elective cholecystectomyPatients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within in last 12 months\nAge = 18 years and = 50 years\nPre-operative hemoglobin >8 g/dl\nWilling to have buccal administration of misoprostol or a placebo at least one hour pre-procedure.Ability to understand and the willingness to sign a written informed consent.Admissible medical/surgical history\nCan be previously treated with Depo-Lupron, Depo-Provera, or Oral Contraceptive pills\nIntraoperative use of vasopressin and uterine tourniquet is permissible\nCan have had prior Cesarean deliveryLiver Transplant Recipients have received liver transplantations for at least 6+1 months prior to enrollment\nLiver Transplant Recipients have no acute rejection episodes within 3 months prior to the enrollment and are clinically stable\nLiver Transplant Recipients have been treated with twice-daily regimen of tacrolimus(TAC) plus everolimus(EVR) and TAC and EVR trough levels have stayed within targeted ranges for at least 6 weeks prior to enrollment\nProvide written informed consent prior to inclusion.Liver transplant recipients who are 18-65 years of age of a primary liver transplant\nAllograft functioning at an acceptable level as defined by the AST, ALT, Total Bilirubin levels =3 times ULN prior to enrollment.Abbreviated MDRD eGFR = 30 mL/min/1.73m2.Age 18 to 75 years old (male or female).Patients with posterior or posterolateral disc herniations at one level between L1 and S1 with radiographic confirmation of neural compression using CT and/or MRI.At least six (6) weeks of failed, conservative treatment prior to surgery, or requires immediate surgery to prevent permanent disability.Minimum posterior disc height of 5mm at the index level(s).Lower back pain and/or sciatica with or without spinal claudication.Oswestry Questionnaire score of at least 40/100 at baseline.VAS leg pain of at least 40/100 at baseline.Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.age>18 years\ncritical limb ischemia (Rutherford class 4-6)\nangiographic stenosis>50% or occlusion of at least one tibial vessel of at least 40mm for which an interventional treatment is scheduledAll patients subjected to deep sedation in ambulant care, having a colonoscopy\nASA 1-330 min or more of (1) continuous clinical seizure activities or (2) recurrent seizure activities without recovery(returning to baseline)between seizures; \nclinical data is complete.Patients who are 19 years or older on screening\nPatients with type 2 diabetes mellitus\nPatients with 7.0% = HbA1c = 11.0% at the screening visit\nPatients with Fasting Plasma Glucose <15mmol/L(270mg/dL) on screening1.Women and men ages 18 years and over.2.Interest in participating in a novel nutritional supplement program.3.Willingness to follow recommendations.At least 18 years of age at the time of screening\nHave stable renal function for one month (30 days) prior to enrollment\nHave Chronic HCV infection prior to transplantation with documented HCV viremia = 1,000 IU/ml at screening and either documented HCV Ab positivity or HCV viremia = 1,000 IU/ml at least 6 months prior to enrollment.Documented genotype 1 HCV infection prior to enrollment and after their transplant in the post-transplantation cohort\nHCV disease staging within 12 months prior to enrollment by liver biopsy, transient elastography, or biochemical testing\nBe able to give informed consent and comply with study guidelines\nWomen of childbearing age will be required to have a negative pregnancy test at enrollment and use birth control throughout the duration of treatment.On the transplant waiting list followed by the University of Maryland's nephrology clinic or the Baltimore VA's nephrology clinic\nOn chronic hemodialysis not yet on the transplant list and followed in the University's hemodialysis center or in the University's nephrology clinic\nHave chronic kidney disease with GFR <50liver transplantElderly patients over 65 years old exhibiting clinical indices of cardiovascular disease \nMale or female \nSubjects who were hospitalized in the Geriatric Unit of the Emile Roux Hospital (AP-HP) \nMMSE (Mini Mental State Examination)score > or = 15 \nSupervision available for study medication \nAble to ingest oral dietsystolic blood pressure between 140-160 mmHG\nbetween 18-80 years oldFor both groups: \nPatients aged from 18 to 65 years old.Both genders eligible for study.Female participants must use a contraceptive method.Feasibility of patch testing.Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol.Patients must be registered in a social security system or with a health insurance coverage \n\xef\x83\x98 First group: allergic patients \nPatients with allergic contact dermatitis to para-phenylenediamine (PPD) based on a history of PPD contact dermatitis and positive PPD patch tests.\xef\x83\x98 Second group : healthy volunteers \nNo history of PPD allergic contact dermatitis, with a negative PPD patch test.singleton, term pregnancy\ncurrently on buprenorphine maintenance therapy\nscheduled for elective CD under spinal anesthesiaT1DM for at least 12 months\npersistent HbA1c levels = 7.5% (58 mmol/mol) despite optimized education therapy,\nrecurrent severe hypoglycemic episodes or high glucose variability\nwillingness to wear the insulin pump1.Age: 18-75 years old, no limitation in gender; \n2.Left ventricular ejection fraction (LVEF) \xe2\x89\xa4 40% (ECHO); \n3.Patients with chronic heart failure (NYHA class II or III); \n4.In the past one month, the clinical condition (including history, clinical symptoms and signs) was relatively stable; \n5.Patients on standard treatment of chronic heart failure at the target dose or maximum tolerance dose for over 1 month ,or unchanged dose in last 1 month; \n6.Understand and sign the informed consent form;At least two of the following additional criteria\nAt least 70 yrs old\nFemale gender\nDiabetes\nCreatinine clearance <60mL/min\nHistory of gastro-intestinal or other organ bleeding\nBaseline anemia\nCurrent treatment with glycoproteins IIb-IIIa inhibitorsSuccessful cardiac ablation for AF\nDocumented freedom from AF recurrence (symptomatic or asymptomatic arrhythmic recurrences lasting longer than 30 seconds) 3 months after successful cardiac ablation (AF recurrence during 3-month blanking period is excluded).Patient must have been on a commercially approved anticoagulation therapy for at least two (2) months prior to randomization in the OAT Study.CHADS2 score = 2 or CHA2DS2-VASc score (=3)\nLeft ventricular ejection fraction > 25%\nLA size < 65\nHigh risk for thromboembolic events (i.e., CHADS2 score = 2 or CHA2DS2-VASc score = 3) and require OAT before undergoing cardiac ablation\nAble and willing to comply with all pre- and follow-up testing and requirements\nSigned informed consent form\nAge 18 years or olderHistory of three or more consecutively failed In Vitro Fertilization (IVF) cycles after embryo transfer.Normal uterine cavity (as assessed by hysteroscopy or HSG).Normal hormonal investigation: TSH, PRL, FBS.Normal acquired/inherited thrombophilia profile: LAC, ACA IgG/IgM, Prot S, Antithrombin III, beta-2 glycoprotein, Factors V, II, MTHFR.Normal semen analysis and mild/moderate male factor (Total motile sperm count > 5 million/ml and/or normal WHO morphology >20%.Patient provides written informed consent.Normal uterine cavity\nNormal Hormonal investigation: TSH,PRL,FBS\nFrozen embryo transfer cycles: at least 2 embryos\nPrimary or secondary infertility: tubal occlusion, male factor, unexplained, endometriosis, ovarian factors\xe2\x80\xa6\nBody mass index (BMI) =18 to =30 kg/m2Informed consent must be obtained prior to any study procedure.Age>18 years.Subjects of STEMI who underwent primary PCI within the first 12 hours.Patients with SOF/VEL treatment for the treatment of chronic HCV genotype 1 through 6.Patient is at least 18 at the day of screening.Patient is able and willing to sign the Informed Consent Form.Patient is able and willing to follow protocol requirements.male and female patients over the age of 18 years.written informed consent (approved by the Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) obtained prior to any study specific procedures.patient with mild to severe carotid artery diseaseToxic epidermal necrolysis with SCORTEN 1 to 5 at admissionPatients with symptomatic FAI\nClinical and radiographic evidence of FAI\nPatients able to provide consent to study participation\nCompletion of 6 weeks of physical therapy programHistologically confirmed colorectal adenocarcinoma\nDisease limited to the liver Unresectable disease by surgery or other local therapies\nAge >18 years\nECOG performance status 0-2,Child pugh A or B\nExpected survival = 3 months\nAdequate hematological, hepatic, and renal functionUndergoing abdominoplasty or TRAM flap breast reconstructionHighly active RMS as defined by:\nOne relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or more T2 lesions, while on therapy with other disease modifying drugs (DMDs)\nTwo or more relapses in the previous year, whether on DMD treatment or not.Expanded Disability Status Scale (EDSS) score less than equals to (<=) 5.0.Other protocol defined inclusion criteria could apply.The cirrhotic malnourished patients who were diagnosed as liver cancer preoperatively and underwent hepatectomy were consecutively enrolled.Patients will be included if they are having an in-patient spinal fusion procedure, are 18 years or older, post and post-operative pain control plan includes opioid medications.presence of stress urinary or urgency incontinenceRA cohort: Receiving MTX at stable doses of 10 to 25 mg weekly for at least 12 weeks, Have a DAS28 of 3.2 or higher (The level of disease activity is considered to be low if the DAS28 is 3.2 or less) (Prevoo et al., 1995)\nOA cohort: Diagnosis of osteoarthritis made by physician.Subject's age is between =12 and 16 years, inclusive\nSubject is scheduled for a procedure that requires general or neuraxial anesthesia\nSubjects must have normal or clinically acceptable physical exam\nSubjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure =128/78 mmHg (sitting, after 5 minutes of rest)\nFemales must have a urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1\nSubject's parent or legal guardian gives informed consent and subject gives assent.eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthyMale or female who is among 20 to 80 years of age at screening.Scheduled to electively undergo open-laparotomy.American Society of Anesthesiology Physical Class 1-3.Ability and willingness to provide informed consent1.Are referred to the Cachexia Clinic with involuntary weight loss of >5% of their premorbid weight within the previous 6 months.2.Are 18 years of age or older \n3.Have a Karnofsky performance score of 60 or higher.4.Can maintain oral food intake during the study \n5.Can understand the study procedures and can sign an informed consent form.6.Are not currently taking melatonin.7.Are taking megestrol acetate and continue to lose weight despite at least 2 weeks of therapy.8.Have a calculated creatinine clearance of >/= 60 cc/min.Rotator cuff tear patients undergoing arthroscopic rotator cuff tearPatients with pulmonary arterial hypertension (PAH) \nPatients with chronic thromboembolic pulmonary hypertension (CTEPH) \nAll prevalent patients (diagnosed >12 month ago) with PAH or distal CTEPH who had a consultation at the PH centre in Zurich between November 2015 and November 2016)Patients scheduled for laser laryngeal surgery under general anesthesia with either Propofol or desflurane based technique.All renal (only) male and female recipients aged = 60, years undergoing kidney transplantation from a living or deceased donor, including Expanded Criteria Donors (ECD).Panel Reactive Antibody (PRA) < 30%.Patients who consented to participate in the study by signing the informed consent form before the transplant surgery to the 1st post-operative day).All adult patients 18 years of age or older admitted to the intensive care units of St. Boniface General Hospital with a diagnosis of acute pulmonary blastomycosis requiring mechanical ventilation.Type I or II diabetes mellitus.Target ulcer area between 0.5 and 5 sqcm, and more than 4 weeks old.Ankle-brachial pressure index above 0.7.Apgar score at 5 minutes >7\nbirthweight greater than 2.4 kg\nAge of at least 10 hours\nAt least one void.The participant has a diagnosis of Parkinson's disease according to the diagnostic criteria of the UK Parkinson's Disease Society Brain Bank.The participant has received a levodopa combination drug for >= 1 month and has either of the following.Wearing off phenomenon \nDecreased response to levodopa combination drugs \nThe participant has received a levodopa combination drug without change in the dose regimen.The participant is an outpatient of either sex aged >= 30 and < 80 years.Endometrial thickness = 7 mm after stimulation\n18-45 years\nIVF/ICSI fertilisation\nBMI > 18,5 <30 kg/m2\ncycle length 25-34 daysages of 7 and 75 years\nmarked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment\ndisease duration of at least 5 years.Consecutive 30 female patients presenting to our clinic for brow lifting with botulinum toxin will be randomized to receive one of the two injection techniques1.Diagnosis of primary immunodeficiency with established plan to undergo myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant for treatment thereof or diagnosis of a form of primary immunodeficiency for which hematopoietic stem cell transplantation is not indicated.2.Active infection with EBV, CMV, and/or Adenovirus, unable to be successfully controlled with standard therapy.3.Steroids less than 0.5 mg/kg/day prednisone \n4.Karnofsky/Lansky score of \xe2\x89\xa5 50 \n5.ANC greater than 500/\xc2\xb5L.6.Bilirubin <2x, AST <3x, Serum creatinine <2x upper limit of normal, Hgb >8.0 \n7.Pulse oximetry of > 90% on room air \n8.Negative pregnancy test (if female of childbearing potential) \n9.Patient or parent/guardian capable of providing informed consent.At the cluster level, ED physicians practicing at a participating site will be eligible.At the patient level, all hip fractures seen by a participating ED physician will be eligiblePatients undergoing thoracic aorta surgery with hypothermic circulatory arrest, over 20-of ageAll patients will be undergoing a primary unilateral total knee arthroplasty for a diagnosis of osteoarthritisInformed consent obtained prior to any screening procedure \nCaucasian male or female patient \nAt least 18 years of age \nWeight at least 45 kg \nPatient with moderate or severe chronic atopic dermatitis \nGood general health ascertained by medical history, physical examination and laboratory determinations, showing no signs of clinically significant findings, except chronic atopic dermatitis \nNegative pregnancy test (premenopausal female patient) at screening and use of adequate contraceptive measures (both male and female patients) throughout the study and 30 days after the last cis-UCA dosePatients eligible for PCI with application of DES, due to ACS.Patients with known or newly diagnosed T2D (type 2 diabetes is diagnosed according to current WHO criteria or by the use of anti-diabetic drugs)\nMale and female subjects 18-80 years.HbA1c (accordingly to IFCC) 47 mmol/mol - 110 mmol/mol.Signed informed consent form.Women without PCOS as defined by the Rotterdam criteria.Presence of at least 2 cryopreserved good quality cleavage-stage embryo (good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments).Histological confirmation of relapsed/refractory diffuse large B-cell lymphoma after prior rituximab and anthracycline-containing systemic treatment regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc.Subjects must have received no more than 2 prior systemic therapies for lymphoma.Prior therapy with systemic rituximab monotherapy or conventional chemotherapy (i.e.bendamustine, CVP (Cyclophosphamide, Vincristine Sulfate, Prednisone) or other) \xc2\xb1 rituximab for indolent non-Hodgkin's lymphoma (NHL) \xc2\xb1 maintenance/extended-use rituximab will count as 1 line of systemic therapy.Eastern Cooperative Oncology Group (ECOG) Performance status \xe2\x89\xa4 2 \nSubjects must have normal organ and marrow function as defined below: \nHemoglobin \xe2\x89\xa5 8.0 g/dl \nAbsolute neutrophil count \xe2\x89\xa5 1,000/mcL \nPlatelet count \xe2\x89\xa5 75,000/mcL \nTotal bilirubin \xe2\x89\xa4 1.5 X the upper limit of normal (ULN) unless a known history of impaired bilirubin conjugation such as Gilbert's, for whom the maximum will be 2.5 ULN.Aspartate transaminase (AST) (SGOT) \xe2\x89\xa4 2.5 X institutional ULN \nAlanine transaminase (ALT) (SGPT) \xe2\x89\xa4 2.5 X institutional ULN \nInternational normalized ratio (INR) > 1.5 \xc3\x97ULN \nPatients must have a calculated serum creatinine clearance > 50 mL/min using Cockcroft-Gault calculation or based on 24-hour urine collection performed within 7 days prior to treatment.Specific guidelines will be followed regarding inclusion of relapsed/refractory DLBCL based on Hepatitis B serological testing as follow: \nHBsAg negative, HBcAb negative, HBsAb positive patients are eligible.Patients who test positive for HBsAg are ineligible \nPatients with HBsAg negative, but HBcAb positive (regardless of HBsAb status) should have a HBV DNA testing performed and protocol eligibility determined as follow: \nIf HBV DNA is positive, the subject is ineligible.If HBV DNA is negative, the subject may be included but must undergo HBV DNA PCR testing monthly x 3 months beginning from the start of treatment \nSubjects must have the ability to understand and the willingness to sign a written informed consent document.For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of rituximab, whichever is longer.A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: \nWith female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab.Men must refrain from donating sperm during this same period.With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo.Surgical patients 60 years of age or older\nSurgery scheduled to last at least 2 hours (including time for anesthesia induction, etc)\nEnglish speaking ability.Ability to give informed consentFluent in reading and writing in English language.= 21 years of age at the time of participation.Cerebral palsy of any types caused by Neonatal JaundiceChildren undergoing ENT surgery under general anaesthesia.Patients who meet 1987 ACR criteria for SLE with 1996 modifications\nSLEDAI >/= 6 at screening visit\nPositive ANA OR anti-dsDNA within one year of screening\nIn the opinion of the investigator there is intent to treat with a biologic (e.g.patient failed standard of care treatment) however there is no organ threatening diseaseAsymptomatic women 45-68 years, residents in the Piedmont Region, attending the regional breast cancer screening programPatient is currently enrolled in a Novartis OGD or GMA-sponsored or Incyte-sponsored clinical study (where Incyte can delegate the sponsorship to a preferred CRO, if applicable) that is approved to enroll into this rollover study, is receiving ruxolitinib and has fulfilled all of the requirements of the parent protocol.Patient is currently benefiting from the treatment with ruxolitinib, as determined by the investigator\nPatient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures\nPatient currently has no evidence of progressive disease, as determined by the investigator, following previous treatment with ruxolitinib\nWritten informed consent obtained prior to enrolling in roll-over study and receiving study medication.If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.The patient and/or the patient's parent/legal guardian is willing and able to provide signed informed consent.The patient has a confirmed GAA enzyme deficiency from skin, blood, or muscle tissue and/or 2 confirmed GAA gene mutations.Infant and toddler Pompe disease patients can be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) will not exceed 3 percent of the total blood volume during a period of 4 weeks and will not exceed 1 percent at any single time.The patient, if female and of childbearing potential, must have a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening.Note: All female patients of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.For patients previously treated with alglucosidase alfa the patient has received alglucosidase alfa for at least 6 months.Age of = 18 years of age and able to give written informed consent;\nActive chronic central serous chorioretinopathy (cCSC);\nSubjective visual loss > 6 weeks, interpreted as onset of active disease;\nFoveal subretinal fluid (SRF), on optical coherence tomography (OCT), at Baseline Examination;\n=1 ill-defined hyperfluorescent leakage areas on fluorescein angiography (FA) with retinal pigment epithelial window defect(s) that are compatible with cCSC;\nHyperfluorescent areas on indocyanine green angiography (ICGA).Moderate to severe CD define as HBI score > 4.Montreal classification: no limitation, except age> 6.Participants must have completed 3 cycles of a bortezomib-based induction regimen (as defined by current NCCN guidelines) and have no evidence of disease progression as defined by IMWG criteria.Participants with light chain and free light chain (FLC) only may be enrolled if they meet all the criteria for a diagnosis of MM.Participants must be considered by their physician eligible to receiving the IRD regimen.Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2 at time of enrollment.An average defecation frequency (DF) of <3 per week based on a 3-week defecation diary (patient-reported)\nMeet at least one other criterion of the Rome-IV criteria for idiopathic constipation based on the 3-week defecation diary (1)\nRefractory to conservative treatment\nAge: 14-80 years\nStraining during =25% of defecations\nLumpy or hard stools in =25% of defecations\nSensation of incomplete evacuation for =25% of defecations\nSensation of anorectal obstruction/blockage for =25% of defecations\nManual manoeuvres to facilitate =25% of defecationsPatients undergoing colon resectionTreated with a stable dose of one of the following for at least 3 months prior to screening: * >=1000 mg/day immediate-release metformin; or metformin >=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy.HbA1c between 7.1% and 11.0%, inclusive.Body Mass Index (BMI) >21 kg/m^2 and <35 kg/m^2.Response assessment of complete response (CR), partial response (PR), long stable disease (SD) for >3 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.Availability of tumor biopsy material extracted and preserved by the investigating site.The patient was on nonsteroid anti-inflammatory drug (NSAID) treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started.The patient was confirmed to have a history of gastric ulcer or duodenal ulcer.Age : from 20 to 90 y/o.HBsAg-positive for more than 6 months and HBV DNA < 2000 IU/ml (Subgroup 1)or HBsAg-negative but anti-HBc positive with HBV DNA < 2000 IU/ml (Subgroup 2).Inflammatory arthritis patients who plan to treat with biological agents, including Humira or Enbrel or Simponi or Orencia or Mabthera or Actemra; as first line biologic treatment is indicated.Adult acute myeloid leukemia \nAge: \xe2\x89\xa518 and \xe2\x89\xa4 60 \nClinical condition of the patient allows to carry out induction therapy: ECOG performance status: \xe2\x89\xa4 2 and the Hematopoietic Cell Transplant-Co-morbidity Index (HCT-I): \xe2\x89\xa43 \nInformed consent to participate in the study (ICF signed) \nThe second early induction start criteria is in addition to the listed above, the percentage of the blasts on the level >10% on 7th day.The diagnosis of chronic bronchitis\nThe diagnosis of community-acquired pneumoniae\nFEV1 value = 30-80%\nThe diagnosis of mild-severe acute exacerbation of chronic bronchitis (AECB)\nOxygen saturation < 90%Menopausal status\nSexually activePatients between 3 to 16 years of age undergoing adenotonsillectomy, with or without myringotomy or myringoplasty\nASA 1 & 2Evidence of Mycoplasma pneumoniae infection\nLobar pneumonia or pneumoniae with pleural effusionPrimary kidney transplant recipients, adultsWeight stable (<3 kg weight change within last 3 months) \nConstant habitual activity patterns (no deviation > 1x/wk at 30 min/session within last 3 months) \nConstant habitual diet patterns within last 3 months \nWillingness to eat a chocolate-flavored snack at test sessions and two week training period \nNo allergies to any test foods \nNot planning to change use of medications known to influence appetite or metabolism \nNot diabetic \nNo history of GI pathology \nNon-smoker for one year or moreMDD Cohort: Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID); CDRS-R score >40; Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g.SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.Anxiety Cohort: Meet DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID); ADIS Clinical Severity Rating \xe2\x89\xa54 (moderately severe) for any of the 4 included anxiety disorders; Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g.SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing; Failure to achieve remission with previous CBT or subject declines current CBT therapy\nStable psychiatric medications and doses for the month prior to enrollment.Subjects may continue to engage in any ongoing psychotherapy.Medically and neurologically healthy on the basis of physical examination and medical history.Parents able to provide written informed consent and adolescents must additionally provide assent.Patients aged 19 or older\nPatients who have submitted a written consent to participate in the clinical trial\nDe novo lesion\nPatients scheduled for elective intervention to treat ischemic cardiovascular diseaseadult patients aged = 55 years with\na radiographically confirmed hip fractureCapacity to provide informed consent before any trial-related activities\nEstablished T2DM (=3months)\nHbA1c = 9% if on triple therapy or = 10% on diet & exercise or monotherapy or dual therapy\nCurrent glucose lowering therapy either mono, dual or triple of any combination of metformin, sulphonylurea, DPP-IV inhibitor, GLP-1 therapy or an SGLT2 +/- diet and exercise\nPoorly managed diet controlled diabetes (with HbA1c > 6.5% , not currently taking any glucose lowering therapy, meeting BMI inclusion range)\nBody mass index > 30Kg/m2 or > 27.5 Kg/m2 (South Asian),\nDiagnosis of T2DM before the age of 60 years of age\nAge =18 and = 65 yearsSelf-identified African American\nSmokes = 1 cigarette per day (cpd)\nSmoke on = 25 days of the past 30 days\nFunctioning telephone\nInterested in quitting smoking\nInterested in taking 3 months of varenicline\nWilling to complete all study visitsEnglish speaking/literate\nAge 18-100 years\nVisual analog score pain >= 5\nGreater than or equal to 3 months of pain after onset of symptoms that has failed conservative treatments\nConfirmation of glenohumeral OA via imaging\nTransient relief of symptoms after diagnostic intra-articular injection into the glenohumeral jointOverweight/Obese Adult patients (age 19 years -65)\neligible based on WALI screening toolWomen with PCOS as defined by the Rotterdam criteria.Presence of at least 2 cryopreserved good quality cleavage-stage embryo (good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments).Moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) 30-79%predicted);\nResting functional residual capacity (FRC) >120% predicted;\nClinically stable and on stable triple therapy with an ICS/LABA and tiotropium;\nSymptomatic: Baseline Dyspnea Index =8 and answer "in the morning" when asked about what time of day their COPD symptoms are worst.Age 19 and more\nOn dual or triple antiplatelet therapy and between 12months and 14months from Bioresorbable Vascular Scaffold implantation\nNo history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding20-70 yrs of age\nASA(American Society of Anesthesiologists) physical status class I or II\nScheduled for gynecological laparoscopic surgeryPatients who have non muscle invasive bladder cancer male patients patients between 40-80 years oldphysical status I - III\npatients scheduled to undergo hip arthroplasty18-80 year, male or female.Chronic Heart failure subjects with medical history of cardiac disease or other related cardiovascular disease.Left ventricular ejection fraction (LVEF) less than or equal to (=<) 40 percent (%).New York Heart Association (NYHA) class of II - IV\nNYHA II : Slight limitation of physical activity.Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue or palpitation.NYHA III:Marked limitation of physical activity.Comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitation.NYHA IV:Unable to carry on any physical activity without discomfort.Symptoms at rest can be present.If any physical activity is undertaken, discomfort increased.Signed Informed Consent Form (ICF).Patients undergoing elective abdominal surgery with an expected blood loss of = 500 ml\nASA Physical Status II - III\nSigned written informed consent form\nBody weight = 140 kg\nSepsis\nBurns\nRenal impairment (AKIN stage = 1) or acute and/or chronic renal replacement therapy\nIntracranial or cerebral haemorrhage\nCritically ill patients (typically admitted to the intensive care unit)\nHyperhydration\nPulmonary oedema\nDehydration\nHyperkalaemia\nSevere hypernatraemia\nSevere hyperchloraemia\nSeverely impaired hepatic function\nCongestive heart failure\nSevere coagulopathy\nOrgan transplant patients\nMetabolic alkalosis\nSimultaneous participation in another interventional clinical trial (drugs or medical devices studies)Patients with osteoarthritis of the hip secondary to degeneration, inflammatory arthritis, gouty arthritis, acetabular dysplasia or osteonecrosis of the femoral head, and undergoing primary unilateral minimally invasive THA\nAge > 18 years and < 90 years\nFailure of medical treatment or rehabilitation.Hemoglobin > 11g/dl,\nNo use of non-steroid anti-inflammatory agent one week before operationPatients of familial cases of POF : \nFemale subjects between 16 and 40 years or women older than 40 years with a cessation of ovarian function before the age of 40 years with increased levels of FSH \nPrimary or secondary amenorrhea for more than three months with LH and FSH> 30mUI/ml \nNo cases of fragile X syndrome in the family or blepharophimosis syndrome \nAt least two cases in the family \nOrigin Caucasian \nPatient signing the consent form for at least the blood sample \nPatient with Social Security \nPopulation Index related topics : \nThe presence of cycles until the age of 40 years with proven fertility, at least one child \nAmenorrhea and FSH> 30mUI/ml according to the criteria of the index subject \nMen of the family of index case \nPopulation control : \nWomen of Caucasian origin \nWomen who had regular cycles until at least age 40 and at least one child \nLack of land autoimmune (no history of thyroid disease or diabetes type 1) \nWoman signing the consent form for at least the blood sampleDSM-IV-TR major depressive disorder\naged between 20 and 80\ndurg-naive or drug-freeChildren, aged between one and 24 months.classified as (American Society of Anesthesiologists) ASA physical status I or II, undergoing TEE were enrolled in the study.Patients undergoing a loop ileostomy closureAge of 18 and over, male or female;\nPatients with histologically confirmed advanced (stage IV) gastric cancer, NSCLC, breast cancer or ovarian cancer, who choose monotherapy of oral vascular targeting drug (apatinib) due to intolerability or inappropriateness of other therapies;\nPresence of measurable lesions (=10mm on spiral CT scan) subject to RECIST 1.1;\nBlood pressured controlled at 150/100 mHg following drug administration;\nAn ECOG PS score of between 0 and 1;\nA life expectancy of at least 3 months;\nSubjects who volunteer to participate in this study and have signed the Informed Consent Form (ICF), with good compliance with treatment and follow-up.Adult (=18 years)\nPresence of intracranial aneurysm (with or without rupture)\nTreating surgeon has recommended surgical repair of the aneurysmHealthy men and women, age 40-75 yrs, without any disease and need of medication.Born, raised and currently living at low altitude (<800m).Written informed consent.Kyrgyz ethnicityAdult patients (age = 18)\nDiagnosed by preoperative imaging modalities to have a brain tumor (including metastatic brain tumors) or vascular lesions (aneurysm, arteriovenous malformation or arteriovenous fistula) requiring surgical intervention.The patient is determined by a board certified neurosurgeon to have a tumor or vascular lesion that would take up fluorescein\nPatient or legally authorized representative provides written informed consent to enroll in this studyAge >= 65 years, < 90 years;\nScheduled to undergo surgery for primary solid organ cancer under general anesthesia, with an expected duration of surgery >=2 hours;\nPlanned to use patient-controlled intravenous analgesia after surgery;\nProvide written informed consent.18 years of age and older,\ndiagnosis of stage II adhesive capsulitis as determined by clinical examination of the treating physician, and\nabsence of abnormal findings on X-ray.age =18 and <75 years;\npatients with stable coronary artery disease referred to PCI in an artery suitable for IVUS pullback;\nsigned informed consent before PCI.3 -15 years old\nClinical symptoms suggestive of pharyngitis with MC Isaac score =3\nRapid-antigen detection test (RADT) positive for GAS-\nSigned informed parental/patient consent formAge18-65\nASA 1-2\nElective TNTS resection of Pituitary Tumor\nNo narcotic before surgery as premedication\nAble to ExtubateKidney transplant recipients at Washington University/Barnes-Jewish Hospital\nExperiencing GI toxicity from MPA as determined by the treating physician within 12 months post-renal transplant\nOn standard immunosuppression with tacrolimus and prednisone19 years old and above.Patients who previously have received a liver transplant over the last six months and within last three years.Patients who are on Tacrolimus immunosuppressive therapy twice a day for at least two weeks.Patients who have normal liver function and renal function.Patients who have been monitored without complication such as acute rejection.Patients willing to sign his/her consent.1.Cognitive impairment from mild to moderate degree defined by a Clinical Deterioration Rating (CDR) score range between 0.5 and 2.0.2.Evidence on brain MRI of white matter hyperintensities (leukoaraiosis of moderate or severe degree according to the modified Fazekas visual scale and/or presence of lacunar infarcts).3.Consent to participation in the study.Males aged 18 years and above\nPatients with a diagnosis of prostatic carcinoma requiring prostate surgeryPatients presenting for elective posterior spinal fusion surgery (lower thoracic, lumbar, sacral)\nAges 18-8018-year or older patients\nPatient hospitalized in neuro-critical care for:\nArachnoid hemorrhage\nIntra parenchymatous hematoma\nstroke\nAcute brain Severe injury\nPost-operative complication of an act of neurosurgery or programmed neuroradiology\nSedation and mechanical ventilation planned > 2 days\nMonitoring of intracranial temperature and pressure by intraparenchymal sensor (Sophysa\xc2\xae)\nBrain temperature > 38.5\xc2\xb0C for more than 30 minutesPregnant women with abdomen discumfort and ultrasound diagnosis of polyhydramnios (AFI>25cm) \nSingle or twin pregnanciesThe informed consent has been obtained from the patient.With confirmed diagnosis of stage II colon cancer.With moderate/good ECOG health rating (PS): 0-1 score.The patient receive no anti-cancer treatment before primary surgery.The patient receive radical operation for colon cancer with negative margin.patient hospitalized in critical care units\npatient infected by multi drug resistant Gram negative bacteria susceptibly only to colistin\nsource of infection: blood, respiratory, intra abdominal or urinaryClinically diagnosed autoimmune encephalitis\nIneffective 1st line treatment (e.g.steroid IV, IVIg) and 2nd line treatment (e.g.Rituximab or cyclophosphamide)Male and females aged 18 to 70 years\nBrain death\nMale and females aged 18 to 70 years\nIndication of kidney transplantation\nInformed consentmale patients with androgenetic alopecia between 18 years and 60 yearsWritten consent for participation in the clinical trial\nAge 18 to 45 years Irregular menstruation (> 35 days) or secondary amenorrhea> 3 monthsUnresectable, histologically confirmed hepatocellular carcinoma with evident disease limited to liver.Tissue from tumor must be available.This may be paraffin embedded tissue from previous biopsy/resection or if it is not available, a repeat biopsy must be performed.The requirement for biopsy may be waived if alpha-fetoprotein is greater than 500 ng/mL and in the investigators opinion not explained by a concurrent hepatic inflammatory process.Patients must agree to have a 20 cc blood sample drawn in addition to routine labs with each cycle of chemotherapy.Patients must have measurable disease.If prior radiation therapy was administered, measurable disease must be outside the radiation field.Patients must have a Zubrod performance status of 0-2.Patients must have a predicted life expectancy of at least 12 weeks.Patients must have a pre-treatment granulocyte count (i.e., segmented neutrophils + bands) of greater than or equal to 1,500/mm3, a hemoglobin level of greater than or equal to 9 gm/dl, and platelet count greater than or equal to 50,000/mm3.The granulocyte requirement may be waived if in the investigator's opinion the lower count reflects hypersplenism with adequate bone marrow reserves.Patients must have adequate renal function as documented by a calculated creatinine clearance \xe2\x89\xa5 60.Patients must have adequate hepatic function as documented by a serum bilirubin less than or equal to 2x the institutional upper limit of normal, regardless of whether patients have liver involvement secondary to tumor.Patients may not have ascites or the ascites must be responsive to diuretics.Age > 18 years\nEastern Cooperative Oncology Group score 0-2\nFirst Diagnosed Head and neck cancer and plan for treatment with cisplatin\nSerum creatinine =1.5 mg/dl or eGFR=60(ml/min/1.73 m2)Newly dignosised type 2 diabetes according to WHO criteria.glycated hemoglobin (HbA1c) was more than 10%;\nSeronegative for antibodies against insulin, islet cells and glutamic acid decarboxylase (GAD);Female subjects aged =/> 18 years and of reproductive age.Capacity to give consent for study participation, after being adequately informed of the aims, benefits, risks, time and motion of the study.Healthy, term, breastfeeding infants who will be predominately breastfed for at least 6-months.This will be determined by answering yes/no to question 'do you intend to breastfeed until your infant is at least 6 months of age.'1.Individuals scheduled for undergoing colonoscopy at the Endoscopy Center of Wuxi people's Hospital in China \n2.Greater than the age of 18 \n3.Individuals living with other family members \n4.OutpatientsAdult patients (= 18 years)\nPatient on hemodialysis treatment for at least 1 month\nPatient with a history of, or presenting a new episode of atrial fibrillation (either permanent or paroxysmal).Patient with a CHADS2VASC score =2\nPatient with high risk of bleeding as defined by (1) HASBLED score =3 OR (2) HASBLED = CHADS2VASC score, OR (3) recent history of severe bleeding (type 3a, 3b, 3c), particularly cerebral or gastrointestinal, OR (4) prior recurrent (>2) history of falls.Patient capable of understanding information about the study and of giving his/her consent\nPatient informed of the preliminary medical exam results\nPatient with healthcare insurance\nWritten consent signedPatient who undergoing gynecologic laparoscopic surgery\nPatient who agrees to participate in this study\nPatient able to speak and understand Thai\nPatient able to complete the questionnaireAge 18 or older with unilateral or bilateral inguinal herna for laparoscopic repair\nAmerican Society of Anesthesiology (ASA) Class I and IIPatients undergoing an operation that is scheduled to last more than 2 hoursFemales undergoing Intra-Cytoplasmic Sperm Injection (ICSI) cycles\nAge between 20 and 40 yearsobtained consent\nsingleton pregnancy\nsubarachnoid anaesthesiaolder than 18 years (of both sexes)\ndiagnosed with stable chronic heart failure NYHA class II-III\nejection fraction < 40 % as assessed by 2D echocardiography\nwho have been optimized on Guideline Directed treatment for heart failure for at least a month prior to enrolling.Patients aged greater than 18 years of age \nAbility to understand and willingness to comply with the study protocol \nWritten informed consent \nPatients meeting the Rotterdam PCOS workshop criteria for polycystic ovary syndrome, defined by oligomenorrhea or amenorrhea and at least one of the following two signs: clinical or biochemical evidence of hyperandrogenism or ultrasound finding of polycystic appearing ovaries.Males or non-pregnant, non-nursing females between the ages of 2-65 years\nLTBI diagnosis as per Canadian TB Standards using either the Tuberculin Skin Test (TST) or the Interferon Gamma Release Assay (IGRA)\nChildren 2-5 years with negative TSTs who have been in close contact with a case of active TB disease recently\nAble and willing to provide fully informed consent or parent/guardian able to provide consentMale or female = 2 years of age;\nHave sickle cell disease (confirmed by Hb electrophoresis or more specific tests) or other conditions with iron overload from repeated blood transfusions (see exclusion criteria for exceptions);\nBaseline LIC >7 mg/g dw (measured by MRI);\nPatients who have received no less than 20 transfusions of RBCs;\nPatients who have received at least 1 transfusion per year in the last 2 years and who are expected to have a continuing requirement (based on Investigator's judgement) during the duration of the trialUncomplicated RYGB performed minimum 3 months prior to the study.Fasting plasma glucose < 7,0 mM, HbA1c < 48 mmol/mol 3 months after RYGB1.Age: 12 to 36 months of age (The diagnosis of CP is often uncertain under the age of 12 months.The cutoff at 36 months is to have a population of young children when the brain is most "plastic" and most susceptible to reorganization).2.Diagnosis: Diagnosis of spastic CP confirmed by a pediatric neurologist or pediatric rehabilitation specialist.3.Etiology: The insult to the central nervous system that caused the motor dysfunction must have occurred during gestation or within one year after birth independent of gestational age.4.Disease severity level: Gross Motor Function Classification System (GMFCS) levels I, II and III.1.Age 18-80 years \n2.Patients with at least 1 \xe2\x89\xa550% stenosis in a coronary vessel, subjected to FFR assessment, who exhibit variation in Pd / Pa ratio \xe2\x89\xa5 0.05 (e.g.difference of max Pd/Pa minus min Pd/Pa) during steady state hyperaemia (determined by visual assessment).3.Written informed consentadults capable of providing consent\nhave a diagnosis of locally advanced or metastatic melanomause of basal-bolus insulin\nonset of diabetes after age 30\nBMI less than 35\neGFR at least 60 ml/mn\nHb A1c 7.0-10.0%\nwillingness to perform home glucose monitoring\nwillingness to transmit glucose and medication information weeklyUnderstand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent\nMale or non-pregnant, non-lactating female patients at least 18 years of age\nDiagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS\nActive AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline\nSpinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline\nTotal back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline\nPatients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications\nStable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit\nPatients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent\nTotal ankylosis of the spine\nUse of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer.History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician.Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa\nPatients who have taken more than one anti-TNFa agent\nAny intramuscular or intravenous corticosteroid injection within 2 weeks before baseline\nAny therapy by intra-articular injections (e.g.corticosteroid) within 4 weeks before baseline\nPrevious treatment with any cell-depleting therapies\nPatients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine)Subjects referred to diagnostic or therapeutic colonoscopy.1.Had a diagnosis of PHN, DN, CRPS, carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy (upon mutual agreement of the sponsor and investigator) \n2.Patients with PHN must have had pain >3 months after rash healing \n3.Patients with DN must have had Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy with or without dynamic allodynia of the lower extremities \n4.Patients with CRPS must have met current IASP (International Association for the Study of Pain) diagnostic criteria \n5.Patients with carpal tunnel syndrome must have had a diagnosis by combination clinical neurological examination (e.g., Phalen's and Tinel's signs), electrodiagnostic testing, and daily painful symptoms of at least 3 months' duration \n6.Patients with HIV neuropathy must have had HIV, subjective symptoms of painful peripheral neuropathy, and daily painful symptoms of at least 3 months' duration \n7.Patients with idiopathic sensory neuropathy must have had pain of at least 3 months' duration \n8.Reached an average daily pain rating during the baseline week of pain ratings greater than 4 on the 0-to-10 numerical pain rating scale (Question 5 of the BPI) \n9.Had never received an analgesic regimen that contained lidocaine or gabapentinPatients are able to provide signed and dated written informed consent prior to any study specific procedures.Women are post-menopausal (defined as at least 1 year post cessation of menses) and aged = 45 and = 70 years.Males are aged = 40 years and = 70 years.Patients should have suitable veins for cannulation or repeated venipuncture.Patients are diagnosed with T2DM for at least the last 6 months.Patients are on no other anti-diabetic drug treatment, or on stable maximum 3000 mg daily dose metformin treatment and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months5.HbA1c levels =6.0% (=42 mmol/mol) and =9.0% (75 mmol/mol).Have a body mass index (BMI) = 35 kg/m2.Patients less than 16 years old with newly diagnosed PML-RARa positive acute promyelocytic leukemia.weigh more than 200 lbs \nare high level ambulators corresponding to levels E to F of the Special Interest Group of Amputee Medicine (SIGAM) mobility grade \nhave the ability to follow multi-step commands.Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol, prior to any study procedures.Healthy obese male and female volunteers aged 18 to 55 years, inclusive.Heterozygous subjects may be 18 to 65 years inclusive.In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities.Body Mass Index of 30-40 kg/m2, inclusive.Heterozygous subjects may have a broader BMI range; to be eligible heterozygous subjects may have a BMI 27 -55 kg/ m2, inclusive.Stable body weight during the previous 6 months, based on Investigator judgment.Blood pressure <140/90 mmHg at Screening and D-1.Measurement may be repeated within 24 hours, based on Investigator judgment.Females must not be pregnant and must have a negative serum pregnancy test result at the Screening Visit and Day -1.Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through the Final Study Visit: hormonal, condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or IUD.Hormonal contraception must have started at least 3 months prior to screening.A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception.Subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal range), do not require contraception during the study.Males with female partners of childbearing potential must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through the Final Study Visit.Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time.Male subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution.ASA I-III patients scheduled for elective one or two level minimally invasive lumbar fusionsMale & female patients >= 18 and < 70 years of age\nPositive HBeAg before starting NA treatment\nTreated by a single NA (lamivudine, adefovir, entecavir or tenofovir) for 6 months to 5 years\nDeveloped HBeAg seroconversion (HBeAg negative and ant-HBe negative) with undetectable HBV DNA by PCR based assay on NA treatment.Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of test drug.Additionally, all females must be using reliable contraception during the study and for 3 months after treatment completionPrevalent NHHD patients who have received >1 year dialysis with unfractionated heparin as anticoagulant\nAge >= 18\nInformed consent availablecurrently on hemodialysis at a CDC dialysis unit\nEnglish speaking\nable to provide informed consentAge=18 years and =80 years;\nPatients with non-cystic fibrosis bronchiectasis diagnosed by high-resolution CT;\nAre sensitive to amikacin;\nAcute exacerbation of bronchiectasis;\nCapable of the completion of bronchoscopy, alveolar lavage, pulmonary function testing etc;\nWilling to join in and sign the informed consent form.Kindergarteners who have joined our outreach dental service will be invited to join this study.Preschool children aged 3-4 years who have tooth decay and are attending the first year of kindergarten will be invited to join this study.Aged at least 18 years with an ability and willingness to give written informed consent.Body mass index 25-35 kg/m2 \nUsers of at least 2 cups of caffeinated coffee per day who are willing to be randomized to any of the interventions.Non-smokingInfertile women with eugonadotrophic anovulation/oligoovulation.Unexplained infertility.Patients age 8- 18 years 2) Patients undergoing minimally invasive pectus excavatum repair via Nuss procedure 3) American Society of Anesthesiology Status I-IIIa licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load.NOTE: The term "licensed" refers to a United States Food and Drug Administration (FDA)-approved kit, which is required for all IND studies, or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally.Non-US sites are encouraged to use US FDA-approved methods for IND studies.WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment.A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (eg, indirect versus competitive), or a Western blot or a plasma HIV-1 RNA.OR\nDocumentation of HIV diagnosis in the medical record by a healthcare provider.Tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF)/TAF-containing fixed-dose combination regimens\nRitonavir (RTV) to cobicistat (COBI)/COBI-containing fixed-dose combination regimens\nTDF to TAF/TAF-containing fixed-dose combination regimens\nRTV to COBI/COBI-containing fixed-dose combination regimens\nHIV-1 plasma RNA less than 50 copies/mL obtained within 90 days prior to study entry by any FDA-approved assay at any United States laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs.No more than one HIV-1 plasma RNA greater than or equal to 50 and less than 200 copies/mL (only one "blip") in the past 6 months with a subsequent HIV-1 plasma RNA less than 50 copies/mL.NOTE: There should be no plasma HIV-1 RNA greater than 200 copies/mL within the 6 months prior to study entry.HAND diagnosis (ANI, MND, or HAD) within 60 days prior to study entry.HAND is defined as at least mild impairment on neurocognitive testing (more than one standard deviation below appropriate normative data in two domains of functioning) and no severely confounding factors.Absolute neutrophil count (ANC) greater than or equal to 500/mm^3\nHemoglobin greater than or equal to 7.5 g/dL\nPlatelet count greater than or equal to 40,000/mm^3\nCreatinine less than or equal to 2.0 x upper limit of normal (ULN)\nAspartate transaminase (AST) less than or equal to 5 x ULN\nAlanine transaminase (ALT) less than 3 x ULN\nAlkaline phosphatase less than or equal to 5 x ULN\nTotal bilirubin less than 1.5 x ULN.NOTE: If the potential participant is taking an indinavir (IDV)- or atazanavir (ATV)-containing regimen at the time of screening, total bilirubin less than or equal to 5 x ULN is acceptable.Creatinine clearance (CrCl) greater than or equal to 60 mL/min, either measured or estimated by Cockcroft-Gault equation.NOTE: A calculator for estimating the CrCl can be found at www.fstrf.org/ACTG/ccc.html\nFemales of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, ie, who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, hysterectomy or bilateral salpingectomy or bilateral oophorectomy or tubal ligation) must have a negative serum or urine pregnancy test by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care (POC) / CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate external quality assurance programs within 48 hours prior to study entry\nFemales of reproductive potential must agree not to participate in the conception process (ie, active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, must use at least one reliable form of contraception.Female participants must use contraceptives while receiving study treatment and for 6 weeks after stopping study treatment.More information on this criterion is available in the protocol.Men and women 18 years of age and older who are able to complete the neuropsychological tests\nAbility and willingness of participant or a legally authorized representative (see protocol for more information) to provide informed consent\nAbility and willingness to take oral study medications19-65 years of age\nASA physical status classification I or II\nScheduled for total hip replacement surgeryMale or female >40 and <70 years old.Has a body mass index >27 and <47 kg/m2.Not diagnosed with Type 2 diabetes.Not currently engaged in > 60 min/wk of exercise\nMeet at least 3 of 5 National Cholesterol Education Adult Treatment Panel III\nIncreased waist circumference (=102 cm in men; =88 cm in women)\nElevated triglycerides (=150 mg/dl), or on medication for treating the condition\nReduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication for treating the condition\nHigh blood pressure (=130 mmHg systolic or =85mmHg diastolic), or on medication for treating the condition\nElevated fasting glucose (=100 mg/dl), or on medication for treating the conditionPatients with a histologically, radiologically or haematologically confirmed malignancy whose pain is judged by the investigator to be caused by the malignancy \nPatients must have been on a stable daily dose of weak opioids or strong opioids for at least 72 hours prior to the start the study and must remain at the same dosage for the duration of the study \nPatients must have a VAS (Visual analog scale) >=40mmNursing homes will be eligible to participate if they meet the following criteria:\nLicensed nursing home in Orange County or Southern Los Angeles County serving adults\nMinimal use of chlorhexidine bathing*\nMinimal use of nasal decolonization* *Minimal use defined as <15% of residents receiving at least one chlorhexidine bath or nasal decolonization treatment during their nursing home stay.Uncomplicated RYGB performed minimum 3 months prior to the study.Fasting glucose < 7,0 mM, HbA1c < 48 mmol/mol 3 months after RYGBAll patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment.This will often be a third or fourth line treatment, i.e.patients with advanced disease.Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.ASA I, II, III presenting for ambulatory surgery to be performed under general anesthesiaAbility to understand and willingness to sign a written informed consent document \nAge \xe2\x89\xa5 18 years \nHistologic diagnosis of chondrosarcoma, verifiable after enrollment \nMeasurable disease \nPreviously treated or incurable disease without options for standard of care therapy \nECOG performance status of 0-2 \nLife expectancy of > 3 months \nFor patients of reproductive potential (males and females), use of reliable means for contraception (e.g., contraceptive pill, intrauterine device [IUD], physical barrier) throughout the trial and for 1 year following their final exposure to study treatmentDSM-5 diagnosis of insomniaInfertile lean women with PCOS as defined by the Rotterdam criteria.CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles).aged 18 or older,\nhave undergone oro-tracheal intubation for a coma (Glasgow Coma Score below or equal to 8),\nwith mechanical ventilation initiated in the first 48 hours following hospital admissionPatient is indicated to have an ocular refractive surgery performed (myopia, astigmatism, hypermetropy) by the Lasik method.Patient presents a normal eye fundus.Patient has intraocular pressure (IOP) \xe2\x89\xa4 20 mmHg.Elevated blood-cholesterolAdult male and female aged 19 to 75 years\nVoluntarily consented to participate in the study and signed the informed consent form after receiving the explanation of the objectives, methods and effects of the study.Adults patients aged 18 to 85 years\nDiagnosed with Major Depressive Disorder, unipolar or bipolar depression\nUndergoing ECT for treatment of their symptoms\nCurrently residing in ManitobaAge between 20 and 40\nNormal menstrual cycles: 25-34 days\nOligomenorrhea/amenorrhea or polycystic syndrome (defined according to the Rotterdam criteria 2004)\nBMI >18 and <35 kg/m2Diagnosis of Heart Failure;\nLower left ventricular ejection fraction 45% (LVEF <45%) assessed by simple and recent echocardiogram;\nFunctional Class II and III by the New York Heart Association (NYHA)\nClinically stable;\nEx-smokers over five years;\nMaximal inspiratory pressure (MIP) <70% of predicted;\nForced expiratory volume/Forced vital capacity (FEV1 / FVC) > 70% of predicted;Body mass index (BMI; weight [kilogram(kg)]/height^2 [meter square (m^2)]) between 18 and 30 kg/m^2, (inclusive) \nBe healthy for their age group with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at Screening or admission.Minor deviations in ECG, which are not considered to be of clinical significance to the investigator, are acceptable \nBe healthy on the basis of clinical laboratory tests performed at Screening.If the results of the serum chemistry panel [including liver enzymes], hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant.This determination must be recorded in the participants' source documents and initialed by the investigator \nMen who are sexually active with a woman of childbearing potential and have not had a vasectomy must agree to use a barrier method of birth control for example, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug.In addition, their female partners should also use an appropriate method of birth control for at least the same duration \nParticipants' must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the studyEarly, intermediate, advanced, non metastatic Hepatocellular Carcinoma.Indication for radioembolization validated after pluridisciplinary committee meeting.Isolated target on initial imagery (invasive hepatocellular carcinoma excluded) \nWHO (World Health organization) Performance status: 0, 1 or 2 \nIf cirrhosis, Child A score with total bilirubin less than 30 micromoles per liter \nCreatinine clearance more or equal to 30 mL/min \nPatient informed and consent signature obtained(1) cases of infertility, older than 20 years of age and not older than 40 years.(2) Body mass index (BMI):20-29.(3) women have experienced two or more implantation failure attributed to inadequate endometrial development.chronic obstructive pulmonary disease (COPD), GOLD grade 2-3\nresidents at low altitude (<800 m)Subjects with a history of moderate to severe psoriatic disease\nGroup 2: Healthy subjects without known psoriatic disease or cardiovascular diseasediagnosed any form of MS (relapsing remitting, primary progressive, secondary progressive), any EDSS (expanded stability status scale) scoreNon-smoking, or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to selection \nNormal weight as defined by a Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2, extremes included \nAble to comply with protocol requirements.Healthy on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, medical history, electrocardiogram (ECG), vital signs, and the results of blood biochemistry, blood coagulation, and hematology tests and a urinalysis carried out at screening.Have had one prior platinum-based chemotherapy regimen for the treatment of primary disease.At least 4 weeks since last surgery or radiation therapy.Must have had a treatment-free interval of greater than 6 months following response to platinum.ECOG performance status of 0,1, or 2.normotensive\nforced expiratory volume in 1s : forced vital capacity ratio > 0.75\nno medical history of cardiovascular and respiratory disease\nnot taking medications other than oral contraceptives\nfree from sleep apnea\nbody mass index less than 30 kg/m2Age 18-65 years\nHistory of snake bite with features of local envenomation with/without systemic features\nLess than 24 hours since bite, AND\nNo prior antibiotic treatmentanyone not excluded and consentingPatients with a clinical diagnosis of depression who in the judgement of their physician require medication management may be eligible for enrollment.A score of 10 or more on the PHQ-9 instrument will be required for enrollment.Some practices utilize the PHQ-2 and PHQ-9 are part of routine screening for depression.If the tests are performed routinely, they do not need to be repeated for study eligibility, and may be performed prior to informed consent for this study.If, however, the PHQ-9 is not routinely performed, informed consent must be performed prior to administration.Patients with a score below 10 will be considered screen failures and will not be enrolled or offered the MYnd testing.Patients with non-psychotic comorbid conditions may be included.Patients must be either medication treatment na\xc3\xafve for behavioral illnesses or have no active medication treatments for at least 1 month prior to enrollment.Prohibited medications at the time of enrollment will include stimulants, benzodiazepines and THC.Prior therapy with these agents is permitted with a washout of >30 days.Patients must have private medical insurance coverage through Horizon Blue Cross Blue Shield.This is limited to insured commercial members, including HMO, and excluding, for the avoidance of doubt, members of self-insured customers or Medicare or Medicaid programs.Subject must be at least 30 years of age.Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the Vitamin C+E or Statin or Dual, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.Subject must have symptoms that are consistent with vasospastic angina with planned Coronary angiography and Provocation test.18-80 years old;\nDiagnosis of posterior circulation ischemic stroke;\nTime from onset to treatment =6 hours;\nNIHSS: 4-25;\nSigned informed consent by patient self or legally authorized representatives.Histologically confirmed PD-L1 status defined NSCLC.Biopsy must be within 70 days of first treatment with pembrolizumab.ECOG performance status 2.Life expectancy > 12 weeks.Uni-dimensionally measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 \nComputerised Tomography (CT) scan of chest and abdomen within 28 days of starting pembrolizumab.Adequate haematological function: \nPlatelet count \xe2\x89\xa5100 x 109 /L.Neutrophils \xe2\x89\xa51.5 x 109/L.Haemoglobin \xe2\x89\xa5 9g/dL.Adequate hepatic function: \nSerum bilirubin \xe2\x89\xa41.5 x upper limit of normal (ULN).Serum transaminases \xe2\x89\xa42.5 x ULN.Adequate renal function: Creatinine clearance <1.5 times ULN concurrent with creatinine clearance >50 ml/min.Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.Stage 3 - 5 Chronic Kidney DiseasePatient over 18 years weighing between 65 and 85 Kg\nReferred for STEMI within 6 hours from beginning of chest pain or stable coronary artery disease requiring a loading dose of Prasugrel or Ticagrelor according to the international recommendations.No previous treatment with Clopidogrel, Prasugrel or Ticagrelor.Patient fasting for at least 6 hours.Affiliate or receiving a social security system.Written informed consent.>= 18 years old the day of inclusion\nPregnancy\nPositive HBs Ag\nInformed consent obtained with information sheet given and explained and the consent form signed by the participant of the project investigator at the latest the day of the inclusionScheduled for arthroscopic labral repair with or without osteoplasty of the hip.18 to 50 years old\nAmerican Society of Anesthesiologists Physical Status (ASA PS) score of I or II.Male and females aged between 18 and 65 years of age inclusive, at the time of signing the informed consent.Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.Body weight >= 50 kilogram (kg) and body mass index within the range 19 - 24.9 kg/m^2 (inclusive).A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter] is confirmatory].Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study.Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment.For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT.Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotrophin (hCG) test at screening or prior to dosing AND; Agrees to use one of the contraception methods listed in protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point.Female subjects must agree to use contraception until the follow-up contact visit; OR has only same-sex partners, when this is her preferred and usual lifestyle.Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Protocol.This criterion must be followed from the time of the first dose of study medication until the follow-up contact visit.Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form \nAlanine aminotransferase, alkaline phosphatase and bilirubin <=1.5x upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).Based on single or averaged corrected QT interval (QTc) values of triplicate electrocardiograms obtained over a brief recording period: QTcF < 450 msecelective primary total knee arthroplasty\nASA I-III\nwritten consentHealthy patients (ASA I)\nBilateral symmetrically impacted lower third molars according to Pel-Gregory's and Winter's classificationPatients with symptomatic persistent atrial fibrillation of less than 1-year duration.Patients must be over 65 years old.Patients give informed consent prior to participating in this study.E.coli in blood culture\nAND identical isolate in urine sample (>= 1.000 CFU) OR relevant clinical signs of UTIType 2 Diabetes Mellitus patients\nPatient who had been diagnosed within the previous 12 months with HbA1c levels of 8.0-12.0%, did not have a medical history related to diabetes, and did not display proliferative retinopathyIdiopathic Granulomatous MastitisInborn preterm infants born between 28 0/7 and 34 0/7 weeks gestation and fed either mother's own milk or donor human milkdiabetic patient;\ntherapy with aspirin and insulin;\npatient well respondersAge > 18 years\nPresumed AJCC (American Joint Committee on Cancer) tumor Stage I or II\nPlanned total or near-total thyroidectomy\nPlanned goal TSH suppression 0.1-0.5 mU/L for at least 18 weeks postoperatively\nNormal serum TSH within 12 months preceding surgeryHospitalised children aged 3-mo to 5-yrs (in Darwin, children have to be Indigenous)\nHave features of severe pneumonia on admission (temperature >37.5 celsius or a history of fever at home or observed at the referring clinic, age-adjusted tachypnoea [respiratory rate>50 if <12-months; respiratory rate>40 if >12-months] with chest wall recession and/or oxygen saturation <92% in air), and consolidation on chest X-ray as diagnosed by treating clinician\nAfter 1-3 days of IV antibiotics, are afebrile, with improved respiratory symptoms and signs, oxygen saturation>90% in air and are ready to be switched to oral amoxicillin-clavulanate, and\nHave symptoms of no longer than 7 days at point of hospitalisation.1) histologically confirmed (patients not receiving a single sputum cytology diagnosis) non-small cell lung cancer patients,with wild-type EGFR and ALK-negative; 2) According to IASLC2009 new TNM staging of lung cancer stage <U+2162>B or <U+2163>, previously untreated or relapsed after 1 year of lung cancer resection; 3) have at least one evaluable lesions,according to version 1.1 of the standard in accordance with a judgment RECIST(longest diameter on a spiral CT at least 10mm,on a regular CT longest diameter at least 20mm); 4) Male or female, aged 18 to 75 years; 5) ECOG PS 0 or 1; 6) expected survival at least 3 months; 7) adequate hematological function: absolute neutrophil count (ANC) at least 2\xc3\x9710^9/L and platelet count at least 100\xc3\x9710^9/L and hemoglobin at least 9 g/dL; 8) adequate liver function: total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN); 9) adequate renal function: serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min; 10) ECG is normal, there is no non-healing wounds on the body; 11) had not received previous treatment anticancer drugs, or had only received for previous non-metastatic tumors adjuvant or neoadjuvant chemotherapy, but when you start to study treatment has ended more than 6 months; 12) have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered; 13) have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days.If the pregnancy test from the first administration more than seven days, urine pregnancy test is required for authentication (less than 7 days before the first dose); 14) previous to biological agents, particularly E.coli genetically engineered products without serious allergic reactions; 15) signed informed consent.female infertile patients eligible for IVF treatmentAdults (= 18 years of age) with World Health Organization Group 2 Pulmonary Hypertension (Mean pulmonary artery pressure = 25 mmHg and pulmonary capillary wedge pressure = 15 mmHg)\nNew York Heart Association class II-IV symptoms\nLeft ventricular ejection fraction (LVEF) = 45%Confirmed diagnosis of non-Burkitt B-lineage ALL\n1 to 17 years of age (before 18th birthday)\nRenal function within normal range for age\nLiver function within normal range for age\nAble to participate in the full 2 years of treatmentAdolescent (10-21 years) undergoing spinal fusion for idiopathic scoliosis, spondylolisthesis or Scheuermann kyphosis.Posterior spinal fusion\nNo contraindication for Pregabalin use\nASA I-III\nWritten informed consentAdult (= 18 years old) subjects with chronic genotype 1 HCV and NCI with a GDS greater than or equal to 0.5 (n=60).Presence of chronic HCV infection based on chart review will be defined as positive for anti-HCV antibody or HCV RNA at least 6 months before screening.For the HIV/HCV co-infected group only, subjects must have HIV.HIV status will be obtained through self report.Self report will be confirmed at screening using a HIV-1 point of care test.In the event that point of care test and self-report are discordant, then HIV status will be confirmed by a licensed Western blot or a second antibody test.HIV/HCV co-infected subjects (n=12) must also have a HIV RNA measurement <50 copies/mL at the pre-treatment visit.Platelets >150,000\nAspartate aminotransferase (AST)/Alanine aminotransferase (ALT) <10x upper limit of normal\nCreatinine clearance >30 milliliters/minute/1.73 centimeter squared18 years or older\nType 1 or 2 diabetes\nPDR patients requiring surgical intervention for complications of vitreous hemorrhage or traction retinal detachment and pre-operative IVC treatment.women postmenopausal for 12 months before the study, surgically sterile, or not pregnant and on effective contraception.Patients with functional dyspepsia that fulfill Rome III criteria with inadequate relief of dyspeptic symptoms\nAge >18\nProvision of written consentChildren between the ages of 4-18 with incomplete ASIA C or D spinal cord injuries at least 12 months before study enrolment \nNon-ambulatory or 'exercise only' ambulators with or without assistive devices \nNormal motor and cognitive development up to time of injury \nMedical StabilityAge: > or = 16 years \nWeight: more than 40 Kg \nAutoimmune Hemolytic anemia with clinical and biochemical evidence of hemolysis refractory to treatment, in relapse or steroids dependant \nIdiopathic thrombocytopenic purpura with platelet counts < 50,000, refractory to treatment, in relapse or steroids dependantAge =1 year, stratified into different age groups\nLiving in the Waya Clinic Catchment Area\nGood health condition, without clinically significant medical history (by participant or guardian, in case of minor)\nNot pregnant for female subjects.Available to participate for the study duration, including all planned follow-up visits for up to 9 months from screening.Signed informed consentPatients must have histologic proof of a malignancy suitable for radiation therapy.Patients must have received prior external beam radiation therapy to the region proposed for HDR brachytherapy treatment; evaluation of doses previously delivered to spinal cord/cauda equine, pelvis, and other critical structures (bowel, kidneys, rectum) will be taken into consideration.If repeat irradiation would exceed any normal tissue constraint set by MSKCC Radiation Oncology Department dose constraint criteria, the patient will potentially be eligible.If the total prior radiation dose to the cord or pelvis exceeds 100 Gy BED equivalent, the patient will be potentially eligible, where a total of 100 BED Gy equivalent is determined by the biological equivalent dose (BED) calculation; BED = nd(1 + d/\xce\xb1/\xce\xb2), where n = number of fractions and d = dose per fraction; \xce\xb1/\xce\xb2 is the constant for spinal cord late effect and equals 2.[Rades 2005, Nieder 2005, Sahgal 2012] \nKPS \xe2\x89\xa5 60 \nAge \xe2\x89\xa5 18 years oldbariatric surgery patients\nlaparoscopic roux-en-y gastric bypass\nuse of EEA stapler anastomosisPatients receiving once daily dosing of methylprednisolone or prednisone in a dose of 10 mg/day or greater\nHyperglycemic (Glucose level > 126 mg/dL)\nDiabetic and nondiabetic patients\nExpected duration of hospital stay and time on steroids >= 3 days\nPatient of appropriate caregiver able to give Informed ConsentAny patient age 4-16 years with sickle cell disease who presents the Pediatric ER with acute sickle cell pain crisis with a pain of 6/10 or higherPregnant women between 34-42 weeks gestation\nSingleton fetus\nAdmitted for labor management & develops a fever of 100.4 F or greaterDuration of SCI =1 year;\nLevel of SCI C3-T1, AIS A & B;\nAge between 18 and 65 years.Is not of reproductive potential, or is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner while receiving trial medication or within 6 months after the last dose of trial medication\nHas chronic back pain of =3 months duration by history\nHas physician-diagnosed active nr-axSpA with disease duration <= 5 years\n\xe2\x80\xa2 Inflammatory back pain\n\xe2\x80\xa2 Arthritis (physician-diagnosed)\n\xe2\x80\xa2 Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia)\n\xe2\x80\xa2 Dactylitis (physician-diagnosed)\n\xe2\x80\xa2 Psoriasis (physician-diagnosed)\n\xe2\x80\xa2 History of physician-diagnosed inflammatory bowel disease (IBD)\n\xe2\x80\xa2 History of uveitis confirmed by an ophthalmologist\n\xe2\x80\xa2 Good response to nonsteroidal anti-inflammatory drugs (NSAID)\n\xe2\x80\xa2 Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD)\n\xe2\x80\xa2 Elevated CRP\n\xe2\x80\xa2 Human leukocyte antigen B27 (HLA-B27)+ gene\nHas a HLA-B27+ gene and 2 or more of the SpA characteristics listed above\nHas elevated CRP at Screening or evidence of active inflammation in the sacroiliac joints on MRI\nHas an ASDAS >= 2.1 at Screening\nShows high disease activity at Screening and Baseline of both a Total Back Pain score of =4 and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of >= 4\nHas an acceptable history of NSAID use\nHas no history of untreated latent or active tuberculosis (TB) prior to Screening\nHas had no recent close contact with a person with active TB or, if there has been such contact, will undergo additional evaluations and receive appropriate treatment for latent TBWomen seeking medication abortion through 70 days gestation\nEligible for Mifeprex(r) at a study clinical site\nEnglish or Spanish speaking\nWilling and able to participate in the study, including willing to go to the study pharmacy to obtain mifepristonePhysically healthy adults age 18-55 who meet DSM-5 criteria for insomnia and Criterion A (exposure to a traumatic event) for PTSD.The index trauma must have occurred within the past 5 years and at least 3 months before enrolling, and insomnia symptoms must have started or worsened after the exposure to the index traumaPatients after throat surgeries: tonsillectomy, adenotonsillectomy, uvulopalatoplasty, uvulopalatopharyngoplasty \nPatients with acute throat diseases: pharyngitis, tonsillitis, pharyngotonsillitisSubjects must be capable of providing signed and dated written informed consent by date of Visit 0 (-2 week).Male and female aged =19 and < 65 years.Subjects diagnosed of schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision or 5th edition (DSM-<U+2163>-TR or 5) criteria, and a history of illness for at least for 3 years prior to screening.Subjects who take atypical antipsychotic drugs, and should be maintained on current antipsychotic drugs (including atypical antipsychotic drugs) and dose for at least 4 weeks prior to the screening.Subjects who need antipsychotic treatment (other than clozapine), and would be stable when switching to long-acting injectable aripiprazole in the investigator's judgement.Subjects must exhibit willingness, physiologic capability, and an educational level sufficient to comply with all protocol procedures.1.Have a finding of a mass lesion on mammography or breast MRI (BIRADS 0, 4 or 5) that is >0.5 cm and < 2 cm in size and has had or will have additional workup with focused ultrasound.2.Have a finding of a mass lesion on ultrasound (BIRADS 0, 4 or 5) that is > 0.5 cm and < 2 cm in size.3.Have a positive finding on MBI that is < 2 cm in size and requires additional diagnostic workup with focused ultrasound.Men or non-pregnant women of any ethnic background between the age of 18 and 45 years old\nSubjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g.cigarettes, cigars, chewing tobacco, gum, patch or electronic cigarettes) over the previous 2 months and are not currently using tobacco products\nProvide written informed consent before initiation of any study procedures\nAvailable for follow-up for the planned duration of the study\nAble to communicate well with the investigators\nAble to adhere to the study protocol schedule, study restrictions and examination schedule\nSubjects who are within their ideal body weight (BMI between >17 and =28 kg/m2)\nSubjects deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination and medication history\nSubjects have no history of the following: ongoing acute or intermittent pain, postoperative pain, respiratory compromise, acute or severe asthma, or constipation (less than 1 bowel movement every 2 days)\nNegative urine drug screening test at the time of screening\nHave normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, ALT (liver function), AST (liver function) and bilirubin\nHave normal screening laboratories for urine protein and urine glucose\nFemale subjects must be of non-childbearing potential (as defined as surgically sterile [i.e.history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year [no bleeding for 12 consecutive months], or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of the first day of each study session, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized parter\nAgrees not to participate in another clinical study/trial during the study period or to participate in an investigational drug study for at least one month after last study session\nAgrees not to donate blood to a blood bank throughout participation in the study and for at least 3 months after last study day\nHave a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block.(sinus rhythm is between 55-100 beats per minute)\nTemperature 35-37.9\xc2\xb0C (95-100.3\xc2\xb0F)\nSystolic blood pressure 90-140 mmHg\nDiastolic blood pressure 60-90 mmHg\nHeart rate 55-100 beats per minute\nRespiration rate 12-18 breaths per minuteMeets Diagnostic and Statistical Manual of Mental Disorders (Versions 4 and 5) criteria for and Major Depressive Disorder.Hamilton Depression Rating Scale-17 score greater than 18.Men and women between ages >=18 and 65.hypoechoic uterine leiomyoma (echogenicity <3),\nintramural leiomyomas with an ultrasonographic size <20 cm but >4cm,\nindication to surgery (symptoms of menometrorrhagia,\nmenstrual disorder,\ninfertility,\npelvic pain or pelvic pressureAge equal or greater than 70 years\nOnset of symptoms < 3 hours prior to randomisation\n= 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for a minimum combined total of = 4 mm ST-elevation or\n= 2 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined total of = 4 mm ST-elevation\nInformed consent receivedMild male factor infertility or unexplained infertility.Pregnant women with APS diagnosed according to the revised classification criteria for APS in 2006 in Sydney, Australia\nEarly pregnancy body weight is 50-90 KgAdults 18-65 years, who are diagnosed with functional neurologic symptom or conversion disorder.If diagnosis of seizure type then video EEG with diagnosis confirmed by board-certified neurologist with subspecialty training in epilepsy and clinical neurophysiology using the criteria of the International Classification of the Epilepsies is required.If diagnosis of motor type, documented and clinically established levels of diagnostic certainty (Williams,1995) confirmed by 2 neurologists is required.Participants must have at least one symptom per month in the month prior to enrollment \nFluency in English spoken language= 18 years\nHigh risk patients: General Surgery AKI Risk Index Class III, IV or V\nMajor abdominal surgeryPlanned gynecological lower abdomen surgery with epidural pain treatment\nInformed consent obtainedage > 18\nwritten informed consent\nSVD defined on echocardiography by an alteration of bioprosthesis leaflets function with a mean transvalvular gradient > 20 mmHg and maximal velocity = 3 m/s and effective orifice area =1.2 cm\xc2\xb2, and/or an aortic regurgitation more or equal to grade 2 on 4.15 weeks 0 days gestational age - 23 weeks 5 days gestational age at time of dilator insertion\nAble to read and write in English\nActive cell phone with text messaging capability\nRide home from dilator insertion clinic appointmentAge 18 or older\nWilling and able to comply with the study procedures and provide written informed consent to participate in the study\nDiagnosis of probable pancreatic cancer, distal common bile duct (CBD) cholangiocarcinoma and other periampullary cancers (histology not required)\nBiliary obstructive symptoms or signs\nBilirubin level at/above 100 umol per liter (5.8 mg/dL)\nDistal biliary obstruction consistent with pancreatic cancer, distal CBD cholangiocarcinoma or other periampullary malignancy\nLocation of distal biliary obstruction is such that it would allow the proximal end of a stent to be positioned at least 2cm from the hilum\nPatients deemed as resectable by pancreatic protocol CT or MRI\nSurgical candidate per pancreatobiliary surgeon after multi-disciplinary discussion\nSurgery intent within 4 weeks\nEndoscopic and surgical treatment to be provided by same team>18 to < 90 years old\nBoth sexes\nMild to moderate tear film dysfunction clinical diagnose\nTBUT > 5 sec.and < 10 sec.Schirmer: > 4 mm and < 14 mm\nOSDI < 30 points\nCorneal staining < grade III on the Oxford scale\nAvailability to go to each revision when indicated.Pregnant gestational age >= 28 weeks\nSystolic blood pressure >=160 mm Hg OR a diastolic blood pressure of >=110 mm Hg measured twice more than 15 minutes apart\nAble to swallow pills\n>= 18 yearsWoman who had 2 miscarriage before 12(th) week of gestation.The patient who is diagnosed as thrombophilia with recurrent pregnancy loss.Signed consent form.American Society of Anesthesiologist physical status 1-3\nScheduled for elective video-assisted thoracic surgery\nAble to operate a patient-controlled analgesia device (PCA)Female age 20-50 y/o who plan to undergo abdominal myomectomy for symptomatic myomatous uterusHealthy male volunteers, 18 to 45 years of age, inclusive.Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology and urinalysis \nBody mass index (BMI) 18 to 30 kg/m2 inclusive \nMale subjects (whether surgically sterilized or not) with female partners of child-bearing potential must use two forms of contraception, one of which must be a barrier method, for the duration of the study and for 77 days after the last doseAre at least 18 years of age \nDemonstrate a positive cough stress test during complex multi-channel urodynamic testing \nDemonstrate impact of stress urinary incontinence on quality of life questionnaire \nAre able to comprehend and sign a written informed consent \nUnderstand and are willing to comply with the study requirements, including agreeing to be available for the follow-up evaluations \nAre psychologically stable and suitable for interventions determined by the investigator \nAre ambulatory and able to use a toilet independentlyAge 10 to 65 years\nTemperature less than 100.4 F\nNormal neurologic exam and normal mental statusMale and/or female patients from 30-80 years of age with a diagnosis of Type 2 diabetes (WHO criteria).Incipient and established diabetic nephropathy (urinary albumin excretion \xe2\x89\xa5 100 mg/day but \xe2\x89\xa4 2000 mg/day).Glomerular filtration rate (GFR) \xe2\x89\xa5 40 ml/min (estimated using Modification of Diet in Renal Disease (MDRD) formula) in the last 4 months.Female patients must be postmenopausal or must have had a bilateral oophorectomy or must have been surgically sterilized or hysterectomized at least 6 months prior to screening.To be eligible patients must fulfill the following criteria: Patients on ongoing hypertensive therapy must have a blood pressure \xe2\x89\xa5 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1) AND patients must be on stable antihypertensive medications for at least 8 weeks prior to baseline (Day -1).; Newly diagnosed hypertensive patients must have a blood pressure \xe2\x89\xa5 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1).Patients must be on stable hypoglycemic medications for at least 8 weeks prior to Visit 2 ( Day -1).Patients must be willing and medically able to discontinue all Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study.Oral body temperature within the range 35.0-37.5 \xc2\xb0C \nAble to provide written informed consent prior to study participation..Able to communicate well with the investigator and comply with the requirements of the study.Only patients with atrial fibrillation, above 18 years, and with TTR <50% based on the last three values of INR will be included in this study.Patient has been fully informed and has signed an IRB approved informed consent form within 7 days (Day 7-13) prior to POD 15 and is willing and able to follow study procedure\nPatient is a primary liver transplant recipient\nPatient is 20 to 70 years of age\nPatient should be clearly conscious, fully understand and able to answer questionnaireAged at least 18 years \nThe presence of a solid, malignant tumour, excluding lymphoma, that is resistance to standard therapies or for which no standard therapies exist \nThe presence of at least one lesion that can be accurately assessed at baseline by Computerised Tomography (CT), Magnetic Resonance Imaging (MRI) or plain X-ray and is suitable for repeated assessment \nEstimated life expectancy of more than 12 weeksAdvanced solid tumor malignancy (during expansion at the maximum tolerated dose, entry will be limited to patients wtih adenocarcinoma of the colon or rectum) \nEastern Cooperative Oncology Group (ECOG) 0 or 1Patient is currently enrolled in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs study receiving nilotinib and has fulfilled all their requirements in the parent study\nPatient is currently benefiting from the treatment with nilotinib, as determined by the investigator\nPatient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements\nWillingness and ability to comply with scheduled visits, treatment plans and any other study procedures\nWritten informed consent obtained prior to enrolling in roll-over studyAdult participants with low or intermediate-1 risk MDS\nNo previous treatment with hematopoietic growth factors within 3 months prior to screening\nSymptomatic anemia (hemoglobin <10 g/dL) as determined by investigator\nSerum erythropoietin <500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment\nRequire no red blood cell transfusion or dependent on <4 units within 8 weeks prior to screening\nClinically stable for at least 1 month prior to entry into the study\nFor female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraceptionkidney transplant recipientThe patient or his/her representative must have given free and informed consent and signed the consent\nThe patient must be insured or beneficiary of a health insurance plan\nThe patient is available for 12 months of follow-up\nThe patient underwent a successful transcutaneous implant procedure for an aortic valve within the past 24 hours\nThe patient was receiving anti-vitamin K (AVK) treatment before percutaneous implantation of the aortic valveage > 17 and < 60 years;\nAmerican Society of Anesthesiology (ASA) I-III;\nadmitted for living donor renal transplantation.Patients 18 years of age or older with >3 unformed stools/24 hours with positive stool test for C. difficile.Patients receiving = 1 high or medium risk antibiotic for treatment of an infection other than CDI, for an anticipated duration of = 5 days from the time of enrollment.Age between 1 month and 24 months of age (not beyond second birthday at baseline).Diagnosis of epilepsy confirmed.At least an average of 4 seizures/week in baseline period.Failed response to previous trial of two anti-epileptic drugs.In the case of infantile spasms this could include a trial of corticosteroids.Children with written informed consent from parent/guardian.Habitual exerciser defined as = 30 minutes of at least moderate or high intensity exercise = 3 times per week.After consent, and at the subsequent screening visit, a VO2 max test will be performed, and subjects with a low value (< 35 mL/kg/min) will be excluded (screen failure).Based on our previous experience, we anticipate that <10% of the subjects will fall into this category\nMen: (0.006012 x H3) + (14.6 x W) + 604 = TBV\nWomen: (0.005835 x H3) + (15 x W) + 183 = TBV [H=height in inches; W=weight in pounds]\nHas access to transportation to visit the blood collection facility and to return to Stony Brook for all study visits.Diabetes mellitus \nFoot ulcer at the malleoli area between 0,25 cm\xc2\xb2 and 5,0 cm\xc2\xb2 \nFoot ulcer duration more than 6 weeks \nAnkle-brachial index above 0,40 or presence of palpable pulses in arteria dorsalis pedes and/or arteria tibialis posterior \ninformed consentHealthy, women ages 18 to 39yo with BMI <30\nRegular menstrual cycles with duration between 24-35 days\nCompletion of screening visit where ovulation will be assessed with blood draw for progesterone level (must be 5ng/mL or greater)\nNot seeking pregnancy during the study period\nUse of a non-hormonal form of contraception, such as: sterilization (tubal ligation, Essure), copper IUD (intrauterine device), barrier methods or abstinence\nMust speak English or SpanishAll patients (excluding neonates) requiring one or more allogeneic RBC transfusions for the treatment of anemia will be included.Overweight and obese PCOS patients with newly diagnosed IGR;\nPCOS diagnosis based on 2003 Rotterdam criteria\nOverweight / obesity diagnostic criteria according to WHO-WPR\nImpaired glucose regulation diagnostic criteria according to 1998 WHO diagnostic criteria.Fulfills NIH criteria for bariatric surgery\nPlanned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedureAny allogeneic stem cell transplant recipient = 14 years of age and = 60 years of age\nBilirubin/ SGOT/SGPT < 5 \xc3\x97 upper normal limits.Creatinine < 2 \xc3\x97 upper normal limits.Ejection fraction = 50%, no severe arrhythmia.Estimated life expectancy = 6 months.Patients' CMV-DNA = 1000cp/ml in treatment group and being negative in prophylactic group.Patients with PN during their hospitalization\nPatients hospitalized in medical, surgical or ICU wards\nSigned informed consent either from the patient, their legally authorized representative or a direct family memberAdult women at least 18 years of age\nElective Female Pelvic Medicine and Reconstructive Surgery or Gynecologic Minimally Invasive surgeries including hysterectomy, suburethral sling, and pelvic organ prolapse repair that require cystoscopy.American society of anesthesiologist (ASA) physical status I or IIComplex kidney stone (staghorn calculi GUYS III and IV)Males and females with confirmed disease: Fabry (by GLA enzymes and/or DNA testing) na\xc3\xafve and on ERT, Mitochondrial diseases (electron transport chain and/or DNA testing) or connective tissue diseases (clinical criteria and/or DNA testing when available) \nConsenting adults (18 years and older) who agrees and consents to skin biopsy and QSART procedureestimated glomerular filtration rate (eGFR) > 60 ml/min\npreserved left ventricular ejection fraction (>= 50%) on echocardiography\nHEALTHY: normal cardiac structure and function on echocardiography, BP < 140/90\nHYPERTENSIVE: history of BP >140/90, 1 or more antihypertensive medications, LV ejection fraction (LVEF) at least 50%, current BP < 160/90\nHFpEF: physician-confirmed diagnosis of HF, symptomatic HF, LVEF at least 50%, elevated LV filling pressure by catheterization, echocardiographic criteria or B-type-natriuretic peptide > 100, current BP < 160/90patients with =20\xc2\xb0 passive extension deficit (PED) in metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint, or TPED of =30\xc2\xb0 in MP and PIP joints of finger/fingers II-V\nage > 18 years\npalpable cord\nprovision of informed consent\nability to fill the Finnish versions of questionnaires.1.Must have given written informed consent (signed and dated) and any authorizations required by local law \n2.18 to 75 years old (inclusive) \n3.Male or female with a diagnosis of PBC, by at least two of the following criteria: \nHistory of AP above ULN for at least six months \nPositive Anti-Mitochondrial Antibodies (AMA) titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies \nDocumented liver biopsy result consistent with PBC \n4.On a stable and recommended dose of UDCA for the past twelve months \n5.AP \xe2\x89\xa5 1.67 \xc3\x97 ULN \n6.For females of reproductive potential, use of at least one barrier contraceptive and a second effective birth control method during the study and for at least two weeks after the last dose.For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dosePatients undergoing robotic-assisted laparoscopic prostatectomy\n=18 years old males\nASA class 1-4Healthy pregnant women age 18 to 50\nSingleton pregnancy at gestational age 36 weeks or more\nAble to read and understand Norwegian.elective Laparoscopic myomectomy patients 24hr post-operative patient controlled analgesia analgesia no mild or severe liver or renal disfunctionMale or female\nAge 18 to 65 years\nDiagnosed with spinal cord injury between 3 days and 4 weeks\nAmerican Spinal Injury Association Impairment Scale A or B\nInformed consent for inclusion into the database is obtainedType of subject: outpatient.Informed consent: Subjects must give their signed and dated written informed consent to participate.Gender: Male or female.Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy.The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception.Age: >=40 and <=80 years of age at Screening (Visit 1).Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette smoking at screening (Visit 1).Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1.Airflow Obstruction: \nSubjects with a measured post-albuterol/salbutamol forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio of <=0.70 at Screening (Visit 1).Subjects with a measured post-albuterol/salbutamol FEV1 >=50 and <=70% of predicted normal values calculated using NHANES III reference equations [Hankinson, 1999; Hankinson, 2010] at Screening (Visit 1).Post-bronchodilator spirometry will be performed approximately 15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI )with a valved-holding chamber.The FEV1/FVC ratio and FEV1 percent predicted values will be calculated.Symptoms of COPD: Subjects must score 2 or higher on the modified Medical Research Council Dyspnea scale (Visit 1) \nCardiovascular disease: \nFor patients >= 40 years of age: any one of the following: \nEstablished (i.e.by clinical signs or imaging studies) coronary artery disease (CAD) Established (i.e.by clinical signs or imaging studies) peripheral vascular disease (PVD) Previous stroke Previous MI Diabetes mellitus with target organ disease OR \nFor patients >=60 years of age: any 2 of the following: \nBeing treated for hypercholesterolemia Being treated for hypertension Being treated for diabetes mellitus Being treated for peripheral vascular diseasePatient harboring a GRE or CRE bacteria\nColonization confirmed by our microbiology department, including at least 3 positives swabs in the last monthmen and women 30-55 years with BMI 30-40 and waist 95 cm or more \nnormal OGTT \nnormal treadmill stress test \nplus 2 of 4: \n1. low serum levels of HDL cholesterol (<40 mg\xe2\x81\x84dL for men or < 50 mg \xe2\x81\x84dL for women); \n2. hypertriglyceridemia (triglyceride levels of 150 mg\xe2\x81\x84dL or greater); \n3. impaired glucose homeostasis (fasting plasma glucose concentration of 110 mg\xe2\x81\x84dL or greater or glucose of 140 mg\xe2\x81\x84dL or greater after OGTT or \n4. hypertension (systolic blood pressure \xe2\x89\xa5 140 or diastolic blood pressure \xe2\x89\xa590 mmHg or treatment with antihypertensive drugs).Patients with anaemia (males Hb <130 g/L, females <120 g/L) undergoing elective cardiac surgery, and available to receive trial drug 1- 10 weeks prior to surgeryAge 1 day to less than 18 years\nCared for in the pediatric intensive care unit or pediatric cardiac intensive care unit\nreceiving venovenous or venoarterial ECMOWilling to receive three doses of an FDA-approved Hepatitis B vaccine\nVolunteer chronically infected with HCV (as demonstrated by serology and/or viral load laboratory studies)\nHealthy volunteer without significant medical problemsSubjects age 21 and older\nSubjects with healthy eyes\nSubjects who have previously undergone LASIK surgery\nSubjects with residual refractive error.Inpatients having major foot and ankle surgery that will benefit from continuous popliteal sciatic nerve block with an indwelling catheter\nAmerican Society Anesthesiologists (ASA) physical status I-III\n18-85 years of age, inclusive\n40-120 kg, inclusive\n150 cm of height or greaterGenerally healthy, postmenopausal woman who seeks treatment for hot flushes.Meets 1 of the following: At least 12 months of spontaneous amenorrhea; At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL; At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy).Hysterectomized without bilateral oophorectomy and with serum FSH levels >40 mIU/mL.ASA classification II or III females\nAge: 18-45 years old\nBMI = 50 kg/m2\nSingleton pregnancy\nSimple prophylactic cervical cerclage\nPlanning neuraxial anesthesiaWomen stimulated with Syntocinon\xc2\xae infusion for induction of labour (with or without cervical priming by prostaglandin)Pathologically proven unresectable adenocarcinoma of stomach \nWith uni-dimensionally measurable disease (at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1cm on spiral CT scan) \nAge 18 to 70 years old \nEstimated life expectancy of more than 3 months \nECOG performance status of 2 or lower \nAdequate bone marrow function(absolute neutrophil count [ANC] \xe2\x89\xa51,500/\xc2\xb5L, hemoglobin \xe2\x89\xa59.0 g/dL,and platelets \xe2\x89\xa5100,000/\xc2\xb5L) \nAdequate kidney function (serum creatinine < 1.5 mg/dL) \nAdequate liver function (serum total bilirubin < 2 times the upper normal limit (UNL); serum transaminases levels <3 times [<5 times for patients with liver metastasis] UNL) \nNo prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed.(but, prior adjuvant chemotherapy with capecitabine or S-1 or camptothecin analogues was excluded) \nNo prior radiation therapy for at least 4 weeks before enrollment in the studySubjects over the age of 18 years who agree informed consent and who have at least one polyp of eligible size (6-10mm)Chronic HCV Infection of Genotype 1, 4, 5, or 6\nHCV RNA > 103 IU/mL at screening\n18 years of age or older\nDiagnosis of chronic HCV infection, defined as positive HCV antibody or HCV RNA more than 6 months prior to screening OR an assessment of fibrosis F2 or greater prior to screening.NYHA Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.They are comfortable at rest.Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain.NYHA Class IV: Patient with cardiac disease resulting in inability to carry on any physical activity without discomfort.Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest.If any physical activity is undertaken, discomfort is increased.ejection fraction = 30%\nhospitalized for heart failure in last 12 months\nILD criteria: diagnosis of interstitial lung disease with chronic supplemental oxygen requirement at rest and/or with exertion.Forced expiratory volume (FEV1)< 30% predicted\nOR any FEV1 with chronic supplemental oxygen requirement at rest and/or with exertion\nOR any FEV1 with chronic hypercapnia (baseline partial pressure of arterial carbon dioxide [PaCO2] > 45)Type 2 diabetic inpatient\nFasting glucose >140 mg/dl or random glucose >180 mg/dlHealthy patients\naged 3-13 years\nLevel I or level II on the American Society of Anesthesiologists (ASA) physical status classification system (as determined by the anesthesiologist)\nobstructive sleep apnea or recurrent throat infections\nundergoing elective tonsillectomy with or without adenoidectomy\nParents who agree to complete documentation and follow up at 14 days post-operation.Women\n= 3 UTIs within the last 12 months or = 2 UTIs within the last 6 months;\nLaboratory urine culture: <103 CFUs\nAge > 18 yearsDiagnosis of asthmaHealthy men and women, age 40-75 yrs, without any disease and need of medication.Born, raised and currently living at low altitude (<800m).Written informed consent.Kyrgyz ethnicityCytologically proven acute lymphoblastic leukemia (ALL)\nNo relapse of a previously unrecognized ALL\nPatients must meet one of the following risk criteria:\nStandard-risk (SR) group meeting all of the following criteria:\nBlasts < 1,000/\xc2\xb5L in peripheral blood (PB) on day 8\nAged 1 to < 6 years\nInitial WBC < 20,000/\xc2\xb5L\nM1 (5%) or M2 (= 5% to < 25%) blasts in bone marrow on day 15;\nM1 marrow on day 33.Aged < 1 or = 6 years and/or WBC = 20,000/\xc2\xb5L\nBlasts < 1,000/\xc2\xb5L in PB on day 8\nM1 or M2 marrow on day 15\nM3 (= 25%) marrow on day 15 OR meets SR criteria but M3 marrow on day 15 and *M1 marrow on day 33.Meets IR criteria and M3 marrow on day 15 (not SR and M3 on day 15)\nBlasts = 1,000/\xc2\xb5L in PB on day 8\nM2 or M3 marrow on day 33\nTranslocation t(9;22) [BCR/ABL+] (Philadelphia chromosome-positive) or t(4;11) [MLL/AF4+].Women aged 25-75 years old.Women with recently diagnosed breast cancer and who will receive NAC to reduce tumor burden before surgery.(including locally advanced breast cancer (LABC) according to clinical assessment; or tumor size > 2cm, that is, at least T2 in TNM staging).Acquired acute ankle injury (injured less than 48 hours ago);\nClinical diagnosis of a Grade I or II ankle sprain\nIs eligible to receive comprehensive medical care from Garrison PetawawaHBsAg-positive for more than 6 months (HBeAg-positive or HBeAg-negative).Age > 20 y/o.Under lamivudine/adefovir treatment for more than 1 year due to previous lamivudine resistance (LAM-R), current HBV DNA is undetectable (< 20 IU/ml) during enrollment.colorectal cancer above to 12 cm from the anal verge\nunresectable synchronous metastases\nno contraindications for chemotherapy\nabsence of peritoneal carcinomatosis, central nervous system o bone metastasis.performance status ECOG = 2 (Eastern Cooperative Oncology Group)\nuncontrolled concomitant medical conditions that may compromise to chemotherapy\nsignificant symptomatic cardiac disease\nnot pregnancy or breastfeedingWomen subjected to ICSI through controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRHa.Willing and capable of providing informed consent \nHas an indication for implantation of a single or dual chamber ICD or CRT-D system in their respective geography \nSubjects planned to be implanted with the RELIANCE 4-FRONT Passive Fixation Lead \nWilling and capable of participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol \nAge 18 or above, or of legal age to give informed consent specific to state and national lawPatient has provided signed informed consent \nPatient is aged greater than or equal to 40 and less than or equal to 89 years of age \nPatient has a prostate size between 90g and 200g, as determined by MRI \nPatient has experienced lower urinary tract symptoms (LUTS) for at least 6 months prior to study enrollment \nPatient has an IPSS score of at least 13 at baseline \nPatient is either: refractory to medical treatment, contraindicated to medical treatment, OR refuses medical treatment \nPatient either: refuses surgical treatment OR is contraindicated for surgical treatment \nPatient meets ONE of the following criteria: baseline PSA < 4.0ng/mL (no prostate biopsy required) OR baseline PSA >/= 4 ng/mL AND a negative prostate biopsy (minimum 12 core biopsy) within the prior 12 monthsClinical diagnosis of allergic rhinitis based on sneeze attacks, runny/blocked/itchy nose in the absence of a common cold during the previous 12 months.History of positive skin prick test or blood radio-allergosorbent test (RAST) to grass and/or ragweed pollenPatients with angina or silent ischemia and documented ischemia\nPatients who are eligible for intracoronary stenting\nAge > 18 years\nDe novo lesion CTO\nReference vessel size 2.5 mm by visual estimation\nAt least one CTO lesions located in proximal or mid epicardial coronary artery.(If the patient has two CTO lesions, one CTO lesion should be located in proximal or mid epicardial coronary artery)\nAngiographically defined total occlusion over 3 months\nIf no definite symptom with total occlusion, two experienced operators decide CTO in consideration of angiographical morphology (degree of calcification, bridging collaterals, non-tapered stump, angiographic filling from collaterals)Children 6 month to 14 years who will be presented to the pediatric emergency or attended by emergency medical service who have active seizure and had no intravenous access would be eligible for the study.Age: 20-70 years old;\nGender: male or female;\nclinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients;\nThe expected survival> 3 months;\nChild-Pugh grade in A-level;\nKPS score with 50-100 points;\nBCLC stage of 0-B;\nconform to the indications of hepatectomy;\nViable tumor resection confirmed by two highly qualified surgical doctors;\nNo other surgical contraindications.women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment;\nMen must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment;\nAll patients must be prohibited donation during the treatment process and in 28 days after treatment;\nIn addition to the subjects, prohibitting other people taking this product.patients have a good understanding and could coordinate with investigators for the trial.Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial.Healthy\nMale\n>7 Metabolic Equivalents\nWritten informed consent\nChronic pain syndrome\nDrug abuse\nAlcohol abuse\nSuspicion of neurologic dysfunction at tested sites\nOngoing treatment with antidepressants\nOngoing treatment with analgesics\nPretreatment with any CYP3A inducers or inhibitors\nKnown allergy to tested drugs\nElevated eye pressure\nObstructive uropathy\nHeart disease\nPulmonary disease\nNeurological disease\nPsychiatric illnessASA physical status 1-3\nelective thoracotomy\ncan operate patient-controlled analgesia (PCA) machineAdult patients (> 18 years) scheduled for cardiopulmonary bypass surgery with Glomerular Filtration Rate (GFR) greater than or equal to 60 and left ventricular ejection fraction greater than or equal to 40%Type 2 diabetes mellitus with HbA1c > 7.5 %\nBody mass index > 35 and < 50 kg/m2\nCandidate for Gastric By-Pass\nTreatment with GLP1 (glucagon-like peptide) analogue or insulinPatient must be 18 years or older\nMust meet the following definition for adhesive capsulitis as defined by the American Academy of Orthopedic Surgeons: Self-limiting condition resulting from any inflammatory process about the shoulder in which capsular scar tissue is produced, resulting in pain and limited range of motion; also called frozen shoulder\nMust be amenable to randomization into either cohortAre negative for human immunodeficiency virus (HIV) infection at screening \nIs healthy on the basis of physical examination, medical history, electrocardiogram (ECG), and vital signs measurement performed at screening \nAre willing/able to adhere to the prohibitions and restrictions specified in the protocol and study procedures \nFemale participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [beta hCG]) at the Screening visit, and a negative urine pregnancy test pre-dose on Day 1 \nAre assessed by the clinic staff as being at low risk for HIV infectionDiagnosis reviewed at transplant center and confirmed to fit the criterion for high risk blood disease or cancer, as defined for the study \nEstimated life expectancy of at least 6 weeks following study entry \nCancer and Leukemia Group B (CALGB) performance status less than or equal to 2 \nWhite blood cell count, platelet, hematocrit, tuberculosis, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, and HIV test results reviewed by transplant center \nMultiple gated acquisition (MUGA), echocardiogram, cardiac MRI, and/or pulmonary function tests (PFT) performed and reviewed by transplant center (for individuals with an ejection fraction and diffusing capacity [DLCO] of 40-50%, the appropriate cardiology or pulmonary consultations should be considered if the individual has severe heart or lung disease at the initiation of therapy) \nSufficient number of umbilical cord blood units available for transplantation \nIf female, willing to use contraception throughout the studyParticipants must present a diagnosis of osteoporosis based on DXA measurement of the bone mineral density at the femur neck and/or total hip and/or lumbar spine (T value 2.5 SD or more below the young female adult mean) within the past 24 months.Not in treatment with anti-resorptive agents (like bisphosphonates and denosumab) for more than 4 consecutive years, in order to reduce the risk of medication-related osteonecrosis of the jaws (Lo et al., 2010).= 50 years old.In self-reported menopause, defined as the permanent cessation of ovulation, for at least one year (Soules et al., 2001).Edentulous area involving a maximum of two teeth (wisdom teeth and second molars are excluded) and presenting at least one neighbouring tooth (e.g.gap in the area of a second premolar and first molar, with first premolar in place).Residual alveolar width = 4 mm (Milinkovic and Cordaro, 2014), residual alveolar height >8 mm, enough inter-arch space for a crown (at least 5 mm) and a minimum distance of 7 mm from the adjacent teeth (Shah and Lum, 2008).The width and height will be confirmed after x-ray examination in Visit 2.Possibility to restore a functional occlusion with a minimum of four occlusal units (i.e.pairs of occluding posterior teeth).Willingness to replace the missing tooth/teeth with dental implants\nRegistration with a GDPSigned informed consent form (ICF)\nAge 18 to 55 years old (inclusive) as of the date the ICF is signed\nDiagnosis of MS according to the McDonald criteria 2010 and cranial MRI scan demonstrating white matter lesions attributable to MS within 10 years before Screening\nOnset of MS symptoms (as determined by a neurologist, either at present or retrospectively) within 10 years of the date the ICF is signed\nEDSS score 0.0 to 5.0 (inclusive) at Screening\nPatients with (highly) active RRMS disease course indicated to receive alemtuzumab according to the following conditions (at least 1 out of 3 conditions has to be fulfilled): 1.=2 MS relapses within 24 months, 2. clinical (=1 relapse) or MRI (new gadolinium enhancing lesions) disease activity under therapy with other diseasemodifying therapies, 3. severe relapse with high disease activity (=9 T2 hyperintense Lesions and =1 gadolinium enhancing lesion) on MRI.Completion of all vaccinations required by the applicable immunization guidelines published by "st\xc3\xa4ndige Impfkommission" (STIKO)\nHistory of chickenpox or positive test for antibodies against varicella zoster virus (VZV)Age > 50 years\nSmoking history > 10 packs/year\nFEV1 30 - 79% of predicted and FEV1/FVC < 70% (GOLD 2-3)\nFRC > 120 % predicted\nBorg dyspnea score > 3 during the 3-min constant rate shuttle walking test at V3Adults = 18 years of age\nAdmitted to any ICU and receiving invasive mechanical ventilation\nAnticipated ventilation of =72 hours at the time of screening, as per the ICU physician.Patients undergoing urologic surgery.English speaking\nbetween 18 and 75 years old\nAmerican Society of Anesthesiologists (ASA) 1-3 patients undergoing primary total hip arthroplastyAccident & Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.OsteoporosisMen 18 years or older\nONB within 1 year post-surgery.1.PPROM with gestational age between 27 to 34 weeks \n2.Cephalic presentation \n3.Clear amniotic fluid \n4.Oral temperature > 38 C \n5.Near distance from the hospital (the patient can reach hospital within one hour ) \n6.Home environment safe and amenable to rest , availability of family support such as a sister or mother who will help the patient at home .7.Maternal and fetal condition remain stable after hospitalization for 72 hoursgestational age between 20 weeks and 23 weeks and 6 days\nsingleton pregnanciesMale and female patients between the ages of 18-65 years, inclusive\nPatients (or legal representative) willing and able to provide written Informed Consent Form.Psychiatric patients already diagnosed of schizophrenia or bipolar disorder, according to the Diagnostic and Statistical Manual of Mental Disorders- IV, Diagnostic and Statistical Manual of Mental Disorders- V or International Code of Disease criteria.Patients with an on-going agitation episode, or with a previous one within the 6 months prior to screening, attended and managed in the hospital setting.Previously treated with ADASUVE\xc2\xae with a positive outcome (responders) according to (CGI-I) scale (defined as having a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation)\nPatients free of active respiratory disease such as acute respiratory signs/symptoms (e.g., wheezing) or with active airways disease (asthma, chronic obstructive pulmonary disease or emphysema).Requirement of family or other caregiver support at study investigator criteria (defined as a patient's relative or caregiver (male or female) = 80 year old, who spend = 3 consecutive hours with patient, with good physical and psychological health status and without physical limitations, reading and writing educational level and able to understand and follow the study procedures).Availability of patient's medical records data about the previous treatment with ADASUVE\xc2\xae at hospital setting.If a female is of childbearing potential and sexually active (except if female is surgically sterile or post-menopausal with history of no menses for at least 24 months), patient must be non-lactating and non-pregnant (with a negative pregnancy test result at baseline visit) and have to agree to use a medically acceptable and effective birth control method throughout the study and for one week following the end of the study.Patient meets protocol criteria for diagnosis of IBS-C, abdominal pain, abdominal bloating and abdominal girthPatients with Ph (BCR/ABL) positive de novo < 55 years old (it is advisable to include patients over 55 years LAL07OPH protocol).Performance status 0-2 (Appendix B) may include patients with performance status > 2 attributable to LAL.Patients without functional impairment of organs: liver function: total bilirubin, AST, ALT, alfa-GT and alkaline phosphatase less than 3 times the upper limit of normal laboratory renal function: serum creatinine < 2 mg/dL or clearance creatinine > 30 ml/min (except renal function attributable to LAL) cardiac function (Appendix B) normal: ventricular EF > 50%, absence of severe chronic respiratory disease.In the event that alterations are secondary to the disease is at the discretion of the investigator to determine if the patient can be included in the trial.Thoracoscopic surgery candidate.Over 18 years old.No known allergy to Bupivacaine.Patient is able to read understand and singe an inform consent.After half-dose ticagrelor (loading dose 90mg, and then 45mg bidpo.)treatment for 3 days, the platelet aggregation is effectively inhibited by light transmission aggregometry method and thromboela-stogram.planned to undergo PCI recently\nplanned to DAPT for 1 year after PCISystemically healthy adults.Minimum of 24 permanent teeth.No gingivitis (Community Periodontal Index score = 0).No periodontitis (Community Periodontal Index score = 0).Absence of untreated caries.French Native language\n18 years old or older\nSigned consent\nCovered by the French social care systemIndividuals of both sexes from 18 years with a diagnosis of community-acquired pneumonia, COPD or Bronchial Asthma;\nThe presence of signed and dated informed consent to participate in a clinical study;\nThe ability to perform the requirements of the Protocol;\nFor women of childbearing age is a negative result of a pregnancy test before vaccination.community-acquired pneumonia: the presence of radiologically confirmed infiltration of the lung tissue; the presence of at least two of the following clinical signs: acute fever early in the disease (temperature > 38.0\xc2\xb0C), cough with sputum, the physical signs of pneumonia (focus of crepitate and/or fine bubble rales, bronchial breathing hard, shortening of percussion sounds), leukocytosis > 10*10 9 /l and/or stab shift > 10%; the occurrence of the disease outside the hospital and the organized groups (such as nursing homes, sanatoriums, etc.).COPD: dyspnea: progressive (worsens over time), increases with exertion, persistent; chronic cough (may appear sporadically and may be unproductive); chronic expectoration; the impact of risk factors in the medical history (Smoking, occupational dust pollutants and chemicals); widespread wheeze on auscultation of the chest and/or distant wheezing in the chest; family history of COPD; spirometric data confirming the presence of fixed bronchial obstruction.need mechanical ventilation for more than 2 days\nmean blood pressure more than 60mmHg\npredicted ICU stay more than 7 days\ntolerance of parenteral or enteral nutritionInclusion Criteria Patients: Fulfilling the diagnostic criteria of schizophrenia or schizoaffective disorder according to ICD-10 (International Classification of Diseases version 10) or DSM-IV/V (Diagnostic and Statistical Manual version 4 /5), Age 18-45 years, Never treated with antipsychotic compounds or central nervous system (CNS) stimulants, Legally competent\nInclusion criteria controls: Matching patients on age (+/- 2 years), sex and parental socioeconomic status, Age 18-45 years, No psychiatric or physical disease.English or Spanish speaking*\nEmergency Department patient\nAged 18-80\nHave had >4 emergency department visits within 12 months for 2 consecutive 12-month periods.Period of time can be extended by up to 6 months if incarcerated or institutionalized for \xe2\x89\xa5 6 months.Meet Diagnostic and Statistical Manual version IV (DSM-IV) criteria for alcohol dependence or & DSM-V criteria for alcohol use disorder, severe.Have \xe2\x89\xa52 days/week of heavy drinking (>4 drinks/day)\nCapable of giving informed consent.A positive 13 C-urea breath test\nFormal H.pylori treatment more than two times\nAge >18 yearswomen undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old.Patients with chronic heart failure of New York Heart Association Class II or III, a left ventricular ejection fraction of = 40% for patients in NYHA class II or = 45% for patients in NYHA class III, a hemoglobin level at the screening visit between 9.5-13.5 g/dl, and iron deficiency, which is defined as serum ferritin level < 100\xc2\xb5g/l or between 100 and 299 \xc2\xb5g/l, when transferring saturation is < 20%.Age =18 years\nObtained informed consent\nStable pharmacological therapy during the last 4 weeks (with the exception of diuretics)treatment-naive patients with lymphoma\nHBsAg negative/HBcAb positive/hepatitis B virus DNA negative at baseline\ntreated with chemotherapy and/or immunosuppressive therapy\nlife expectancy of more than 3 monthsPatients diagnosed at the out-patient cystoscopy with papillary bladder tumour will be legible for inclusionover 18 years \nsuccessful angioplasty (residual stenosis < 30%) on a significant stenosis (maximal systolic speed 3 times > from basal maximal systolic speed, stenosis > 70% on angiography) on the venous-prosthesis anastomosis or on the venous segment 5 cm after the anastomosis of a prosthetic haemodialysis vascular access (at least 1 month old) \nsocial security affiliation \nsigned informed consentWomen age 18-45\nWithin 6 months of expiration or beyond the end of the FDA-approved duration of use of the levonorgestrel intrauterine device (LNG-IUD = 5 years) OR the etonogestrel-releasing subdermal implant (ENG implant = 3 years)\nAble to consent in English or Spanish.Not pregnant at the time of enrollmentPatients with foot fracture scheduled for surgical repair in spinal anesthesia\nInformed consentPatients must be more than 18 years of age and referred for coronary angiography1.Patients with stable (Canadian Cardiovascular Society 1, 2, 3 or 4) or unstable (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC) angina pectoris and ischemia, or patients with atypical chest pain or even those who are asymptomatic provided they have documented myocardial ischaemia (e.g.treadmill exercise test, radionuclide scintigraphy, stress echocardiography, Holter tape); \n2.Patients who are eligible for coronary revascularization (angioplasty or CABG); \n3.At least 2 lesions (located in different vessels and in different territories) potentially amenable to stent implantation; \n4. de novo native vessels; \n5.Multivessel disease with at least one significant stenosis in LAD and with treatment of the lesion in another major epicardial coronary artery.A two-vessel disease or a three-vessel disease may be viewed as a combination of a side branch and a main epicardial vessel provided they supply different territories; left anterior descending, left circumflex and right coronary artery); \n6.Total occluded vessels.One total occluded major epicardial vessel or side branch can be included and targeted as long as one other major vessel has a significant stenosis amenable for SA, provided the age of occlusion is less than one month e.g.recent instability, infarction with ECG changes in the area subtended by the occluded vessel.Patients with total occluded vessels of unknown duration or existing longer than one month and a reference over 1.50 mm should not be included, not even as a third or fourth vessel to be dilated; \n7.Significant stenosis has been defined as a stenosis of more than 50% in luminal diameter (in at least one view, on visual interpretation or preferably by QCA); \n8.Left ventricular ejection fraction should be at least 30%.Clinical suspicion of Morton neuroma confirmed in ultrasound scan\nSymptoms present more than six months\nThe thickness of the nerve must be at least 2 mm in short axis and at least 5 mm in the longitudinal axis.ASA I-IV Age 55 or older Scheduled for operative repair of isolated intertrochanteric hip fracture= 20years of age;\ndiagnosis of stroke (>6months);\nsedentary or insufficiently active;\nhave a writing medical permission to participate in the training program.Subject has provided informed consent.Subject is \xe2\x89\xa5 18 years of age \nSubject is willing and able to comply with all aspects of treatment and evaluation schedule.Subject has known CD and a recent history (within last 2 years) of mucosal disease (diagnosis based on radiologic, endoscopic, or histological evidence).Patients over the age of 18 years who are able to give their informed consent\nLobar and sublobar resections\nOpen, video-assisted thoracoscopic or robotic surgeries\nDiagnostic or therapeutic proceduresend diastolic diameter >60 mm and/or an ejection fraction <50%\nwritten informed consent\nage >18 yearsWilling and able to provide written informed consent and accept study procedures and time schedule.Age = 18 years.Patients suffering from chronic heart failure (the heart failure diagnosis must have been made or confirmed by a cardiologist and/or hospital physician at any time in the patient's medical history).Patients with reduced ejection fraction (= 40%) as confirmed at any time point in the patient's medical history.Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, willingness and ability to complete collection of data via wearable device and study mobile must be obtained and documented according to the local regulatory requirements.Female or male patients.Age = 18 years old.Metastatic invasive hormone receptor positive and HER2 negative breast cancer (histologically confirmed).Patients who in the opinion of the treating physician are candidates suitable for randomization for mono-chemotherapy treatment, that has either an approved label in Europe and/or is supported by guidelines for the treatment of first-line advanced BC, which are based on evidence on safety and efficacy in this setting.Symptomatic or asymptomatic metastatic breast cancer.Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.0 grade = 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).Life-expectancy > 6 months.For female patients: The patients need to be either A) of non-childbearing potential (documented postmenopausal or post hysterectomy) B) childbearing potential with negative serum or urinary pregnancy test (in this case patients need to use highly effective non-hormonal contraceptive methods).Be categorized as American Society of Anesthesiologists (ASA) Physical Status Class 1, 2, or 3.Have a planned non-emergent surgical procedure or clinical situation (e.g., intubation) that requires moderate or deep NMB with either rocuronium or vecuronium.Have a planned surgical procedure or clinical situation that would allow objective neuromuscular monitoring techniques to be applied with access to the arm for neuromuscular transmission monitoring.Age between 2 to <17 years at Visit 2.If female, may participate if she is not pregnant, not breastfeeding, and at least one of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who agrees to follow the study contraceptive guidance during the treatment period and for at least 7 days after the last dose of study treatment.pregnant women in 30 to 32 weeks of gestation, with positive HBsAg and HBeAg,serum viral load above 8log10 copies per mLpatients undergoing partial or full resection of the pancreas due to a benign or malignant tumorbiopsy proven NASH\nType 2 DM\nHbA1c :>6.5%\nBMI < 45kg/m2\nAny anti-diabetic agent except SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists)Patients aged between 40 and 60 years old.With Child score B or C\nPresented for elective gastrointestinal endoscopyPatient's written informed consent.Adequate cognitive capacity.Adequate family support\nNo acute diverticulitis episode in the last 3 months\nmNeff 0 acute diverticulitis (abdominal computed tomography scan)\nNo antibiotic treatment in the last 2 weeks\nImmunocompetence*\nNo significant comorbidities**\nGood oral tolerance\nGood symptom control\nMaximum one of the following SIRS criteria (* T>38 \xc2\xbaC or <36\xc2\xbaC, L>12,000 or <4000/uL, HR>90 bpm, RR<20 rpm) or CRP>15 mg/dLASA physical status I-II\nage between 18-80 years old\ndNMB with rocuronium during ear nose and throat (ENT) surgeryAge 18 years or older\nMechanical ventilation\nIAP between 12 and 20 mmHg in at least two consecutive measurements within 1-12 h\nSpontaneous breathing activity of at least 6 breaths/minute\nRASS score between 0 and -4\nPhysician-led sedation (if sedated; as opposed to nurse-led protocol)Written informed consent obtained\nMale and female subjects aged 20 years or older at informed consent\nEssential hypertension who had never received angiotensin II receptor antagonists and calcium channel blockersIdiopathic Parkinson's disease ( Hughes AJ et al.2001)\nPatients with motor fluctuations\nChronic Insomnia disorder criteria according to the criteria of DMS- V ( American Psychiatric Association, 2013) and insomnia severity index > 15\nAble to use independently the device required for treatment by apomorphine\nCollection of written informed consent (legal obligation for any project under the public health law , bioethics laws and / or CNIL) .Affiliate to social security or beneficiary of such a regimeAge 18-80 years old;\nIFG: 5.6mmol/L (100mg/dl)=FPG<7.0mmol/L (126mg/dl), or IGT: 7.8mmol/L (140mg/dl)=OGTT 2-h PG<11.1mmol/L (200mg/dl), or HbA1C 5.7-6.4% (39-47mmol/mol);\n2.6mmol/L (100mg/dl)=LDL-C=5.2mmol/L (200mg/dl), and TG<5.7mmol/L (500mg/dl);\n130mmHg=SBP<180mmHg, or 80mmHg=DBP<110mmHg or ongoing anti-hypertensive therapy;\nPatients volunteered for the study and signed informed consent.Supracondylar fracture\nAge 2-17 years\nAmerican Society of Anesthesiologists Status 1 -3\nScheduled for closed reduction with percutaneous pinning under general anesthesiaAge equal or superior to 18 years;\nBoth genders;\nLucid and without diagnosis of any psychiatric disorder;\nDiagnosed with head and neck cancer and treated for a period of up to 5 years with radiotherapy where the major salivary glands (parotid, submandibular and sublingual) were included in the radiation field;\nPrimary Sj\xc3\xb6gren's syndrome with the diagnosis made by the American-European criteria.Pregnant\nAmerican Society of Anesthesiologists risk classification I and II\nAge > 18 years\nNon-laboring\nPatients with elective cesarean sectionspatients classified with American Society of Anesthesiologists Physical Status Classification System as 1 or 2 status\nplanned eye surgery under sedationcroup children between 6 month and 5 years old\nWestley croup score between 3 and 11Age 65 years and older \nHypertension - untreated (Systolic Blood Pressure (SBP) \xe2\x89\xa5 140 mm Hg or Diastolic Blood Pressure (DBP) \xe2\x89\xa5 90 mm Hg) or treated \nPhysical limitations evidenced by either: \nScore \xe2\x89\xa4 10 on the Short Physical Performance Battery OR Walking speed < 1.2 m/sec during 400 m usual-paced test \nSedentary lifestyle, defined as <150 min/wk of moderate physical activity as assessed by CHAMPS questionnaire \nWillingness to participate in all study proceduresPatient aged 18 years or older.Patient suffering from mild to moderate active proctitis or distal proctosigmoiditis (MAYO score \xe2\x89\xa5 3 and \xe2\x89\xa4 10) at inclusion based on clinical and endoscopic findings within 6 months before study inclusion.Patient with evidence of endoscopic active proctitis or distal proctosigmoiditis (Montreal classification E1 or E2 defined by an involvement not exceeding 25 cm from the anal margin) within 6 months before study inclusion.Treatment of the current flare with Pentasa\xc2\xae to induce a remission initiated by the patient, the general practitioner or the gastroenterologist, during the inclusion visit or during the week before the inclusion visit.Patient having received oral and written information on the study, without any objections for the use of his/her personal data, and having signed a written Informed Consent Form.Undergoing right upper extremity surgery with supraclavicular block as the primary anesthetic\nAge greater than or equal to 18 years of age\nAmerican Society of Anesthesiologists (ASA) physical status 1 to 3\nAble to give informed consentMen between 45 and 80 years age\nParticipants with low serum testosterone concentrations (< 300 ng/dL) who exhibit at least one sign or symptom of hypogonadism and have evidence of cardiovascular (CV) disease or are at an increased risk for CV disease.Subject or subject's legally acceptable representative has provided informed consent.Male or female >=18 years of age.Histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum.Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status.Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.Measurable or non-measurable disease per RECIST Version 1.1.Must have failed after fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens for metastatic disease.Failure is defined as either disease progression (clinical or radiological) or intolerance to the regimen.Metastatic relapse within 6 months after completing adjuvant chemotherapy (with either an irinotecan or oxaliplatin containing regimen) will also be considered as treatment failure of a prior regimen for metastatic disease.Laboratory: Adequate baseline organ function defined by (<=7 days prior to first dose of study treatment).Hematologic function, as follows: Absolute neutrophil count (ANC) >=1.5 x 10^9/Liter (L), Platelet count >=75 x 10^9/L, Hemoglobin >=8.0 gram/deciliter (g/dL).Renal function, as follows: Creatinine <=1.5 x upper limit of normal (ULN).Hepatic function, as follows: Aspartate aminotransferase (AST) <=3 x ULN, Alanine aminotransferase (ALT) <=3 x ULN, Total Bilirubin <=1.5 x ULN.Metabolic function, as follows: Serum Magnesium within normal limits.Serum Calcium within normal limits.Serum Potassium within normal limits.All prior treatment related toxicities common terminology criteria for adverse events (CTCAE) version 4.03 <=Grade 1 at the time of enrollment.Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use adequate contraception, during the study and for 2 months following the last dose of study treatment.Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use adequate contraception, from time of signing informed consent until 5 months after the last dose of study treatment.Age from 40 to 80 years old, either gender;\nPatients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation;\nWilling to undergo second eye surgery within 7 days after first eye surgery;\nThe potential postoperative visual acuity of 20/40 or better in both eyes;\nPreoperative measurement of corneal astigmatism indicate the subjects are suitable for multifocal intraocular lenses implantation;\nCapability to understand the informed consent and willing and able to attend studyWritten informed consent\nAdult patients (older than 18 years of age), male and female, with chronic non-cancer and cancer pain (at least 3 months in duration)\nPatients experiencing an average weekly pain intensity score greater than 4 on a 11 points NRS\nSubject agreed to follow the protocol\nNa\xc3\xafve cannabis patients with chronic non-cancer and cancer pain (not used cannabis in any presentation in the last 12 weeks)\nPatients receiving opioids and other concomitant pain medications should have a stable dose for the last 15 days.Normal cognitive status according to MiniCog\nNormal liver function (defined as aspartate aminotransferase 10-40 U/L and alanine aminotransferase 7-56 U/L)\nNormal renal function (defined as serum creatinine level <133 \xc2\xb5mol/L and Estimated Glomerular Filtration Rate (eGFR) greater than or equal to 60)\nNegative result on \xc3\x9fhuman chorionic gonadotropin pregnancy test (if applicable)\nAbility to read and respond to questions in French or English.A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must be surgically sterile or agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration.medical indication for induction of labor\n18 years of age\nsigned informed consent\ncephalic presentation\nno PROM\n37+0 - 42+0 weeks of gestation\nBishop-Score = 6\nno contra-indication for medical induction of labor\nno clinical signs of infectionSubjects must: \n1.Be able to give valid informed consent \n2.Be 18 55 years of age.1.Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals.In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age.2.Screening tool: History.Government-issued forms of identification (e.g.driver s license, birth certificate) will be required when participant appears to be out of age range.3.Be in good health.1.Justification: Many illnesses may alter neural functioning as well as fMRI signals.2.Screening tools: Medical Assessment, Medical History and Physical Examination.Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample.Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV).The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+.The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation.(Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment.Those with fasting glucose below 100 mg/dl may be considered for the protocol.Others will be rejected and referred for work-up.)MAI will make the final judgment on any questionable lab results.4.Right-handed.1.Justification: Using right-handed individuals will reduce variability in BOLD MRI data.2.Screening tool: Edinburgh Handedness Inventory.5.Estimated IQ greater than or equal to 85 \n1.Justification: Subjects must be able to perform a cognitively challenging task to a high standard.2.Screening tool: Wechsler Abbreviated Scale of Intelligence.1) age 50-70 \n2) stroke within the past 6 to 60 months, \n3) major depressive disorder (PHQ-9 > 10) and diagnosed using the Structured Clinical Interview for Depression (SCID) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), \n4) residual paresis in the lower extremity (Fugl-Meyer LE motor score <34), \n5) ability to walk without assistance and without an AFO on the treadmill \xe2\x89\xa5 30 seconds at speeds ranging from 0.2-0.8 m/s, \n6) no antidepressant medications or clinically able to discontinue medications, \n7) HRSD question #9 regarding suicide <2, \n8) provision of informed consent.In addition, all subjects who meet criteria for the training portion must complete an exercise tolerance test and be cleared for participation by the study cardiologist.Subject has curettage for retained product after second trimester abortion25-50 years of age\nPTSD related to physical or sexual assault\nMedically healthy\nEnglish speakingNAAge 18-65\nDiagnosis of MDD (Major Depressive Disorder), made or affirmed by a senior psychiatrist in Shalvata\nMADRS score > 20\nTreated with conventional anti-depressant, administered within a formal psychiatric clinic or by a certified psychiatrist.All patients with esophageal cancer who are deemed candidates for minimally invasive robot assisted Ivor Lewis esophagogastrectomy.Patients who provide written informed consent for the study.Prior Myocardial Infarction and\nSustained monomorphic VT documented on 12-lead ECG or rhythm strip terminated by pharmacologic means or DC cardioversion\n=3 episodes of VT treated with antitachycardia pacing (ATP), at least one of which was symptomatic\n= 5 episodes of VT treated with antitachycardia pacing (ATP) regardless of symptoms\n=1 appropriate ICD shocks,\n=3 VT episodes within 24 hoursAge =18 years\nSubjects undergoing elective total knee or hip replacement or a revision of at least one component of a total knee or hip replacementM. perstans mg-positive status Good general health without any clinical condition requiring long-term medication.Normal renal and hepatic laboratory profiles1.Patient age \xe2\x89\xa5 12 years \n2.Presence of P. knowlesi malaria, confirmed by positive blood smear with asexual forms of P. knowlesi.3.Temperature >38C on admission or fever during the preceding 48 hours \n4.Enrolled within 18 hours of commencing antimalarial treatment \n5.Written informed consent from patient or attending relative able to and willing to give informed consent.Consent form and information sheets will be translated into Malay and copies provided to the patient.Age = 75 years,\nSevere, symptomatic aortic stenosis,\nHigh risk for cardiac surgery (STS and logistic Euroscore ),\nAccording multidisciplinary (heart) team decision TAVI is preferable,\nWilling to participateHistopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in remission (Group A) or with active disease (Group B).CMV-positive GBM \nCMV seropositive \nLife expectancy 6 weeks or greater \nKarnofsky/Lansky score 50 or greater \nPatient or parent/guardian capable of providing informed consent \nBilirubin less than 1.5x upper limit of normal, AST less than 3x upper limit of normal, serum creatinine less than 1.5x normal and Hgb 8.0 g/dL or greater \nPulse oximetry of 90% or greater on room air \nSexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion.The male partner should use a condom.Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study.Informed consent explained to, understood by and signed by patient/guardian.Patient/guardian given copy of informed consent.Provide signed and dated informed consent form.Willing to comply with all study procedures and be available for the duration of the study.Male or female, aged = 18 to = 60 years on day of inclusion.In good general health based on medical history and physical examCPPE along with evidence of septated pleural effusion on pleural ultrasonography and/or chest CT scan\nempyema.age over 40\ncomposite head and neck tumor resection\ntreated hypertension\nhypertension medications taken on morning of surgery (except diuretics)Cohort 1: Recurrent or refractory medulloblastoma in which current standard treatment approaches have failed; biopsy is not required for recurrent disease.Cohort 2: Newly-diagnosed high-grade glioma (World Health Organization [WHO] grade 3 or 4) \nLife expectancy \xe2\x89\xa5 3 monthsPatients with hepatocirrhosis: according to the standard of child- pugh, liver functions to achieve class A or B patients, Including C class patients but can achieve B class after treatmentpremenopausal women\nBRCA1 carrierSubject has been diagnosed with symptomatic paroxysmal atrial fibrillation as defined above and at least two symptomatic episodes in the last six months prior to inclusion.At least one episode of AF must be documented during the prior year by any kind of ECG recording.Subject has structural normal heart with an LVEF = 50%, thickness of the inter-ventricular septum =12 mm and left atrium diameters (short axis) < 46 mm obtained by transthoracic echocardiography.Subject has normal ECG parameters (QRS width in the 12 channel surface ECG =120 ms, QTc - interval < 440 ms, PQ - interval = 210 ms; all parameters should be measured at sinus rhythm).Subject is at least 18 and not older than 75years old.Subject is able and willing to give informed consent.Age>18 years\nScheduled 1 or 2-level ACDF spine surgery\nThe capacity to provide informed consent.Degenerative Disc Disease (as defined by neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies)\nTrauma (including fractures)\nTumors\nDeformities or curvatures (including kyphosis, lordosis, or scoliosis)\nPseudoarthrosis\nFailed previous fusion\nDecompression of the spinal cord following total or partial cervical vertebrectomy\nSpondylolisthesis\nSpinal stenosis\nPatients with current or recent history of malignancy or infectious disease.The inability to provide informed consent.Subject has marked local inflammation\nSubject has any mental or neuromuscular disorder which would create an unacceptable risk of fixation failure or complications in postoperative care.Subject has a bone stock compromised by disease, infection or prior implantation which cannot provide adequate support and/or fixation to the devices.Subject has bone abnormalities preventing safe screw fixation.Subject has any open wounds.Subject has rapid joint disease, bone absorption, osteopenia, osteomalacia, and/or osteoporosis.Osteoporosis or osteopenia are relative contraindications, since this condition may limit the degree of obtainable correction and/or the amount of mechanical fixation.Subject has a documented or suspected metal sensitivity.Subject is pregnant.Subject has anatomical structures or physiological performance that would interfere with implant utilization.Subject has inadequate tissue coverage over the operative site.Subject has other medical or surgical conditions which would preclude the potential benefit of surgery, such as congenital abnormalities, immunosuppressive disease, elevation of sedimentation rate unexplained by other diseases, elevation of white blood count (WBC), or marked left shift in the WBC differential count.Note: The Aviator Anterior Cervical Plating System is not approved or intended for screw attachment to the posterior elements (pedicles) of the cervical, thoracic, or lumbar spine.The surgeon must consider the levels of implantation, patient weight, patient activity level, and other patient conditions which may impact on the performance of the system.Healthy postmenopausal women with 50 or more moderate to severe hot flushes.Women between 40 to 70 years of age.1.HIV infection with plasma and CSF HIV RNA concentrations (using Roche Amplicor assay) > 1,000 copies/ mL (available after baseline LP).2.Off antiretroviral therapy (ART) for > 6 weeks before the study and no plans to begin treatment for the study duration.(The decision of whether or not a subject takes antiretroviral therapy will be made by the subject in consultation with his/her primary care provider prior to screening for this study.)3.Predicted adherence to the medication.4.Capable of providing informed consent.5.> 18 years old \n6.CD4 cell counts >150 cells/\xce\xbcL (though likely most, if not all, will be >250 cells/\xce\xbcL).7.When available, subjects will be screened for stability of blood CD4 and HIV RNA levels.First single stroke ischaemic or haemorrhagic responsible of an hemiplegia\nStoke since less than 2 month\nA sufficient understood\nA spasticity : a Tardieu score upper or equal to 2 on at least one of the following muscle-triceps surae, flexors of fingers, of wrist and of elbow\nA free consentApproved clinical indication for pectoral pacemaker exchange (e.g.elective replacement indication (ERI), end of service (EOS))\na single or dual chamber MRI conditional pacemaker (BSCI) or\nAny comparable successor IPG (MRI conditional system, BSCI) compatible with\nImplanted Fineline-II-leads (BSCI), MRI conditional\nThe ascertained lead impedance is between 200 and 1500 Ohm.All pacing capture thresholds (PCT) do not exceed 2.0 V @0.4 or 0.5 ms in pacemaker dependent patients\nMale or female 18 years or older\nUnderstand the nature of the procedure\nGive written informed consent\nAble to complete all testing required by the clinical protocol\nAbility to measure atrial and/or ventricular pacing threshold(s) at 0.4 or 0.5 ms\nPatient body height greater or equal to 140 cm\nPectoral implanted device\nSubjects who are able and willing to undergo elective cardiac magnetic resonance (MR) scanning without sedation (MRI-group)\nSubjects who are geographically stable and available for follow-up at the study center for the length of the studyage > 18 y.o.American Society of Anesthesiologists Physical Status Classification (ASA) 1-2\nsigned informed consent form after reading the information about the study and talking with one of the investigatorsHas given written informed consent before any study-related activity is performed\nAdvanced hormone-dependent prostate cancer for which androgen deprivation therapy is indicated, and independently from this trial, Firmagon\xc2\xae is intended to be used for treatment\nAge greater than or equal to 18 years and less than 80 years\nAdvanced hormone-dependent prostate cancer without any other clinically significant disorder\nEasten Cooperative Oncology Group score = 2\nPSA = 2 ng/mL at screening\nLife expectancy of at least 12 months as per the investigator's judgementMale and females between ages 18-85 years\nRight handed\nAble to complete precision grips with both hands\nAble to complete full wrist flexion-extension bilaterally\nAble to walk unassisted\nAble to complete full ankle flexion-extension bilaterally\nMale and females between ages 18-85 years\nSCI ( 2 months of injury)\nSpinal Cord injury at or above L5\nThe ability to produce a visible precision grip force with one hand\nAble to perform some small wrist flexion and extension\nThe ability to perform a small visible contraction with dorsiflexion and hip flexor muscles\nNo subjects will be excluded based on their race, religion, ethnicity, gender or HIV status.ASIA A,B,C, or DMale and female Active-duty SMs or Veterans aged 18 or older who are in good general health.History of blast and/or impact head trauma mTBI meeting Defense and Veterans Brain Injury Center (DVBIC) mTBI criteria, which define mTBI as an injury to the head causing at least one of the following: alteration in consciousness (for up to 24 hours after the injury), loss of consciousness 0-30 minutes, and/or post-traumatic amnesia up to 1 day post-injury.If available, the Glasgow Coma Scale score must be 13-15, and head imaging findings (if imaging was performed) must be negative.Frequent HAs that started within 3months after a head injury.The HAs either 1) must last 4 or more hours a day and reach a moderate to severe intensity at any point during the headache, or 2) may be of any severity or duration if the participant takes a triptan or ergotamine.HAs meeting these criteria must have been present on average at least 8 days per 4-week period, starting within 30 days after head injury and occurring by self-report for at least 3 months prior to the Initial Screening Visit.The 4-week HA frequency/severity criteria must be confirmed during the Preliminary Screening Period.Women of childbearing potential must agree to abstain from sexual relations that could result in pregnancy or use an effective method of birth control acceptable to both participant and the clinician prescriber during the study.Men are not required to use contraception during the study.Participants must have English fluency sufficient to complete study measures.definite unilateral vestibulopathy\nno pathological HINTS (examination criteria in acute vestibular syndrome)\ncapable of making their own decisionsHLA-A2 melanoma patients with : \neither loco-regional or lymph node metastasis \ntransit nodules not surgically resectable \nmeasurable cutaneous or visceral metastasis \nPatients' tumor express Melan-A/MART-1 antigen.No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion.No other melanoma treatment during the protocol.Life expectancy should be greater than 6 months.General state with Karnowsky greater than 80, ECOG = 0, 1 or 2.Patient should be negative for HIV and B and C hepatitis.Biological parameters at the beginning of the study: leucocytes \xc2\xb3 2000 elements per mm3, hemoglobin \xc2\xb3 10.5g/dl, platelets \xc2\xb3 100 000 per mm3, phosphatases alcalines transaminases \xc2\xa3 1 time 1/2 compared to the normal.Signed informed consentAmbulatory status (outpatient) at time of consent \nAge 10-55 years \nClinical diagnosis of Autism Spectrum Disorder \nIQ greater than or equal to 70 \nScore greater than 8 on Children's Yale-Brown Obsessive Compulsive Scale \nFree of psychoactive medication for at least: one month for fluoxetine; two weeks for other SSRIs and neuroleptics; and five days for stimulants prior to MRI scanning [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder]body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusiveAdult patients scheduled for arthroscopic knee ligament reconstructionAge =18 years\nObjectively confirmed diagnosis of acute PE by multidetector CT angiography, ventilation/perfusion lung scan, or selective invasive pulmonary angiography, according to established diagnostic criteria, with or without symptomatic deep vein thrombosis\nAbsence of hemodynamic collapse, or decompensation, at presentation; Hemodynamic collapse or decompensation\nAt least one sign of RV pressure overload/dysfunction on CT angiography or echocardiography\nSigns of myocardial injury as indicated by elevated troponin levels\nSigns of (RV) failure as indicated by NT-proBNP levels >600 pg/ml at baseline.Ability of the subject to understand the character and individual consequences of the clinical trial; signed and dated informed consent of the subject available before the start of any specific trial procedures100 orphans/vulnerable youth aged 15 to 25 will be recruited through their participation at the day care center, on a voluntary basis.HCV RNA evidence of HCV infection\nDocumented history of chronic HCV RNA infection with Genotype 1\nAble to provide informed consent\nAvailable for ongoing follow-up if requiredHistologically confirmed locally advanced gastric (primary endpoint includes proximal and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral) adenocarcinomas are eligible for enrolment but will not be included in the primary analysis\nLocally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)\nAll patients must have diagnostic laparoscopy with diagnostic washings for cytology; both cytology positive and negative patients are eligible for enrolment, but only cytology negative patients will be included in the primary analyses; gross peritoneal disease is not eligible\nEastern Cooperative Oncology Group (ECOG) performance status =< 1\nEligible for surgery with curative intent\nAbsolute neutrophil count (ANC) >= 1250/ul\nHemoglobin >= 9 g/dL\nPlatelets >= 100,000/ul\nTotal bilirubin < 1.5 x upper limit of normal\nSerum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver metastases\nCreatinine =< 1.5 x upper limit of normal\nMeasurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 will be allowed\nWomen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment; should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately\nPatients taking substrates, inhibitors, or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan\nSigned informed consentWomen with a singleton pregnancy undergoing cesarean section after 37 weeks of gestation.Age >=19 patients who complained of dizziness\nOrthostatic hypotension after 3-minute standing (systolic blood pressure drop >=20 or diastolic blood pressure drop >=101.Patients with histologically confirmed diagnosis of colorectal cancer presenting with unresectable stage IV (UICC) disease (primary tumor may be present) \n2.Patients who are feasible for treatment with FOLFOX (prior adjuvant or palliative treatment is allowed) \n3.ECOG Performance status \xe2\x89\xa4 1 \n4.Life expectancy > 3 months \n5.Age \xe2\x89\xa518 years \n6.Haematologic function as follows (5% deviation allowed): \nANC \xe2\x89\xa5 1.5 x 109/L \nplatelets \xe2\x89\xa5 100 x109/L \nhemoglobin \xe2\x89\xa5 9 g/dl or 5.59 mmol/l \n7.Adequate liver function as follows (10% deviation allowed) \nserum alanine transaminase (ALT) \xe2\x89\xa4 2.5 x ULN (in case of liver metastases < 5 x ULN) \ntotal bilirubin \xe2\x89\xa4 1.5 x ULN (patients with Gilbert's syndrome total bilirubin \xe2\x89\xa42.5 x ULN) \n8.Adequate renal function as follows (10% deviation allowed) \n\xc2\xb7 creatinine \xe2\x89\xa4 1.5 x ULN \n9.Signed written informed consent \n10.Women of child-bearing potential must have a negative pregnancy testPerson is >18 years old.Person is a unilateral transfemoral or knee-disarticulation amputee with stabilized residual limb.Person is a K2, K3 or K4 ambulator based on Medicare Functional Classification Level (MFCL).Person is currently fitted with a prosthesis using a non-microprocessor controlled prosthetic knee for at least 6 months.Person was never fitted with microprocessor controlled prosthetic knee joint.Person is willing and able to independently provide informed consent.Person is willing to comply with study procedures.Person wears prosthesis daily and = 8 hours/day.Person is walking on average 1km/day.Person is walking not slower than 3km/h (~0.8m/s) (based on 10m walk test conducted during recruiting).Person is walking on level ground in a step over step manner.1.Subject is at least 18 years old.2.Subject requires single- or multi-vessel percutaneous coronary intervention (PCI) of de novo or restenotic target lesion (including in-stent restenotic lesions).3.Subject's lesion(s) is (are) amenable to stent treatment with currently available FDA-approved bare metal or drug eluting stents.4.Subject is an acceptable candidate for elective, urgent or emergency coronary artery bypass graft (CABG).5.Subject has clinical evidence of ischemic heart disease in terms of a positive functional study, or documented symptoms.6.Documented stable angina pectoris [Canadian Cardiovascular Society Classification (CCS) 1, 2, 3, or 4], unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), non-ST segment elevation myocardial infarction, or documented silent ischemia.7.Subject is willing and able to undergo percutaneous intervention at SOS hospital, if randomized to SOS study arm.8.Subject and the treating physician agree that the subject will comply with all follow-up evaluations.9.Subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site.10.The target lesion(s) is (are) de novo or restenotic (including in-stent restenotic) native coronary artery lesion(s) with greater than 50 and less than 100% stenosis (visual estimate), or the target lesion is an acute (less than 1 month) total occlusion as evidenced by clinical symptoms.11.Target lesions(s) is (are) located in an infarct (if not treated with primary PCI) or non-infarct-related artery with a 70% or greater stenosis (by visual estimate) more than 72 hours following the ST segment elevation myocardial infarction (STEMI).Lesions treated with PCI more than 72 hours following STEMI would be subject to the same protocol inclusion/exclusion criteria listed above and below with the exception that a target lesion of 70% or greater stenosis may be treated with or without symptoms or abnormal stress test).Have diagnosis of prostate cancer and have received treatment with GnRH agonist or antagonist therapy for at least 1 month prior to enrollment.Willing and able to complete survey questionnaires in English without assistance through the duration of the study.This stipulation is in place because not all of the proposed quality of life or cognitive tests are available or validated in other languages.Age = 18 years.Ability to understand and the willingness to sign a written informed consent document written in English that is approved by an institutional review board.Have either newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) or castration-resistant metastatic prostate cancer (mCRPC) and eligible to undergo treatment with abiraterone acetate (mHSPC or mCRPC) or enzalutamide (mCRPC)\nPatients may have received the following prior AR directed therapy prior to enrollment: bicalutamide, ketoconazole.Prior to enrollment, patients may have received treatment with abiraterone acetate or enzalutamide for no more than 14 days before completing baseline studies.Patients may have received chemotherapy for hormone-sensitive metastatic prostate cancer only, but it must not have lasted for more than 6 months.At least 12 months must have elapsed since completion of chemotherapy.Patients may have received prior definitive radiation therapy or surgery.At least 60 days must have elapsed since completion of definitive radiation therapy or surgery and patient must have only grade 2 or less adverse effects at the time of registration.Enrollment during palliative radiation of = 10 days, or radiation of = 10 days during the duration of the study is allowed.Patients must be able to take oral medication.Newly diagnosed and untreated sputum smear positive tuberculosis patient\nPulmonary lesion consistent with TB by radiological examination\nPositive sputum culture, identification of bacterial type confirmed Mycobacterium tuberculosis.MGIT drug sensitivity test (DST) results are sensitive of the first-line drugs (isoniazid, streptomycin, rifampicin and ethambutol).Age 18 years-65 years old\nMales or non-pregnant, non-nursing females\nSerum or plasma aminotransferases (AST, ALT) less than 3 times the upper limit of normal\nSerum or plasma total bilirubin less than or equal to 2.5 times the upper limit of normal\nSerum or plasma creatinine level less than or equal to 2 times the upper limit of normal\nSerum or plasma potassium level greater than or equal to 3.5 meq/L\nHemoglobin level of 7.0 g/dL or greater\nPlatelet count of 100,000/mm3 or greater\nFor women of childbearing potential, a negative pregnancy test is required during screening\nProvides written informed consent\nWillingness and ability to attend scheduled follow-up visits and undergo study assessments.Likely suffer moderate-to-severe OSA based on history and physical or have an established diagnosis of OSA (20=AHI=65) based on a prior in-lab Polysomnography\nDocumentation the subject not effectively treated with CPAP therapy.(Examples include non-compliance, discomfort, undesirable side effects, symptoms persist despite use).Subjects who have been prescribed, but refuse to try CPAP would be considered intolerant.Age 22 or above\nWilling and capable to have stimulation hardware permanently implanted, and to use the patient remote to activate the stimulation\nWilling and capable to return for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires\nWilling and capable of providing informed consentArrestees examined by a physician during detention in police cells\naged 18 or older\nsmoking at least 10 cigarettes per day\ngiving written consent to participate in the study\nhealth status compatible with detention in police cellsSigned Informed Consent Form\nPatients having physical and mental ability to participate in the study\nPatients of both sexes aged 35 to 65 years\nPresence of documented ST-elevation myocardial infarction confirmed by ECG, as well as troponin I and CK-MB levels.Presence of hemodynamically relevant stenosis of one artery (i.e., the infarct-related artery) confirmed by coronary angiography (CAG), with the occlusion of other arteries not exceeding 30%.Septic shock patients despite early goal directed therapy\nAgree to participate this studyElective open abdominal hysterectomy with midline incision, age > 18 years, American Society of Anesthesiologist classification score (ASA classification) 1-3.Outpatient with primary DSM- IV OCD\nCompletion of a 14-week open label trial of one the following SRI's: fluoxetine 80 mg/day, paroxetine 60 mg/day, fluvoxamine 300 mg/day, clomipramine 250 mg/day, sertraline 200 mg/day, citalopram 60 mg/day, escitalopram 30 mg/day and demonstrating a non or partial responses to SRI treatment (CGI-I of 3 or 4, Y-BOCS reduction of < 35%)\nStable (8 wks or longer) concurrent medications including benzodiazepines, sedative hypnotics, antipsychotics, and antidepressants.Adult patients aged (>18), males and females, undergoing elective coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).uterine size <12 weeks.presence of benign cause for the hysterectomy e.g.fibroid uterus, perimenopausal beeding not responding to medical treatment or complex endometrial hyperplasia without atypia.Absence of significant scarring in the pelvis from previous surgeries.Between the ages of 21-60\nRight-handed\nCapable of giving informed consent and complying with study procedures\nReports drinking a minimum of 5 standard drinks for men or 4 standard drinks for women on at least 4 days per week on average over the past 28 days\nMeets DSM-V criteria for current Alcohol Use Disorder\nSeeking treatment for Alcohol Use Disorder\nAgree to not seek additional treatment, apart from Alcoholics Anonymous\nWilling to attempt to abstain from alcohol completely for the duration of the study\nWilling to be hospitalized on a research unit for 24 hours, longer if detoxification is needed.